Disease,Phase,PNUM,Candidate vaccine,Candidate Vaccine Status,Platform,Immunogen Type,Immunogen,Adjuvant Type,Registry ID,Trial Status,Sponsor Name,Sponsor Type,Study Start date,Primary Completion Date (anticipated or actual) (see notes),Completion Date (anticipated or actual) (see notes),Age,"Sample Size, Enrollment",Location,Results Reporting Status,Full Publication Date,Full Publication Link / PMID,Clinical Trials Registry,source,URL
Dengue,Phase 2,2,TV003/ TV005,Active candidate / in development,Recombinant viral vector,Protein: specify,Whole virus,None,ctri17222,"Open, not recruiting",Panacea Biotec,Industry,2/20/2017,11/20/2017,11/20/2017,Child | Adult,200,India,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Dengue,Phase 1,1,rDEN4Δ30-4995,Inactive / no longer in development,"Live, attenuated target organism",Protein: specify,Whole virus,None,NCT00322946,Completed,NIAID,Government,1/1/2007,8/1/2009,8/1/2009,Adult,84,United States of America,Results reported in peer-reviewed journal,11/1/2009,19861619,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Dengue,Phase 2,2,T-DEN,Inactive / no longer in development,"Live, attenuated target organism",Protein: specify,Whole virus,None,NCT00370682,Completed,USAMRMC,Government,4/1/2007,2/1/2008,2/1/2008,Adult,120,Thailand,Results reported in peer-reviewed journal,5/27/2014,24865677,clinicaltrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Dengue,Phase 1,1,"rDEN1Δ30, rDEN2/4Δ30(ME)",Inactive / no longer in development,Recombinant viral vector,Protein: specify,Whole virus,None,NCT00458120,Completed,NIAID,Government,3/1/2007,8/1/2008,8/1/2008,Adult,36,United States of America,Results reported in peer-reviewed journal,12/14/2010,21208923,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Dengue,Phase 2,2,T-DEN,Inactive / no longer in development,"Live, attenuated target organism",Protein: specify,Whole virus,None,NCT00468858,Completed,USAMRMC,Government,7/1/2007,4/1/2010,4/1/2010,Child | Adult,636,Puerto Rico,Results reported in peer-reviewed journal,7/14/2015,26175027,clinicaltrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Dengue,Phase 1,1,rDEN1Δ30,Inactive / no longer in development,"Live, attenuated target organism",Protein: specify,Whole virus,None,NCT00473135,Completed,NIAID,Government,5/1/2007,1/1/2010,1/1/2010,Adult,60,United States of America,Results reported in peer-reviewed journal,8/2/2011,21829748,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Dengue,Phase 2,2,CYD-TDV,Registered,Recombinant viral vector,Protein: specify,PrM + E,None,NCT00617682,Completed,Sanofi Pasteur,Industry,4/1/2008,12/1/2009,2/1/2010,Adult,260,United States of America,Results reported in peer-reviewed journal,10/17/2013,24021313,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Dengue,Phase 1,1,rDEN3-3'D4Δ30,Inactive / no longer in development,"Live, attenuated target organism",Protein: specify,Whole virus,None,NCT00714064,Completed,NIAID,Government,12/1/2008,9/1/2009,9/1/2009,Adult,29,United States of America,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Dengue,Phase 2,2,CYD-TDV,Registered,Recombinant viral vector,Protein: specify,PrM + E,None,NCT00740935,Completed,Sanofi Pasteur,Industry,8/1/2008,10/1/2009,1/1/2010,Adult,154,Mexico,Results reported in peer-reviewed journal,10/31/2014,25483647,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Dengue,Phase 2,2,CYD-TDV,Registered,Recombinant viral vector,Protein: specify,PrM + E,None,NCT00792909,Completed,Sanofi Pasteur,Industry,10/1/2008,8/1/2010,12/1/2010,Child,300,Peru,Results reported in both peer-reviewed journal & registry,9/7/2012,22863660,EudraCT,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Dengue,Phase 1,1,rDEN3Δ30/31‐7164,Inactive / no longer in development,"Live, attenuated target organism",Protein: specify,Whole virus,None,NCT00836498,Completed,NIAID,Government,9/1/2009,6/1/2011,6/1/2011,Adult,56,United States of America,Results reported in peer-reviewed journal,6/2/2013,23735680,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Dengue,Phase 2b,2,CYD-TDV,Registered,Recombinant viral vector,Protein: specify,PrM + E,None,NCT00849069,Completed,Sanofi Pasteur,Industry,2/1/2009,9/1/2013,2/1/2014,Child,4002,Thailand,Results reported in both peer-reviewed journal & registry,11/3/2012,22975340,EudraCT,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Dengue,Phase 2,2,CYD-TDV,Registered,Recombinant viral vector,Protein: specify,PrM + E,None,NCT00880698,Completed,Sanofi Pasteur,Industry,3/1/2009,8/1/2014,12/1/2014,Child | Adult,180,Viet Nam,Results reported in registry,,,EudraCT,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Dengue,Phase 2,2,CYD-TDV,Registered,Recombinant viral vector,Protein: specify,PrM + E,None,NCT00889616,Completed,Sanofi Pasteur,Industry,4/1/2009,10/1/2014,6/1/2015,Child | Adult,1198,Singapore,Results reported in both peer-reviewed journal & registry,8/16/2012,22894958,EudraCT,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Dengue,Phase 1,1,rDEN4Δ30,Inactive / no longer in development,"Live, attenuated target organism",Protein: specify,Whole virus,None,NCT00920517,Completed,NIAID,Government,7/1/2009,5/1/2010,5/1/2010,Adult,70,United States of America,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Dengue,Phase 1,1,rDEN2/4Δ30,Inactive / no longer in development,Recombinant viral vector,Protein: specify,Whole virus,None,NCT00922363,Completed,NIAID,Government,1/1/2009,1/1/2010,1/1/2010,Adult,25,United States of America,Results reported in peer-reviewed journal,6/2/2013,23735680,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Dengue,Phase 1,1,V180 (DEN1-80E),Inactive / no longer in development,"Subunit (e.g., toxoid, carbohydrate) from target organism",Protein: specify,PrM + E,Aluminum salts (alum),NCT00950612,Completed,Hawaii Biotech,Industry,7/1/2009,7/1/2010,1/1/2011,Adult,16,United States of America,Results reported in peer-reviewed journal,10/14/2015,26458804,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Dengue,Phase 2,2,CYD-TDV,Registered,Recombinant viral vector,Protein: specify,PrM + E,None,NCT00993681,Completed,Sanofi Pasteur,Industry,10/1/2009,9/1/2011,3/1/2012,Child,600,Colombia | Mexico | Honduras | Puerto Rico,Results reported in both peer-reviewed journal & registry,10/1/2013,24067553,clinicaltrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Dengue,Phase 2,2,CYD-TDV,Registered,Recombinant viral vector,Protein: specify,PrM + E,None,NCT01073306,Completed,Sanofi Pasteur,Industry,1/1/2010,9/1/2012,11/1/2012,Child,210,Philippines,Results reported in registry,,,EudraCT,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Dengue,Phase 1,1,TV003/ TV005,Active candidate / in development,Recombinant viral vector,Protein: specify,Whole virus or PrM + E,None,NCT01084291,Completed,NIAID,Government,7/1/2010,6/1/2012,6/1/2012,Adult,141,United States of America,Results reported in peer-reviewed journal,1/17/2013,23329850,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Dengue,Phase 1,1,rDEN2/4Δ30(ME),Inactive / no longer in development,Recombinant viral vector,Protein: specify,Whole virus,None,NCT01086436,Completed,NIAID,Government,2/1/2010,6/1/2010,6/1/2010,Adult,18,United States of America,Results reported in peer-reviewed journal,6/2/2013,23735680,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Dengue,Phase 1,1,rDEN1Δ30,Inactive / no longer in development,"Live, attenuated target organism",Protein: specify,Whole virus,None,NCT01095055,Completed,NIAID,Government,4/1/2010,5/1/2010,6/1/2010,Adult,18,United States of America,Results reported in peer-reviewed journal,6/2/2013,23735680,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Dengue,Phase 1,1,TDV,Active candidate / in development,Recombinant viral vector,Protein: specify,Whole virus or PrM + E,None,NCT01119625,Completed,NIAID,Government,5/1/2010,4/1/2012,12/1/2012,Adult,72,United States of America,Results reported in peer-reviewed journal,3/19/2015,25791116,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Dengue,Phase 3,3,CYD-TDV,Registered,Recombinant viral vector,Protein: specify,PrM + E,None,NCT01147445,Completed,Sanofi Pasteur,Industry,10/1/2010,11/1/2012,2/1/2013,Adult,712,Australia,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Dengue,Phase 2,2,CYD-TDV,Registered,Recombinant viral vector,Protein: specify,PrM + E,None,NCT01198769,Completed,Sanofi Pasteur,Industry,8/1/2010,10/1/2012,12/1/2012,Child,150,Brazil,Results reported in both peer-reviewed journal & registry,11/4/2013,24189367,clinicaltrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Dengue,Phase 1,1,TDV,Active candidate / in development,Recombinant viral vector,Protein: specify,Whole virus or PrM + E,None,NCT01260727,Completed,Inviragen,Industry,10/1/2010,6/1/2011,11/1/2011,Adult,96,Colombia,Results reported in peer-reviewed journal,7/23/2014,25087476,clinicaltrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Dengue,Phase 3,3,CYD-TDV,Registered,Recombinant viral vector,Protein: specify,PrM + E,None,NCT01262976,Completed,Sanofi Pasteur,Industry,12/1/2010,9/1/2012,1/1/2013,Child,250,Malaysia,Results reported in both peer-reviewed journal & registry,10/14/2013,24135573,EudraCT,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Dengue,Phase 3,3,CYD-TDV,Registered,Recombinant viral vector,Protein: specify,PrM + E,None,NCT01375647,"Open, not recruiting",Sanofi Pasteur,Industry,6/1/2011,8/1/2014,11/1/2017,Child,10278,Indonesia | Malaysia | Thailand | Philippines | Viet Nam,Results reported in both peer-reviewed journal & registry,10/11/2014,25018116,clinicaltrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Dengue,Phase 3,3,CYD-TDV,Registered,Recombinant viral vector,Protein: specify,PrM + E,None,NCT01377571,"Open, not recruiting",Sanofi Pasteur,Industry,6/1/2011,11/1/2014,4/1/2018,Child,20875,Brazil | Colombia | Honduras | Mexico | Puerto Rico,Results reported in both peer-reviewed journal & registry,1/8/2015,25365753,EudraCT,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Dengue,Phase 3,3,CYD-TDV,Registered,Recombinant viral vector,Protein: specify,PrM + E,None,NCT01432158,Completed,Sanofi Pasteur,Industry,7/1/2011,2/1/2014,4/1/2014,Child,720,Mexico,Results reported in registry,,,EudraCT,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Dengue,Phase 3,3,CYD-TDV,Registered,Recombinant viral vector,Protein: specify,PrM + E,None,NCT01443117,Completed,Sanofi Pasteur,Industry,9/1/2011,9/1/2013,3/1/2014,Child,792,Colombia | Peru,Results reported in registry,,,EudraCT,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Dengue,Phase 1,1,TV003/ TV005,Active candidate / in development,Recombinant viral vector,Protein: specify,Whole virus or PrM + E,None,NCT01443416,Completed,NIAID,Government,8/1/2011,3/1/2014,3/1/2014,Adult,112,United States of America,Results reported in peer-reviewed journal,3/22/2015,25801652,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Dengue,Phase 1,1,V180,Active candidate / in development,"Subunit (e.g., toxoid, carbohydrate) from target organism",Protein: specify,PrM + E,Novel other: specify,NCT01485406,Completed,Merck,Industry,7/1/2012,1/1/2014,12/1/2014,Adult,98,United States of America,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Dengue,Phase 2,2,CYD-TDV,Registered,Recombinant viral vector,Protein: specify,PrM + E,None,NCT01502735,Completed,Sanofi Pasteur,Industry,12/1/2011,9/1/2013,4/1/2014,Adult,390,United States of America,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Dengue,Phase 1,1,TVDV,Active candidate / in development,DNA,Protein: specify,PrM + E,Novel other: specify,NCT01506570,Completed,USAMRMC,Government,12/1/2011,12/1/2013,12/1/2013,Adult,40,United States of America,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Dengue,Phase 1,1,DENV1-PIV,Inactive / no longer in development,Inactivated whole target organism,Protein: specify,Whole virus,None,NCT01509846,Completed,USAMRMC,Government,12/1/2011,9/1/2013,9/1/2013,Adult,20,United States of America,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Dengue,Phase 1,1,TV003/ TV005,Active candidate / in development,Recombinant viral vector,Protein: specify,Whole virus or PrM + E,None,NCT01513551,Completed,NIAID,Government,12/1/2011,9/1/2013,9/1/2013,Adult,58,United States of America,Results reported in peer-reviewed journal,3/22/2015,25801652,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Dengue,Phase 2,2,TDV,Active candidate / in development,Recombinant viral vector,Protein: specify,Whole virus or PrM + E,None,NCT01531530,Completed,Takeda,Industry,11/1/2011,4/1/2016,4/1/2016,Child | Adult,344,Colombia | Puerto Rico | Singapore | Thailand,Results reported in peer-reviewed journal,12/23/2015,26704612,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Dengue,Phase 1,1,TDV,Active candidate / in development,Recombinant viral vector,Protein: specify,Whole virus or PrM + E,None,NCT01575197,Completed,Takeda,Industry,1/1/2012,1/1/2014,1/1/2014,Adult,140,United States of America,Results reported in both peer-reviewed journal & registry,9/15/2015,26384447,clinicaltrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Dengue,Phase 2,2,CYD-TDV,Registered,Recombinant viral vector,Protein: specify,PrM + E,None,NCT01599897,Completed,Sanofi Pasteur,Industry,3/1/2012,12/1/2013,2/1/2014,Adult,189,India,Results reported in both peer-reviewed journal & registry,8/20/2015,26291554,clinicaltrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Dengue,Phase 1,1,TDENV-PIV,Active candidate / in development,Inactivated whole target organism,Protein: specify,Whole virus,Novel other: specify,NCT01669512,"Open, not recruiting",USAMRMC,Government,9/1/2012,11/1/2016,2/1/2017,Adult,100,United States of America,Results reported in peer-reviewed journal,7/1/2017,28719287,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Dengue,Phase 2,2,TV003/ TV005,Active candidate / in development,Recombinant viral vector,Protein: specify,Whole virus or PrM + E,None,NCT01709019,"Open, not recruiting",Butantan,Industry,10/1/2013,4/1/2016,12/1/2018,Adult,300,Brazil,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Dengue,Phase 1,1,TDENV-PIV,Active candidate / in development,Inactivated whole target organism,Protein: specify,Whole virus,Novel other: specify,NCT01728792,Completed,USAMRMC,Government,11/1/2012,12/1/2016,12/1/2019,Adult,100,Puerto Rico,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Dengue,Phase 1,1,TDV,Active candidate / in development,Recombinant viral vector,Protein: specify,Whole virus or PrM + E,None,NCT01739036,Completed,Takeda,Industry,1/1/2013,11/1/2013,11/1/2013,Adult,80,United States of America,Results reported in registry,,,clinicaltrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Dengue,Phase 1,1,TDV,Active candidate / in development,Recombinant viral vector,Protein: specify,Whole virus or PrM + E,None,NCT01799954,Completed,Takeda,Industry,2/1/2013,6/1/2014,6/1/2014,Adult,67,United States of America,Results reported in registry,,,clinicaltrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Dengue,Phase 1,1,TV003/ TV005,Active candidate / in development,Recombinant viral vector,Protein: specify,Whole virus or PrM + E,None,NCT01813071,Completed,NIAID,Government,1/1/2013,3/1/2015,6/1/2016,Adult,48,United States of America,Results reported in peer-reviewed journal,2/16/2016,26908742,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Dengue,Phase 1,1,rDEN2Δ30-7169,Inactive / no longer in development,"Live, attenuated target organism",Protein: specify,Whole virus,None,NCT01937455,Completed,NIAID,Government,6/1/2013,12/1/2014,5/1/2015,Adult,14,United States of America,Results reported in peer-reviewed journal,9/28/2015,26424605,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Dengue,Phase 2,2,CYD-TDV,Registered,Recombinant viral vector,Protein: specify,PrM + E,None,NCT01954563,Completed,Sanofi Pasteur,Industry,9/1/2013,3/1/2016,3/1/2016,Adult,90,United States of America,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Dengue,Phase 1,1,TV003/ TV005,Active candidate / in development,Recombinant viral vector,Protein: specify,Whole virus or PrM + E,None,NCT02038842,Completed,NIAID,Government,11/1/2013,3/1/2015,12/1/2015,Adult,48,United States of America,Results reported in peer-reviewed journal,3/16/2016,27089205,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Dengue,Phase 2,2,TDV,Active candidate / in development,Recombinant viral vector,Protein: specify,Whole virus or PrM + E,None,NCT02218125,Completed,Takeda,Industry,7/1/2014,5/1/2015,5/1/2015,Adult,1002,United States of America,Results reported in registry,,,clinicaltrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Dengue,Phase 1,1,PIV & LAV Prime-boost,Research Tool,Prime-boost: specify,Protein: specify,Whole virus,Aluminum salts (alum),NCT02259608,Completed,USAMRMC,Government,11/1/2014,12/1/2016,12/1/2019,Adult,80,United States of America,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Dengue,Phase 2,2,TDV,Active candidate / in development,Recombinant viral vector,Protein: specify,Whole virus or PrM + E,None,NCT02315703,"Open, not recruiting",Takeda,Industry,12/1/2014,7/1/2019,7/1/2019,Child,1800,Dominican Republic | Panama | Philippines,Results reported in peer-reviewed journal,6/1/2017,28365225,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Dengue,Phase 1,1,TV003/ TV005,Active candidate / in development,Recombinant viral vector,Protein: specify,Whole virus or PrM + E,None,NCT02334462,Completed,NIAID,Government,12/1/2014,11/1/2016,11/1/2016,Adult,48,United States of America,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Dengue,Phase 2,2,TV003/ TV005,Active candidate / in development,Recombinant viral vector,Protein: specify,Whole virus or PrM + E,None,NCT02360475,"Open, recruiting",NIAID,Government,11/1/2014,8/1/2018,8/1/2018,Child | Adult,266,Thailand,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Dengue,Phase 1,1,"rDEN1Δ30, rDEN2Δ30-7169",Research Tool,"Live, attenuated target organism",Protein: specify,Whole virus,None,NCT02414828,"Open, not recruiting",NIAID,Government,5/1/2015,12/1/2017,12/1/2017,Adult,12,United States of America,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Dengue,Phase 3,3,TV003/ TV005,Active candidate / in development,Recombinant viral vector,Protein: specify,Whole virus or PrM + E,None,NCT02419391,"Open, recruiting",Butantan,Industry,2/1/2016,5/1/2018,11/1/2022,Child | Adult,16944,Brazil,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Dengue,Phase 2,2,TDENV-PIV,Active candidate / in development,Inactivated whole target organism,Protein: specify,Whole virus,Novel other: specify,NCT02445963,"Open, recruiting",USAMRMC,Government,8/1/2015,6/1/2017,6/1/2017,Adult,140,United States of America,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Dengue,Phase 2,2,TDV,Active candidate / in development,Recombinant viral vector,Protein: specify,Whole virus or PrM + E,None,NCT02447432,"Open, not recruiting",Takeda,Industry,6/1/2015,8/1/2017,8/1/2017,Adult,400,Singapore,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Dengue,Phase 1,1,Recombinant live attenuated trivalent dengue vaccine,Research Tool,Recombinant viral vector,Protein: specify,Whole virus or PrM + E,None,NCT02458092,Completed,NIAID,Government,9/1/2015,11/1/2016,11/1/2016,Adult,24,United States of America,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Dengue,Phase 1,1,V180/TV003/TV005,Inactive / no longer in development,Prime-boost: specify,Protein: specify,Whole virus or PrM + E,Aluminum salts (alum),NCT02482636,Completed,NIAID,Government,4/1/2015,10/1/2015,10/1/2015,Adult,20,United States of America,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Dengue,Phase 2,2,CYD-TDV,Registered,Recombinant viral vector,Protein: specify,PrM + E,None,NCT02646371,"Open, not recruiting",Sanofi Pasteur,Industry,4/1/2016,1/1/2019,8/1/2019,Child | Adult,252,Brazil | Colombia | Honduras | Mexico | Puerto Rico,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Dengue,Phase 2,2,CYD-TDV,Registered,Recombinant viral vector,Protein: specify,PrM + E,None,NCT02654080,"Open, not recruiting",Sanofi Pasteur,Industry,5/1/2016,2/1/2020,7/1/2020,Child | Adult,1050,Colombia | Philippines,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Dengue,Phase 2,2,TV003/ TV005,Active candidate / in development,Recombinant viral vector,Protein: specify,Whole virus or PrM + E,None,NCT02711735,"Open, not recruiting",NIAID,Government,3/1/2016,2/1/2020,2/1/2020,Child | Adult,192,Bangladesh,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Dengue,Phase 1,1,rDEN3Δ30,Research Tool,"Live, attenuated target organism",Protein: specify,Whole virus,None,NCT02712424,Completed,NIAID,Government,Unspecified,7/1/2016,7/1/2016,Adult,14,United States of America,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Dengue,Phase 2,2,CYD-TDV,Registered,Recombinant viral vector,Protein: specify,PrM + E,None,NCT02788227,Not yet open,Sanofi Pasteur,Industry,3/1/2017,5/1/2019,5/1/2019,Adult,150,Brazil,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Dengue,Phase 3,3,TDV,Active candidate / in development,Recombinant viral vector,Protein: specify,Whole virus or PrM + E,None,NCT02794870,"Open, recruiting",Takeda,Industry,9/1/2016,6/1/2018,12/1/2021,Child,20100,Brazil | Colombia | Dominican Republic | Nicaragua | Panama | Philippines | Sri Lanka | Thailand | Viet Nam,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Dengue,Phase 2,2,CYD-TDV,Registered,Recombinant viral vector,Protein: specify,PrM + E,None,NCT02864628,"Open, recruiting",Sanofi Pasteur,Industry,7/1/2016,9/1/2018,12/1/2018,Child | Adult,260,Singapore,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Dengue,Phase 1,1,TV003/ TV005,Active candidate / in development,Recombinant viral vector,Protein: specify,Whole virus or PrM + E,None,NCT02891980,"Open, recruiting",NIAID,Government,Unspecified,6/1/2017,12/1/2017,Adult,48,United States of America,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Dengue,Phase 1,1,TV003/ TV005,Active candidate / in development,Recombinant viral vector,Protein: specify,Whole virus or PrM + E,None,NCT02914184,"Open, recruiting",NIAID,Government,2/1/2016,9/1/2017,3/1/2019,Adult,28,United States of America,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Dengue,Phase 2,2,TDV,Active candidate / in development,Recombinant viral vector,Protein: specify,Whole virus or PrM + E,None,NCT02987972,Not yet open,Takeda,Industry,3/1/2017,7/1/2017,8/1/2020,Child,200,Panama | Philippines,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Dengue,Phase 3,3,CYD-TDV,Registered,Recombinant viral vector,Protein: specify,PrM + E,None,NCT03026348,"Open, recruiting",Sanofi Pasteur,Industry,11/1/2016,10/1/2018,10/1/2018,Child,480,Mexico,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Dengue,Phase 3,3,CYD-TDV,Registered,Recombinant viral vector,Protein: specify,PrM + E,None,NCT03049488,Not yet open,Sanofi Pasteur,Industry,12/1/2016,3/1/2019,3/1/2019,Child | Adult,688,Philippines,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Dengue,Phase 3,3,CYD-TDV,Registered,Recombinant viral vector,Protein: specify,PrM + E,None,NCT03069703,Not yet open,Sanofi Pasteur,Industry,12/1/2016,10/1/2018,10/1/2018,Child,528,Malaysia,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Dengue,Phase 1,1,PIV & LAV Prime-boost,Inactive / no longer in development,Prime-boost: specify,Protein: specify,Whole virus,Novel other: specify,NCT03163121,Withdrawn,USAMRMC,Government,1/1/2016,4/1/2017,4/1/2018,Adult,0,United States of America,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Dengue,Phase 1,1,PIV & LAV F17 Prime-boost,Active candidate / in development,Prime-boost: specify,Protein: specify,Whole virus,Aluminum salts (alum),NCT03191383,Not yet open,USAMRMC,Government,7/1/2018,1/1/2020,1/1/2022,Adult,40,United States of America,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Dengue,Phase 3,3,TDV,Active candidate / in development,Recombinant viral vector,Protein: specify,Whole virus or PrM + E,None,PACTR201105000289276,Not yet open,Takeda,Industry,11/29/2017,6/16/2018,11/28/2018,Child,400,Mexico,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Dengue,Phase 3,3,TDV,Active candidate / in development,Recombinant viral vector,Protein: specify,Whole virus or PrM + E,None,PACTR201403000646306,Not yet open,Takeda,Industry,11/27/2017,3/7/2018,2/5/2019,Adult,900,United States of America,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Ebola,Phase 1,1,VRC-EBODNA012-00-VP,Active candidate / in development,DNA,"Protein: EBOV GP, SUDV GP, EBOV NP","Glycoprotein, nucleoprotein",None,NCT00072605,"Completed, published",NIAID/ NIH CC,Government,10/30/2003,,8/1/2007,Adult,27,USA,Results reported in peer-reviewed journal,9/20/2006,https://www.ncbi.nlm.nih.gov/pubmed/16988008,clinicaltrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Ebola,Phase 1,1,VRC-EBOADV018-00-VP,Active candidate / in development,Recombinant viral vector,"Protein: EBOV GP, SUDV GP",Glycoprotein,None,NCT00374309,"Completed, published",NIAID/ NIH CC,Government,9/5/2006,,5/5/2009,Adult,48,USA,Results reported in peer-reviewed journal,10/27/2010,http://www.sciencedirect.com/science/article/pii/S0264410X10015070,clinicaltrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Ebola,Phase 1,1,VRC-EBODNA023-00-VP,Active candidate / in development,DNA,"Protein: EBOV GP, SUDV GP",Glycoprotein,None,NCT00605514,"Completed, published",NIAID/ NIH CC,Government,1/25/2008,6/21/2010,6/21/2010,Adult,20,USA,Results reported in peer-reviewed journal,9/14/2014,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4318920/,clinicaltrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Ebola,Phase 1,1,VRC-EBODNA023-00-VP,Active candidate / in development,DNA,"Protein: EBOV GP, SUDV GP",Glycoprotein,None,NCT00999739,"Completed, published",NIAID,Government,2/1/2010,4/1/2012,4/1/2012,Adult,108,Uganda,Results reported in peer-reviewed journal,12/23/2014,http://www.sciencedirect.com/science/article/pii/S0140673614623850,clinicaltrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Ebola,Phase 1,1,ChAd3-EBO-Z,Active candidate / in development,Recombinant viral vector,Protein: EBOV GP,Glycoprotein,None,NCT02247726,"Completed, published",NIAID/ NIH CC,Government,8/27/2014,4/5/2017,4/5/2017,Adult,50,USA,Results reported in peer-reviewed journal,3/9/2017,http://www.nejm.org/doi/full/10.1056/NEJMoa1410863,clinicaltrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Ebola,Phase 1,1,VRC-EBOADC069-00-VP (ChAd3),Active candidate / in development,Recombinant viral vector,"Protein: EBOV GP, SUDV GP",Glycoprotein,None,NCT02252640,"Completed, published",NIAID/ NIH CC,Government,8/27/2014,4/5/2017,4/5/2017,Adult,50,USA,Results reported in peer-reviewed journal,3/9/2017,http://www.nejm.org/doi/full/10.1056/NEJMoa1410863,clinicaltrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Ebola,Phase 1,1,ChAd3-EBO-Z & MVA-BN-Filo,Active candidate / in development,Recombinant viral vector,"Protein: EBOV GP, SUDV GP, MARV GP, TAFV NP","Glycoprotein, nucleoprotein",None,NCT02266628,"Open, not recruiting",University of Oxford,Academic,9/17/2014,8/1/2017,8/1/2017,Adult,92,UK,Results reported in peer-reviewed journal,4/28/2016,https://www.ncbi.nlm.nih.gov/pubmed/25629663,clinicaltrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Ebola,Phase 1,1,ChAd3-EBO-Z & MVA-BN-Filo,Active candidate / in development,Recombinant viral vector,"Protein: EBOV GP, SUDV GP",Glycoprotein,None,NCT02283099,"Open, not recruiting",University of Maryland,Academic,10/1/2014,4/1/2016,6/1/2018,Adult,91,Mali,Results reported in peer-reviewed journal,11/3/2015,https://www.ncbi.nlm.nih.gov/pubmed/26546548,clinicaltrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Ebola,Phase 1,1,rVSV-ZEBOV,Active candidate / in development,Recombinant viral vector,Protein: EBOV GP,Glycoprotein,None,NCT02285036,"Completed, published",Merck,Industry,10/1/2014,8/1/2015,8/1/2015,Adult,39,USA,Results reported in peer-reviewed journal,1/26/2017,https://www.ncbi.nlm.nih.gov/pubmed/25830322,clinicaltrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Ebola,Phase 1,1,rVSV-ZEBOV,Active candidate / in development,Recombinant viral vector,Protein: EBOV GP,Glycoprotein,None,NCT02289027,"Completed, published",Merck,Industry,10/1/2014,12/1/2015,12/1/2015,Adult,39,USA,Results reported in peer-reviewed journal,1/26/2017,https://www.ncbi.nlm.nih.gov/pubmed/25830322,clinicaltrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Ebola,Phase 1,1,rVSV-ZEBOV,Active candidate / in development,Recombinant viral vector,Protein: EBOV GP,Glycoprotein,None,NCT02289820,"Completed, published",Universitätsklinikum Hamburg-Eppendorf,Academic,11/1/2014,11/1/2015,11/1/2015,Adult,30,Germany,Results reported in peer-reviewed journal,4/5/2017,http://www.ebiomedicine.com/article/S2352-3964(17)30141-X/fulltext,clinicaltrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Ebola,Phase1/2,1.5,rVSV-ZEBOV,Active candidate / in development,Recombinant viral vector,Protein: EBOV GP,Glycoprotein,None,NCT02296541,"Completed, unpublished",University of Geneva,Academic,11/1/2014,4/1/2015,1/1/2016,Adult,115,Switzerland,Interim results reported,,,clinicaltrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Ebola,Phase 1/2,1.5,ChAd3-EBO-Z,Active candidate / in development,Recombinant viral vector,Protein: EBOV GP,Glycoprotein,None,NCT02296983,"Completed, published",Centre Hospitalier Universitaire Vaudois,Academic,10/1/2014,6/1/2015,6/1/2015,Adult,120,Switzerland,Results reported in peer-reviewed journal,12/22/2015,https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT02289027,clinicaltrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Ebola,Phase 1,1,rVSV-ZEBOV,Active candidate / in development,Recombinant viral vector,Protein: EBOV GP,Glycoprotein,None,NCT02313077,"Open, not recruiting",University of Oxford,Academic,12/1/2014,2/1/2016,9/1/2016,Adult,40,Kenya,Interim results reported,,,clinicaltrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Ebola,Phase 1,1,Ad26-ZEBOV & MVA-BN-Filo,Active candidate / in development,Recombinant viral vector,"Protein: EBOV GP, SUDV GP, MARV GP, TAFV NP","Glycoprotein, nucleoprotein",None,NCT02325791,"Completed, published",Crucell Holland BV,Industry,12/17/2014,4/17/2015,3/15/2016,Adult,87,UK,Results reported in peer-reviewed journal,4/19/2016,https://www.ncbi.nlm.nih.gov/pubmed/27092831?dopt=Abstract,clinicaltrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Ebola,Phase 1,1,rVSV-ZEBOV,Active candidate / in development,Recombinant viral vector,Protein: EBOV GP,Glycoprotein,None,NCT02326194,"Completed, published",Merck,Industry,12/5/2014,6/23/2016,6/23/2016,Adult,512,USA,Results reported in peer-reviewed journal,6/9/2017,http://www.thelancet.com/journals/laninf/article/PIIS1473-3099(17)30313-4/fulltext,clinicaltrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Ebola,Phase 1,1,Ad26-ZEBOV & MVA-BN-Filo,Active candidate / in development,Recombinant viral vector,"Protein: EBOV GP, SUDV GP, MARV GP, TAFV NP","Glycoprotein, nucleoprotein",None,NCT02337270,"Completed, unpublished",Janssen Vaccines & Prevention B.V.,Industry,1/8/2015,7/2/2015,5/8/2017,Adult,164,USA,Interim results reported,,,clinicaltrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Ebola,Phase 1,1,Ad5-EBOV,Active candidate / in development,Recombinant viral vector,Protein: EBOV GP,Glycoprotein,None,NCT02354404,"Completed, published",Jiangsu Province CDCP,Government,12/1/2014,2/1/2015,7/1/2015,Adult,120,China,Results reported in peer-reviewed journal,12/22/2016,https://www.ncbi.nlm.nih.gov/pubmed/28017642,clinicaltrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Ebola,Phase 2,2,rVSV-ZEBOV,Active candidate / in development,Recombinant viral vector,Protein: EBOV GP,Glycoprotein,None,NCT02368119,"Open, not recruiting",NIAID,Government,1/20/2015,6/1/2016,6/1/2020,Adult,1500,Liberia,Results reported in both peer-reviewed journal & registry,10/13/2017,https://www.ncbi.nlm.nih.gov/pubmed/29020589?dopt=Abstract,clinicaltrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Ebola,Phase 2,2,ChAd3-EBO-Z,Active candidate / in development,Recombinant viral vector,Protein: EBOV GP,Glycoprotein,None,NCT02370589,"Open, not recruiting",NIAID,Government,1/20/2015,6/1/2016,6/1/2020,Adult,1500,Liberia,Results reported in both peer-reviewed journal & registry,10/13/2017,https://www.ncbi.nlm.nih.gov/pubmed/29020589?dopt=Abstract,clinicaltrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Ebola,Phase 1,1,"ChAd3-EBO-Z, VRC-EBOADC069-00-VP (ChAd3) & VRC-EBOMVA079-00-VP (MVA-EbolaZ) boost",Active candidate / in development,Recombinant viral vector,"Protein: EBOV GP or EBOV GP, SUDV GP",Glycoprotein,None,NCT02374385,"Open, not recruiting",NIAID,Government,1/1/2015,1/1/2017,6/1/2017,Adult,90,Uganda,Results not yet reported,,,clinicaltrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Ebola,Phase 1,1,ChAd3-EBO-Z & MVA-BN-Filo,Active candidate / in development,Recombinant viral vector,"Protein: EBOV GP, SUDV GP, MARV GP, TAFV NP","Glycoprotein, nucleoprotein",None,NCT02376426,"Completed, unpublished",University of Maryland,Academic,3/1/2015,9/27/2016,9/27/2016,Adult,60,Mali,Results not yet reported,,,clinicaltrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Ebola,Phase 1,1,EBOV GP nanoparticle,Active candidate / in development,Recombinant subunit (VLP),Protein: EBOV GP,Glycoprotein,Licensed other: specify,NCT02378207,"Completed, unpublished",Novavax,Industry,2/1/2015,4/1/2016,4/1/2016,Adult,230,Australia,Interim results reported,,,clinicaltrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Ebola,Phase 1,1,rVSV-ZEBOV,Active candidate / in development,Recombinant viral vector,Protein: EBOV GP,Glycoprotein,None,NCT02378753,"Completed, published",Dalhousie University,Academic,11/1/2014,3/1/2015,6/1/2015,Adult,40,Canada,Results reported in peer-reviewed journal,6/19/2017,https://www.ncbi.nlm.nih.gov/pubmed/28630358,clinicaltrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Ebola,Phase 1,1,Ad26-ZEBOV & MVA-BN-Filo,Active candidate / in development,Recombinant viral vector,"Protein: EBOV GP, SUDV GP, MARV GP, TAFV NP","Glycoprotein, nucleoprotein",None,NCT02389322,"Completed, unpublished",Crucell Holland BV,Industry,4/1/2015,12/1/2015,9/1/2016,Adult,78,"Tanzania, Uganda",Results not yet reported,,,clinicaltrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Ebola,Phase 1,1,Ad26-ZEBOV & MVA-BN-Filo,Active candidate / in development,Recombinant viral vector,"Protein: EBOV GP, SUDV GP, MARV GP, TAFV NP","Glycoprotein, nucleoprotein",None,NCT02391415,"Completed, unpublished",Crucell Holland BV,Industry,3/1/2015,9/1/2015,6/1/2016,Adult,72,Kenya,Interim results reported,,,clinicaltrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Ebola,Phase 2/3,2.5,rVSV-ZEBOV,Active candidate / in development,Recombinant viral vector,Protein: EBOV GP,Glycoprotein,None,NCT02401373,"Completed, unpublished",CDC,Government,4/1/2015,11/8/2016,12/5/2016,Adult,8651,Sierra Leone,Results reported in peer-reviewed journal,,,clinicaltrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Ebola,Phase 1,1,Ad5-EBOV,Active candidate / in development,Recombinant viral vector,Protein: EBOV GP,Glycoprotein,None,NCT02416453,"Completed, published",First Affiliated Hospital of Zhejiang University,Academic,3/1/2015,7/1/2015,7/1/2015,Adult,61,China,Results reported in peer-reviewed journal,7/14/2017,http://www.tandfonline.com/doi/abs/10.1080/21645515.2017.1342021?journalCode=khvi20,clinicaltrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Ebola,Phase 1,1,ChAd3-EBO-Z & MVA-BN-Filo,Active candidate / in development,Recombinant viral vector,"Protein: EBOV GP, SUDV GP, MARV GP, TAFV NP","Glycoprotein, nucleoprotein",None,NCT02420444,"Completed, unpublished",NIAID,Government,3/26/2015,4/6/2017,4/6/2017,Adult,64,USA,Results not yet reported,,,clinicaltrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Ebola,Phase 2,2,Ad26-ZEBOV & MVA-BN-Filo,Active candidate / in development,Recombinant viral vector,"Protein: EBOV GP, SUDV GP, MARV GP, TAFV NP","Glycoprotein, nucleoprotein",None,NCT02430506,"Open, not recruiting",Janssen Vaccines & Prevention B.V.,Industry,6/15/2015,11/17/2017,11/17/2017,Adult,408,"France, UK",Results not yet reported,,,clinicaltrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Ebola,Phase 1,1,ChAd3-EBO-Z & MVA-BN-Filo,Active candidate / in development,Recombinant viral vector,"Protein: EBOV GP, SUDV GP, MARV GP, TAFV NP","Glycoprotein, nucleoprotein",None,NCT02485301,"Open, not recruiting",University of Oxford,Academic,4/1/2015,8/1/2017,8/1/2017,Adult,38,UK,Interim results reported,,,clinicaltrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Ebola,Phase 1,1,"INO-4212, with & without INO-9012",Active candidate / in development,DNA,Protein: EBOV GP,Glycoprotein,None,NCT02491463,"Open, not recruiting",Inovio Pharmaceuticals,Industry,5/1/2015,5/1/2018,7/1/2018,Adult,240,USA,Interim results reported,,,clinicaltrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Ebola,Phase 2,2,ChAd3-EBO-Z,Active candidate / in development,Recombinant viral vector,Protein: EBOV GP,Glycoprotein,None,NCT02503202,"Completed, unpublished",GSK,Industry,7/1/2015,12/1/2016,12/1/2016,Adult,3024,"Cameroon, Mali, Nigeria, Senegal",Interim results reported,,,clinicaltrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Ebola,Phase 1,1,ChAd3-EBO-Z & MVA-BN-Filo,Active candidate / in development,Recombinant viral vector,"Protein: EBOV GP, SUDV GP, MARV GP, TAFV NP","Glycoprotein, nucleoprotein",None,NCT02503839,"Completed, unpublished",University of Oxford,Academic,7/1/2015,1/1/2016,1/1/2016,Adult,40,Senegal,Results not yet reported,,,clinicaltrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Ebola,Phase 1,1,ChAd3-EBO-Z & Ad26-ZEBOV,Active candidate / in development,Recombinant viral vector,Protein: EBOV GP,Glycoprotein,None,NCT02509494,"Open, not recruiting",University of Oxford,Academic,9/1/2015,12/1/2017,12/1/2017,Adult,32,UK,Results not yet reported,,,clinicaltrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Ebola,Phase 3,3,rVSV-ZEBOV,Active candidate / in development,Recombinant viral vector,Protein: EBOV GP,Glycoprotein,None,NCT02531685,"Completed, published",Merck,Industry,8/17/2015,5/2/2016,9/29/2017,Adult,1198,"Canada, Spain, US",Results reported in peer-reviewed journal,5/26/2017,https://www.ncbi.nlm.nih.gov/pubmed/28549145?dopt=Abstract,clinicaltrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Ebola,Phase 3,3,Ad26-ZEBOV & MVA-BN-Filo,Active candidate / in development,Recombinant viral vector,"Protein: EBOV GP, SUDV GP, MARV GP, TAFV NP","Glycoprotein, nucleoprotein",None,NCT02533791,"Open, recruiting",Janssen Vaccines & Prevention B.V.,Industry,9/30/2015,5/3/2019,5/13/2019,"Child, Adult",1019,Sierra Leone,Results not yet reported,,,clinicaltrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Ebola,Phase 1,1,Ad5-EBOV,Active candidate / in development,Recombinant viral vector,Protein: EBOV GP,Glycoprotein,None,NCT02548078,"Completed, published",Jiangsu Province CDCP,Government,7/1/2015,9/1/2015,10/1/2015,Adult,110,China,Results reported in peer-reviewed journal,12/22/2016,https://www.ncbi.nlm.nih.gov/pubmed/28017642?dopt=Abstract,clinicaltrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Ebola,Phase 3,3,Ad26-ZEBOV & MVA-BN-Filo,Active candidate / in development,Recombinant viral vector,"Protein: EBOV GP, SUDV GP, MARV GP, TAFV NP","Glycoprotein, nucleoprotein",None,NCT02561871,"Completed, unpublished",Crucell Holland BV,Industry,9/1/2015,1/1/2016,7/1/2016,Adult,329,USA,Results not yet reported,,,clinicaltrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Ebola,Phase 3,3,Ad26-ZEBOV & MVA-BN-Filo,Active candidate / in development,Recombinant viral vector,"Protein: EBOV GP, SUDV GP, MARV GP, TAFV NP","Glycoprotein, nucleoprotein",None,NCT02564523,"Completed, unpublished",Janssen Vaccines & Prevention B.V.,Industry,9/21/2015,6/7/2016,11/29/2016,Adult,525,USA,Results not yet reported,,,clinicaltrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Ebola,Phase 2,2,ChAd3-EBO-Z,Active candidate / in development,Recombinant viral vector,Protein: EBOV GP,Glycoprotein,None,NCT02572388,"Completed, unpublished",GSK,Industry,11/9/2015,5/15/2017,5/15/2017,Child,600,"Mali, Senegal",Results not yet reported,,,clinicaltrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Ebola,Phase 2,2,Ad26-ZEBOV & MVA-BN-Filo,Active candidate / in development,Recombinant viral vector,"Protein: EBOV GP, SUDV GP, MARV GP, TAFV NP","Glycoprotein, nucleoprotein",None,NCT02575456,"Open, recruiting",Janssen Vaccines & Prevention B.V.,Industry,11/6/2015,1/21/2019,7/21/2019,"Child, Adult",1056,"Burkina Faso, Cote D'Ivoire, Kenya, Uganda",Results not yet reported,,,clinicaltrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Ebola,Phase 1,1,HPIV3-EbovZ,Active candidate / in development,Recombinant viral vector,Protein: EBOV GP,Glycoprotein,None,NCT02584816,"Completed, unpublished",NIAID,Government,8/1/2015,11/1/2016,11/1/2016,Adult,30,USA,Interim results reported,,,clinicaltrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Ebola,Phase 2,2,Ad5-EBOV,Active candidate / in development,Recombinant viral vector,Protein: EBOV GP,Glycoprotein,None,NCT02601612,"Completed, published",Jiangsu Province CDCP,Government,10/1/2015,6/1/2016,7/1/2016,Adult,500,Sierra Leone,Results reported in peer-reviewed journal,12/22/2016,http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)32617-4/fulltext,clinicaltrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Ebola,Phase 2,2,Ad26-ZEBOV & MVA-BN-Filo,Active candidate / in development,Recombinant viral vector,"Protein: EBOV GP, SUDV GP, MARV GP, TAFV NP","Glycoprotein, nucleoprotein",None,NCT02613520,"Open, recruiting",Janssen Vaccines & Prevention B.V.,Industry,12/10/2015,8/3/2018,12/28/2018,Adult,575,"USA, Kenya, Mozambique, Nigeria, Tanzania, Uganda",Results not yet reported,,,clinicaltrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Ebola,Phase 3,3,Ad26-ZEBOV & MVA-BN-Filo,Active candidate / in development,Recombinant viral vector,"Protein: EBOV GP, SUDV GP, MARV GP, TAFV NP","Glycoprotein, nucleoprotein",None,NCT02685020,"Open, recruiting",Janssen Vaccines & Prevention B.V.,Industry,5/31/2016,5/1/2022,4/11/2023,"Child, Adult",5500,"USA, Kenya, UK, Burkina Fasa, Cote d'Ivoire, France, Mozambique, Nigeria, Tanzania, Uganda, Sierra Leone",Results not yet reported,,,clinicaltrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Ebola,Phase 1,1,rVSVN4CT1-EBOVGP1,Active candidate / in development,Recombinant viral vector,Protein: EBOV GP,Glycoprotein,None,NCT02747927,"Completed, unpublished",Profectus Biosciences,Industry,12/22/2015,9/15/2016,9/15/2016,Adult,38,USA,Interim results reported,,,clinicaltrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Ebola,Phase 2,2,rVSV-ZEBOV,Active candidate / in development,Recombinant viral vector,Protein: EBOV GP,Glycoprotein,None,NCT02824198,"Open, recruiting",NIAID/ NIH CC,Government,1/12/2016,10/31/2021,10/31/2022,Adult,7,USA,Results not yet reported,,,clinicaltrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Ebola,Phase 1,1,Ad26-ZEBOV & MVA-BN-Filo,Active candidate / in development,Recombinant viral vector,"Protein: EBOV GP, SUDV GP, MARV GP, TAFV NP","Glycoprotein, nucleoprotein",None,NCT02879266,"Open, not recruiting",Janssen Vaccines & Prevention B.V.,Industry,8/1/2016,5/1/2017,1/1/2018,Adult,72,USA,Results not yet reported,,,clinicaltrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Ebola,Phase 2,2,rVSV-ZEBOV,Active candidate / in development,Recombinant viral vector,Protein: EBOV GP,Glycoprotein,None,NCT02905019,"Open, recruiting",NIAID,Government,3/31/2017,3/1/2019,3/1/2019,"Child, Adult",5500,"Guinea, Liberia",Results not yet reported,,,clinicaltrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Ebola,Phase 2,2,Ad26-ZEBOV & MVA-BN-Filo,Active candidate / in development,Recombinant viral vector,"Protein: EBOV GP, SUDV GP, MARV GP, TAFV NP","Glycoprotein, nucleoprotein",None,NCT02907216,"Open, recruiting",NIAID,Government,3/31/2017,3/1/2019,3/1/2019,"Child, Adult",5500,"Guinea, Liberia",Results not yet reported,,,clinicaltrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Ebola,Phase 1,1,Ad26-ZEBOV & MVA-BN-Filo,Active candidate / in development,Recombinant viral vector,"Protein: EBOV GP, SUDV GP, MARV GP, TAFV NP","Glycoprotein, nucleoprotein",None,NCT02925403,Not yet open,NIAID,Government,,1/5/2018,,Adult,60,USA,Results not yet reported,,,clinicaltrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Ebola,Phase 4,4,GamEvac-Combi (VSV-GP & Ad5-GP),Active candidate / in development,Recombinant viral vector,Protein: EBOV GP,Glycoprotein,None,NCT02927873,"Open, recruiting","Gamaleya Research Institute of Epidemiology & Microbiology, Health Ministry of the Russian Federation",Government,10/1/2016,12/1/2017,12/1/2017,Adult,60,Russia,Results not yet reported,,,clinicaltrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Ebola,Phase 1,1,rVSV-ZEBOV,Active candidate / in development,Recombinant viral vector,Protein: EBOV GP,Glycoprotein,None,NCT02952339,"Open, recruiting","University Hospital, Geneva",Other,11/1/2016,1/1/2020,4/1/2020,Adult,100,Switzerland,Results not yet reported,,,clinicaltrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Ebola,Phase 2,2,rVSV-ZEBOV,Active candidate / in development,Recombinant viral vector,Protein: EBOV GP,Glycoprotein,None,NCT03098628,Not yet open,Dalhousie University,Academic,6/30/2017,1/1/2019,12/1/2019,"Child, Adult",200,"Canada, Burkina Faso, Senegal",Results not yet reported,,,clinicaltrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Ebola,Phase 4,4,GamEvac-Combi (VSV-GP & Ad5-GP),Active candidate / in development,Recombinant viral vector,Protein: EBOV GP,Glycoprotein,None,NCT03140774,"Open, recruiting","Gamaleya Research Institute of Epidemiology & Microbiology, Health Ministry of the Russian Federation",Government,8/1/2017,6/1/2019,7/1/2019,Adult,2000,"Guinea, Russia",Results not yet reported,,,clinicaltrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Ebola,Phase 1,1,Ad26-ZEBOV & MVA-BN-Filo,Active candidate / in development,Recombinant viral vector,"Protein: EBOV GP, SUDV GP, MARV GP, TAFV NP","Glycoprotein, nucleoprotein",None,NCT03181789,"Open, not recruiting",University of Oxford,Academic,5/17/2017,10/31/2017,10/31/2018,Adult,56,UK,Results not yet reported,,,clinicaltrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Ebola,Phase 3,3,rVSV-ZEBOV,Active candidate / in development,Recombinant viral vector,Protein: EBOV GP,Glycoprotein,None,NCT03227029,"Open, not recruiting",Epicentre,Other,10/1/2017,12/1/2017,3/31/2018,Adult,500,Uganda,Results not yet reported,,,clinicaltrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Ebola,Phase 1/2,1.5,GamEvac-Combi (VSV-GP & Ad5-GP),Active candidate / in development,Recombinant viral vector,Protein: EBOV GP,Glycoprotein,None,PACTR201411000919191,Completed,"Gamaleya Research Institute of Epidemiology & Microbiology, Health Ministry of the Russian Federation",Government,9/16/2015,,11/30/2015,Adult,84,Russia,Results reported in peer-reviewed journal,2/2/2017,https://www.ncbi.nlm.nih.gov/pubmed/28152326,www.pactr.org,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Ebola,Phase 1,1,rVSV-ZEBOV,Active candidate / in development,Recombinant viral vector,Protein: EBOV GP,Glycoprotein,None,,"Open, not recruiting",Universitaetsklinikum Tuebingen,Academic,11/21/2014,,7/31/2016,Adult,155,Gabon,Results reported in peer-reviewed journal,10/6/2017,http://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1002402,www.pactr.org,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Ebola,Phase 3,3,rVSV-ZEBOV,Active candidate / in development,Recombinant viral vector,Protein: EBOV GP,Glycoprotein,None,,"Completed, published",WHO,Other,3/7/2015,,1/20/2016,"Child, Adult",8851,Guinea,Results reported in peer-reviewed journal,12/22/2016,http://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(15)61117-5.pdf,www.pactr.org,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
E.coli,Phase 3,3,LT patch,Inactive / no longer in development,Recombinant subunit (non VLP),Protein: specify,LT,None,EUCTR2008-008726-75-DE,"Open, not recruiting","Intercell USA, Inc.",Industry,6/16/2009,4/12/2011,4/12/2011,Adult,2400,GER; GTM; MEX; GBR,Results reported in registry,1/15/2017,https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-008726-75/results,ClinicalTrialsRegister.eu,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
E.coli,Phase 2b,2,ETVAX,Active candidate / in development,Inactivated whole target organism,Protein: specify,"CFA/I, CS3, CS5, CS6, B subunit",Novel other: specify,EUCTR2016-002690-35-FI,"Open, recruiting",Scandinavian Biopharma AB,Industry,,,,Adult,800,BEN; FIN,Results not yet reported,,,ClincalTrialsRegoster.edu,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
E.coli,Phase 1,1,BB01,Inactive / no longer in development,"Live, attenuated target organism",Protein: specify,CFA/I,None,ISRCTN05087777,Completed,Berna Biotech Ltd.,Industry,5/13/2005,1/13/2006,1/13/2006,Adult,50,CHE,Results not yet reported,,,isrctn.com,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
E.coli,Phase 2,2,Dukoral,Registered,Inactivated whole target organism,Protein: specify,CTB,None,ISRCTN11806026,"Open, recruiting",University of Gothenburg,Academic,3/1/2016,6/1/2017,6/1/2017,Adult,60,SWE,Results not yet reported,,,isrctn.com,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
E.coli,Phase 1,1,ETVAX,Active candidate / in development,Inactivated whole target organism,Protein: specify,"CFA/I, CS3, CS5, CS6, B subunit",Novel other: specify,ISRCTN23764070,Completed,University of Gothenburg,Academic,12/5/2010,1/6/2011,1/6/2011,Adult,60,SWE,Results not yet reported,,,isrctn.com,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
E.coli,Phase 1,1,ETVAX,Active candidate / in development,Inactivated whole target organism,Protein: specify,"LCTBA, CFA/I, CS3, CS5, CS6",Novel other: specify,ISRCTN27096290,Completed,University of Gothenburg,Academic,12/1/2013,6/1/2014,6/1/2014,Adult,60,SWE,Results not yet reported,,,isrctn.com,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
E.coli,Phase 1,1,ETVAX,Active candidate / in development,Inactivated partial (split) target organism,Protein: specify,"CFA/I, CS3, CS5, CS6, B subunit",Novel other: specify,ISRCTN91363076,Completed,University of Gothenburg,Academic,3/8/2012,3/1/2013,3/1/2013,Adult,120,SWE,Results reported in peer-reviewed journal,12/14/2014,https://www.ncbi.nlm.nih.gov/pubmed/25444830,isrctn.com,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
E.coli,Phase 2b,2,LT Patch,Inactive / no longer in development,Recombinant subunit (non VLP),Protein: specify,LT,None,NCT00516659,Completed,"Intercell USA, Inc.",Industry,5/1/2006,1/1/2007,12/1/2007,Adult,201,"USA, GTM, MEX",Results reported in peer-reviewed journal,6/14/2008,https://www.ncbi.nlm.nih.gov/pubmed/1855471,ClinicalTrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
E.coli,Phase 1,1,Peru-15-pCTB,Inactive / no longer in development,"Live, attenuated target organism",Carbohydrate: specify,LPS,None,NCT00656409,Completed,NIAID,Government,6/1/2008,5/1/2010,12/1/2010,Adult,62,USA,Results reported in peer-reviewed journal,1/22/2015,https://www.ncbi.nlm.nih.gov/pubmed/2541020,ClinicalTrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
E.coli,Phase 1,1,ACE527,Active candidate / in development,"Live, attenuated target organism",Protein: specify,"CFA/I, CS1-3, CS5, CS6, B subunit",Novel other: specify,NCT00907777,Completed,TD Vaccines A/S,Industry,6/1/2009,11/1/2009,11/1/2009,Adult,36,USA,Results not yet reported,,,ClinicalTrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
E.coli,Phase 3,3,LT patch,Inactive / no longer in development,Recombinant subunit (non VLP),Protein: specify,LT,None,NCT00995813,Completed,"Intercell USA, Inc.",Industry,10/1/2009,11/1/2010,4/1/2011,Adult,2036,"GER, GTM, MEX, GBR",Results reported in peer-reviewed journal,3/1/2014,https://www.ncbi.nlm.nih.gov/pubmed/24291168,ClinicalTrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
E.coli,Phase 2,2,LT patch,Inactive / no longer in development,Recombinant subunit (non VLP),Protein: specify,LT,None,NCT01061658,Completed,"Intercell USA, Inc.",Industry,12/1/2009,6/1/2010,12/1/2010,Adult,723,"GER, IND, GBR",Results not yet reported,,,ClinicalTrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
E.coli,Phase 2,2,ACE527,Active candidate / in development,"Live, attenuated target organism",Protein: specify,"CFA/I, CS1-3, CS5, CS6, B subunit",Novel other: specify,NCT01069471,Completed,TD Vaccines A/S,Industry,3/1/2010,10/1/2010,10/1/2010,Adult,70,USA,Results not yet reported,,,ClinicalTrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
E.coli,Phase 1,1,dmLT,Active candidate / in development,Recombinant subunit (non VLP),Protein: specify,LT,None,NCT01153841,Completed,NIAID,Government,9/1/2010,6/1/2012,6/1/2012,Adult,36,USA,Results reported in peer-reviewed journal,11/20/2013,https://www.ncbi.nlm.nih.gov/pubmed/24049109,ClinicalTrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
E.coli,Phase 1,1,dscCfaE,Active candidate / in development,Recombinant subunit VLP (fusion),Protein: specify,CFA/I,Novel other: specify,NCT01411241,Completed,US Army Medical Research & Material Commad,Government,7/1/2011,8/1/2012,4/1/2013,Adult,40,USA,Results not yet reported,,,ClinicalTrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
E.coli,Phase 1,1,dsc14CfaE-sCTA2/LTB5,Active candidate / in development,Recombinant subunit VLP (fusion),Protein: specify,CFA/I,Novel other: specify,NCT01654263,Unknown,US Army Medical Research & Material Commad,Government,8/1/2012,11/1/2016,11/1/2017,Adult,57,USA,Results not yet reported,,,ClinicalTrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
E.coli,Phase 2b,2,ACE527,Active candidate / in development,"Live, attenuated target organism",Protein: specify,"CFA/I, CS1-3, CS5, CS6, B subunit",Novel other: specify,NCT01764126,Completed,PATH,Other,9/1/2012,10/1/2013,1/1/2014,Adult,57,USA,Results not yet reported,,,ClinicalTrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
E.coli,Phase 2b,2,dscCfaE,Active candidate / in development,Recombinant subunit VLP (fusion),Protein: specify,CFA/I,Novel other: specify,NCT01931358,Completed,US Army Medical Research & Material Commad,Government,9/19/2013,2/6/2016,7/14/2016,Adult,56,USA,Results not yet reported,,,ClinicalTrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
E.coli,Phase 1,1,dmLT,Active candidate / in development,Recombinant subunit (non VLP),Protein: specify,LT,None,NCT02063555,Completed,NIAID,Government,3/10/2014,11/2/2016,11/2/2016,Adult,80,USA,Results not yet reported,,,ClinicalTrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
E.coli,Phase 1,1,dmLT,Active candidate / in development,Recombinant subunit (non VLP),Protein: specify,LT,None,NCT02543268,"Open, recruiting",NIAID,Government,6/2/2016,7/7/2018,12/29/2018,Adut,99,USA,Results not yet reported,,,ClinicalTrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
E.coli,Other: Phase1/2,1.5,ETVAX,Active candidate / in development,Inactivated whole target organism,Protein: specify,"CFA/I, CS3, CS5, CS6, B subunit",Novel other: specify,NCT02543567,Completed,PATH,Other,10/1/2015,7/15/2017,7/15/2017,"Child, Adult",500,BGD,Results not yet reported,,,ClinicalTrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
E.coli,Phase 3,3,ETEC/rCTB,Inactive / no longer in development,Inactivated whole target organism,Protein: specify,"CFA/I, CS1, CS2, CS3, CS4, CS5",None,NCT02572635,Completed,US Army Medical Research & Material Commad,Government,10/1/1998,3/1/2001,4/1/2002,Child,356,EGY,Results not yet reported,,,ClinicalTrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
HIV-1,Phase 1,1,VRC-HIVADV038-00-VP; VRC-HIVADV027-00-VP,Active candidate / in development,Recombinant viral vector,Protein: specify,Ad35 Env A; Ad5 Env A,None,NCT00479999,Completed,NIAID,Government,1/2/2009,1/5/2014,,Adult,35,United States of America,Results reported in peer-reviewed journal,Peer-reviewed publication or journal,11/15/2016,27846256,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
HIV-1,Phase 1,1,Ad26.EnvA-01,Active candidate / in development,Recombinant viral vector,Protein: specify,Env A,None,NCT00621322,Completed,NIAID,Government,1/2/2008,1/7/2011,10/1/2015,Adult,60,United States of America,Results reported in peer-reviewed journal,Peer-reviewed publication or journal,11/2/2012,23125443,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
HIV-1,Phase 1,1,Ad5HVR48.ENVA.01,Active candidate / in development,Recombinant viral vector,Protein: specify,Env A,None,NCT00703066,Completed,NIAID,Government,1/2/2009,1/12/2012,,Adult,48,United States of America,Results reported in peer-reviewed journal,Peer-reviewed publication or journal,4/8/2014,24719474,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
HIV-1,Phase 2b,2,DNA multiclade + rAd5 multiclade,Active candidate / in development,"Recombinant viral vector
Other: DNA",Conjugate,"gag-pol, env; rAD5",None,NCT00866242,"Active, not recruiting",DAIDS,Government,1/6/2009,8/4/2018,,Adult,2504,US,Results reported in peer-reviewed journal,,http://www.ncbi.nlm.nih.gov/pubmed/24099601,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
HIV-1,Phase 2b,2,DNA multiclade + rAd5 multiclade,Active candidate / in development,"Recombinant viral vector;
Other: DNA",Conjugate,,None,NCT00962780,Completed,DAIDS,Government,1/9/2011,21/11/2017,,Adult,17,US,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
HIV-1,Phase 1,1,rAd35 clade A + rAd5 clade A + rAd clade B,Active candidate / in development,Recombinant viral vector,Conjugate,env; rAd,None,NCT01107587,Completed,DAIDS,Government,1/10/2010,4/4/2017,,Adult,180,US,Results reported in peer-reviewed journal,15/02/16,http://www.ncbi.nlm.nih.gov/pubmed/26475930,clinicaltrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
HIV-1,Phase 1,1,Ad26.EnvA-01,Active candidate / in development,Recombinant viral vector,Protein: specify,Env A,None,NCT01113281,Completed,NIAID,Government,1/7/2010,1/9/2012,,Adult,24,United States of America,Results reported in peer-reviewed journal,Peer-reviewed publication or journal,8/26/2014,25165165,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
HIV-1,Phase 1b,1,rAd5 multiclade + rAd5 clade B,Active candidate / in development,Recombinant viral vector,Conjugate,"gag-pol, env gag-pol; rAd5",None,NCT01171963,Completed,DAIDS,Government,1/3/2011,30/05/2017,,Adult,100,"US, Brazil, Peru, Switzerland",Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
HIV-1,Phase 1,1,PENNVAX-G DNA MVA CRF01_AE,Active candidate / in development,"Recombinant viral vector
DNA",Protein: specify,"Env, gag-pol",Novel other: specify,NCT01266850,Completed,NIAID,Government,1/8/2014,1/2/2016,2/1/2016,Adult,88,United States of America,Results reported in peer-reviewed journal,Peer-reviewed publication or journal,2/9/2017,28968759,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
HIV-1,Phase 1,1,"ALVAC-HIV (vCP1521)
AIDSVAX® B/E",Active candidate / in development,Recombinant viral vector; Recombinant subunit (non VLP),Protein: specify,"Gag, protease, env",,NCT01441167,Completed,USAMRMC,Government,1/8/2015,1/11/2017,11/1/2017,Adult,94,United States of America,Results reported in both peer-reviewed journal & registry,Peer-reviewed publication or journal,2/24/2017,28235027,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
HIV-1,Phase 1b,1,rAd5 multiclade,Active candidate / in development,Recombinant viral vector,Conjugate,gag-pol/env; rAd5,None,NCT01488890,"Active, not recruiting",DAIDS,Government,1/2/2012,17/01/2018,,Adult,90,US,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
HIV-1,Phase 1,1,DNA clade B + rVSVIN clade B,Active candidate / in development,"Recombinant viral vector 
DNA",Protein,,None,NCT01605786,Completed,DAIDS/NIAID/NIH,Government,1/5/2012,5/9/2016,,Adult,100,US,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
HIV-1,Phase 1,1,AIDSVAX® B/E + DNA clade C +NYVAC clade C,Active candidate / registered,Subunit from target organism; DNA; Recombinant viral vector,Protein,,Aluminum salts (alum),NCT01816113,Completed,EuroVacc Foundation,Other: non-profit,1/8/2012,5/7/2018,,Adult,96,Switzerland,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
HIV-1,Phase 1,1,DNA - CN54ENV & ZM96GPN; CN54gp140; MVA-C,Active candidate / in development,"DNA; Recombinant viral vector; Subunit (e.g., toxoid, carbohydrate) from target organism",Protein: specify,"DNA Gag, Pol, Nef C; MVA Gag, Pol, Nef C; Protein Enc C",Novel other: specify,NCT01931176,Completed,Imperial College London,Academic,1/6/2013,1/1/2014,12/1/2015,Adult,40,United Kingdom of Great Britain & Northern Ireland,Results reported in peer-reviewed journal,Peer-reviewed publication or journal,2/22/2017,28275375,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
HIV-1,Phase 2,2,"ALVAC-HIV (vCP1521)
AIDSVAX® B/E",Active candidate / in development,Recombinant viral vector; Recombinant subunit (non VLP),Protein: specify,"Gag, protease, env",,NCT01939158,"Open, not recruiting",USAMRMC,Government,1/9/2013,1/11/2016,2/1/2017,Adult,360,Thailand,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
HIV-1,Phase 2,2,AIDSVAX® B/E,Active candidate / in development,Recombinant subunit (non VLP),Protein: specify,Env,Novel other: specify,NCT01942174,Completed,USAMRMC,Government,1/7/2014,1/12/2016,2/1/2017,Adult,40,Thailand,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
HIV-1,Phase 1,1,AAV1-PG9,Active candidate / in development,Other: Vectored Immunoprophylaxis,Other: specify,NA,None,NCT01943825,"Open, recruiting",IAVI,Product Development Partner,1/9/2014,1/10/2017,10/1/2017,Adult,24,United Kingdom of Great Britain & Northern Ireland,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
HIV-1,Phase 1,1,CN54gp140,Active candidate / in development,"Subunit (e.g., toxoid, carbohydrate) from target organism",Protein: specify,Env C,Novel other: specify,NCT01979900,Completed,Imperial College London,Academic,1/10/2013,1/11/2015,11/1/2015,Adult,14,United Kingdom of Great Britain & Northern Ireland,Results reported in peer-reviewed journal,Peer-reviewed publication or journal,24/05/17,https://www.frontiersin.org/articles/10.3389/fimmu.2017.00595/full,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
HIV-1,Phase 1,1,Ad4-EnvC150; Ad4-mgag,Active candidate / in development,Recombinant viral vector,Protein: specify,mosaic Env,None,NCT02013687,"Open, recruiting",NIAID,Government,30/10/2013,1/1/2019,1/1/2020,Adult,440,United States of America,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
HIV-1,Phase 2,2,LIPO-5; MVA-B; GTU-MultiHIV,Active candidate / in development,"DNA; Recombinant virall vector; Subunit (e.g., toxoid, carbohydrate) from target organism",Protein: specify,"Gag, Nef, Pol B; MVA Nef, Gag, Pol B; DNA Rev, Nef, Tat, Pol, Env B",None,NCT02052934,Completed,Inserm. ANRS,Government,1/3/2014,1/10/2015,3/1/2016,Adult,92,France,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
HIV-1,Phase 1,1,GTU®-multiHIV B clade,Active candidate / in development,Other: DNA,Protein: specify,"Rev, Nef, Tat, p17, p24 , Pro, RT, Env B",None,NCT02083887,Unknown,Imperial College London,Academic,1/6/2013,1/6/2015,12/1/2015,Adult,30,United Kingdom of Great Britain & Northern Ireland,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
HIV-1,Phase 2,2,"pSG2.HIVconsv DNA, MVA.HIVconsv & Ad35-GRIN",Active candidate / in development,"Subunit (e.g., toxoid, carbohydrate) from target organism",Protein: specify,"MVA consensus; DNA consensus; Ad35 Gag, RT, Integ, Nef A",None,NCT02114255,Completed,University of Oxford,Academic,1/3/2014,1/8/2015,8/1/2015,Adult,72,United States of America,Results reported in peer-reviewed journal,Peer-reviewed publication or journal,7/8/2015,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4529153/,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
HIV-1,Phase 1,1,VRC01 mAb,Active candidate / in development,Other: monoclonal antibody,Protein,VRC01 mAb,None,NCT02181088,Completed,DAIDS/NIAID/NIH,Government,1/9/2014,5/3/2016,,Adult,88,US,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
HIV-1,Phase 2,2,AIDSVAX® B/E,Active candidate / in development,Recombinant subunit (non VLP),Protein: specify,Env,Novel other: specify,NCT02193061,Completed,USAMRMC,Government,1/7/2014,1/12/2016,2/1/2017,Adult,40,Thailand,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
HIV-1,Phase 1b,1,"DNA clade C + AIDSVAX® B/E (Subtypes B, E gp120)",Active candidate / registered,,Other,,,NCT02231866,Completed,DAIDS,Government,1/7/2014,,,Adult,104,US,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
HIV-1,Phase 1,1,MVA Mosaic,Active candidate / in development,Recombinant viral vector,Protein: specify,gag/pol/env mosaics,None,NCT02239614,Completed,Crucell Holand BV,Industry,1/9/2014,1/11/2015,11/1/2015,Adult,25,United States of America,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
HIV-1,Phase 1,1,DNA Nat-B env + DNA Consensus-S env + Trivalent DNA mosaic env + MVA-CMDR,Active candidate / in development,"Recombinant viral vector;
DNA",Congugate,"MVA, env, gag, pol",None,NCT02308540,"Active, not recruiting",DAIDS,Government,15/01/2015,8/9/2020,,Adult,105,"US, Switzerland",Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
HIV-1,Phase 1,1,gp140,Active candidate / in development,"Subunit (e.g., toxoid, carbohydrate) from target organism",Protein: specify,Env,Aluminum salts (alum),NCT02317900,Completed,Crucell Holand BV,Industry,1/12/2014,1/4/2016,4/1/2016,Adult,50,United States of America,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
HIV-1,Phase 2,2,"Ad26.ENVA.01 
MVA Mosaic 1 & 2 gp140 DP",Active candidate / in development,Recombinant viral vector,Protein: specify,"gag, pol, env",Novel other: specify,NCT02332733,"Open, not recruiting",Crucell Holand BV,Industry,1/12/2014,1/5/2016,9/1/2019,Adult,395,United States of America | Rwanda | South Africa | Thailand | Uganda,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
HIV-1,Phase 1,1,"ChAdV63.HIVconsv ; MVA.HIVconsv; AdCh3NSmut1;
MVA-Nsmut",Active candidate / in development,Recombinant viral vector,Protein: specify,ChimpAd63 consensus; MVA consensus; 3NSmut1;,None,NCT02375698,"Open, not recruiting",University of Oxford,Academic,1/10/2014,1/8/2016,10/1/2017,Adult,33,United Kingdom of Great Britain & Northern Ireland,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
HIV-1,Phase 1,1,rcAd26.MOS1.HIV-Env,Active candidate / in development,Recombinant viral vector,Protein: specify,mosaic Env,None,NCT02376400,Completed,IAVI,Product Development Partner,1/1/2015,1/6/2016,1/6/2016,Adult,22,United States of America,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
HIV-1,Phase 1/2,1.5,ALVAC-HIV(vCP2438) + Bivalent Subtype C + gp120/MF59,Active candidate / in development,"Recombinant protein from target organism; 
Recombinant viral vector with genes from target organism",Protein,"ZM96 gp120 env, TM of LAI gp41, LAI gag-pro; TV1.C gp120 Env & 1086.C gp120 Env",Licensed other,NCT02418962,"Active, not recruiting",DAIDS,Government,1/2/2015,13/08/2018,,Adult,252,South Africa,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
HIV-1,Phase 1,1,PENNVAX-GP,Active candidate / in development,Other: DNA,Other,DNA,Novel other,NCT02451891,"Active, not recruiting",DAIDS,Government,1/9/2015,1/1/2018,,Adult,94,US,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
HIV-1,Phase 2b,2,VRC01 mAb,Active candidate / in development,Other: Monoclonal antibody,Protein,VRC01 mAb,None,NCT02589795,Recruiting,DAIDS,Government,16/05/2016,1/6/2020,,Adult,1500,"Botswana, South Africa, Zimbabwe, Kenya, Malawi, Mozambique,Tanzania",Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
HIV-1,Phase 1,1,DNA-C CN54ENV; CN54gp140,Active candidate / in development,"Subunit (e.g., toxoid, carbohydrate) from target organism",Protein: specify,"DNA Env C, Subunit Env C",None,NCT02606526,"Open, recruiting",Imperial College London,Academic,1/11/2015,1/7/2017,12/1/2017,Adult,24,United Kingdom of Great Britain & Northern Ireland,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
HIV-1,Phase 1,1,"HIV nef/tat/vif, env DNA + VSV envC",Active candidate / in development,Other: DNA; Recombinant viral vector,Other,,None,NCT02678455,"Active, not recruiting",DAIDS,Government,16/04/2016,20/05/2019,,Adult,14,US,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
HIV-1,Phase 1,1,Ad26.Mos.HIV Trivalent; gp140 DP,Active candidate / in development,"Recombinant viral vector; Subunit (e.g., toxoid, carbohydrate) from target organism",Protein: specify,Ad26.Mos.1.Env + Ad26.Mos1.Gag-Pol + Ad26.Mos2.Gag-Pol; Clade C gp140,None,NCT02716675,"Open, not recruiting",Janssen Vaccines & Prevention B.V.,Industry,1/3/2016,1/1/2018,1/1/2018,Adult,36,US,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
HIV-1,Phase 2b,2,VRC01 mAb,Active candidate / in development,Other: Monoclonal antibody,Protein,VRC01 mAb,None,NCT02736240,Recruiting,DAIDS,Government,16/04/2016,1/7/2020,,Adult,2700,"Brazil, Peru, US, Switzerland",Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
HIV-1,Phase 1,1,FLSC-001,Active candidate / in development,"Subunit (e.g., toxoid, carbohydrate) from target organism",Protein: specify,Env B,None,NCT02797171,"Open, recruiting",University of Maryland,Academic,1/11/2015,1/7/2017,9/1/2017,Adult,60,United States of America,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
HIV-1,Phase 1,1,"Ad4 + AIDSVAX® B/E + Substypes B, E, gp120",Active candidate / registered,Recombinant viral vector; Subunit from target organism,Conjugate,,Aluminum salts (alum),NCT02797236,"Active, not recruiting",PaxVax,Industry,1/3/2015,25/02/2017,,Adult,60,US,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
HIV-1,Phase 1,1,Ad26.Mos.HIV Trivalent; Ad26.Mos4.HIV; gp140 DP,Active candidate / in development,"Recombinant viral vector; Subunit (e.g., toxoid, carbohydrate) from target organism",Protein: specify,Ad26.Mos.1.Env + Ad26.Mos1.Gag-Pol + Ad26.Mos2.Gag-Pol + Ad26.Mos.2.Env; Ad26.Mos.1.Env + Ad26.Mos1.Gag-Pol + Ad26.Mos2.Gag-Pol; Protein gp140 C,None,NCT02806284,"Open, recruiting",Janssen Vaccines & Prevention B.V.,Industry,1/7/2016,1/12/2017,5/1/2018,Adult,198,United States of America | Rwanda,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
HIV-1,Phase 1,1,VRC01 mAb + VRC01LS mAb,Active candidate / in development,Other: Monoclonal antiodies,Protein,"VRC01, VRC01LS monoclonal antibodies",None,NCT02852005,Recruiting,DAIDS,Government,1/3/2017,30/09/2019,,Adult,101,"US, South Africa",Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
HIV-1,Phase 1,1,AIDSVAX® B/E + MVA/HIV62B,Active candidate / registered,Subunit from target organism; Recombinant viral vector,Protein,,Aluminum salts (alum),NCT02876328,Recruiting,DAIDS,Government,1/1/2017,31/07/2019,,Adult,30,"Peru, US",Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
HIV-1,Phase 1/2a,1.5,DNA Clade C + Bivalent Subtype C gp120/MF59 + Bivalent Subtype C gp120/AS01B,Active candidate / in development,Other: DNA; Subunit from target organism,Other,,Licensed other,NCT02933931,Recruiting,DAIDS,Government,1/12/2016,1/10/2019,,Adult,334,"US, South Africa",Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
HIV-1,Phase 2b/3,2.5,ALVAC-HIV (vCP2438) + Bivalent Subtype C gp120/MF59,Active candidate / in development,"Recombinant protein from target organism;
Recombinant viral vector with genes from target organism",Protein,"ZM96 gp120 env, TM of LAI gp41, LAI gag-pro; TV1.C gp120 Env & 1086.C gp120 Env",Licensed other,NCT02997969,Recruiting,DAIDS,Government,1/10/2016,24/08/2021,,Adult,5400,South Africa,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
HIV-1,Phase 1,1,DNA Clade C + Bivalent Subtype C gp120/MF59,Active candidate / in development,Subunit from target organism; Other: DNA,Other,,Licensed other,NCT03072030,"Active, not recruiting",DAIDS,Government,1/6/2016,1/7/2018,,Adult,132,"South Africa, Zambia, Tanzania",Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
HIV-1,Phase 1,1,p24CE 1/2 DNA + p55 Gag DNA,Active candidate / in development,Other: DNA,Other,DNA,Novel other,NCT03303625,Not yet recruiting,DAIDS,Government,1/10/2017,1/9/2019,,Adult,56,US,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
HIV-1,Phase 1/2a,1.5,ALVAC-HIV (vCP 2438) + Bivalent Subtype C gp120 with MF59 (2 schedules),Active candidate / in development,"Recombinant protein from target organism;
Recombinant viral vector with genes from target organism",Protein,"ZM96 gp120 env, TM of LAI gp41, LAI gag-pro; TV1.C gp120 Env & 1086.C gp120 Env",Licensed other,No. 0373100043215000055,Recruiting,DAIDS,Government,1/3/2017,1/5/2019,,Adult,132,"Mozambique, South Africa, Zimbabwe",Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
HIV-1,Phase 1,1,gp145,Active candidate / in development,Subunit from target organism,Protein,Env,Aluminum salts (alum),PACTR201411000934120,Not yet recruiting,DAIDS,Government,1/11/2017,,,Adult,24,US,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
HIV-1,Phase 1,1,"Env (A, B, C, E)/Gag DNA plasmids + Recombinant gp120 (A, B, C, E) protein",Active candidate / in development,"Other: DNA
Subunit from target organism",Other,,GLA-SE,PACTR201503001057193,Not yet recruiting,DAIDS,Government,1/12/2017,,,Adult,60,US,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Malaria,Phase 1,1,3D7-KAHRP-KO GAP parasite vaccine,Active candidate / in development,Other: Genetically attenuated,Other: specify,Whole parasite with CS protein,None,ACTRN12617000824369,"Open, not recruiting",National Health & Medical Research Council,Government,8/22/2017,,,Adult,6,Australia,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Malaria,Phase 1,1,SE36,Active candidate / in development,Recombinant subunit (non VLP),Protein: specify,N-terminal domain of serine repeat antigen (SERA5),Aluminum salts (alum),ISRCTN71619711,Completed,"Research Foundation for Microbial Diseases of Osaka University, Japan",Academic,9/22/2009,4/21/2010,4/21/2010,Child | Adult,140,Uganda,Results reported in peer-reviewed journal,5/28/2013,23724021,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Malaria,Phase 1,1,GMZ2,Active candidate / in development,Recombinant subunit (non VLP),Protein: specify,"GLURP, MSP3",Novel other: specify,NCT00424944,Unknown,AMANET,Product Development Partner,6/1/2007,7/1/2008,8/1/2008,Adult,40,Gabon,Results reported in peer-reviewed journal,9/24/2010,20696154,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Malaria,Phase 1,1,AMA1-C1,Inactive / no longer in development,Recombinant subunit (non VLP),Protein: specify,AMA | C1,Novel other: specify,NCT00427167,Completed,National Institute of Allergy & Infectious Diseases (NIAID),Government,1/23/2007,11/5/2008,11/5/2008,Adult,300,United States of America,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Malaria,Phase 1,1,AMA1-FVO [25-545],Inactive / no longer in development,Recombinant subunit (non VLP),Protein: specify,AMA-1,None,NCT00431808,Unknown,African Malaria Network Trust,Product Development Partner,5/1/2007,6/1/2008,6/1/2008,Adult,40,Mali,Results reported in peer-reviewed journal,8/30/2016,27577237,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Malaria,Phase 2b,2,"RTS,S/AS01",Active candidate / in development,Recombinant subunit (non VLP),Protein: specify,CSP,Novel other: specify,NCT00436007,Completed,GSK,Industry,4/1/2007,10/1/2009,10/1/2009,Child,511,Gabon | Ghana | United Republic of Tanzania,Results reported in both peer-reviewed journal & registry,2/13/2015,25885325,clinicaltrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Malaria,Phase 2,2,"RTS,S/AS01",Active candidate / in development,Recombinant subunit (non VLP),Protein: specify,CSP,Novel other: specify,NCT00443131,Completed,GSK,Industry,3/1/2007,7/1/2007,7/1/2007,Adult,36,Belgium,Results reported in peer-reviewed journal,6/24/2014,25424924,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Malaria,Phase 1,1,MSP3 [181-276] field,Active candidate / in development,Other: synthetic peptide,Protein: specify,MSP3,Aluminum salts (alum),NCT00452088,Completed,European Vaccine Initiative,Product Development Partner,4/1/2007,5/1/2008,5/1/2008,Child,45,Burkina Faso,Results reported in peer-reviewed journal,10/26/2009,19855847,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Malaria,Phase 2b,2,FMP2.1/AS02A (AMA-1 3D7 E. coli-expressed in AS02 adjuvant),Inactive / no longer in development,Recombinant subunit (non VLP),Protein: specify,AMA-1,Novel other: specify,NCT00460525,Completed,U.S. Army Medical Research & Materiel Command,Government,5/1/2007,7/1/2009,7/1/2009,Child,400,Mali,Results reported in both peer-reviewed journal & registry,9/15/2011,21916638,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Malaria,Phase 1,1,MSP3 [181-276] field,Active candidate / in development,Other: synthetic peptide,Protein: specify,MSP3,Aluminum salts (alum),NCT00469651,Completed,AMANET,Product Development Partner,10/1/2007,8/1/2008,8/1/2008,Child,45,United Republic of Tanzania,Results reported in peer-reviewed journal,7/17/2009,19607731,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Malaria,Phase 1,1,AMA1-C1/ ISA720,Inactive / no longer in development,Recombinant subunit (non VLP),Protein: specify,MSP-1,Novel other: specify,NCT00487916,Completed,National Institute of Allergy & Infectious Diseases (NIAID),Government,6/13/2007,2/5/2009,2/5/2009,Adult,150,Australia,Results reported in peer-reviewed journal,3/2/2011,20051276,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Malaria,Phase 2,2,LSA-3-rec,Inactive / no longer in development,,,LSA3,Novel other: specify,NCT00509158,Completed,Radboud University,Academic,10/1/2007,10/1/2008,10/1/2008,Adult,36,Netherlands,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Malaria,Phase 1,1,"CSP, AMA1 virosomes (PEV 301,302)",Inactive / no longer in development,Other: virosomal,Other: specify,AMA-1 & CS mimotopes,None,NCT00513669,Completed,Swiss Tropical & Public Health Institute,Academic,1/1/2008,3/1/2009,3/1/2009,Child | Adult,50,United Republic of Tanzania,Results reported in peer-reviewed journal,7/22/2011,21799810,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Malaria,Phase 2b,2,MSP3 [181-276] field,Active candidate / in development,Other: synthetic peptide,Protein: specify,MSP3,Aluminum salts (alum),NCT00652951,Completed,AMANET,Product Development Partner,5/1/2008,11/1/2010,12/1/2010,Child,378,Mali,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Malaria,Phase 1,1,FMP010,Inactive / no longer in development,Recombinant subunit (non VLP),Protein: specify,MSP-1,Novel other: specify,NCT00676091,Completed,U.S. Army Medical Research & Materiel Command,Government,4/1/2008,12/1/2008,6/1/2009,Adult,26,United States of America | Kenya,Results reported in peer-reviewed journal,1/23/2013,23342996,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Malaria,Phase 1,1,GMZ2,Active candidate / in development,Recombinant subunit (non VLP),Protein: specify,"GLURP, MSP3",Novel other: specify,NCT00707798,Unknown,AMANET,Product Development Partner,6/1/2008,7/1/2009,8/1/2009,Child,30,Gabon,Results reported in peer-reviewed journal,7/28/2011,21829466,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Malaria,Phase 1,1,AMA1-C1,Inactive / no longer in development,Recombinant subunit (non VLP),Protein: specify,AMA | C1,Novel other: specify,NCT00740155,Completed,National Institute of Allergy & Infectious Diseases (NIAID),Government,8/11/2008,6/9/2009,6/9/2009,Child,200,Mali,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Malaria,Phase 3,3,"RTS,S/AS01",Active candidate / in development,Recombinant subunit (non VLP),Protein: specify,CSP,Novel other: specify,NCT00870987,Completed,GSK,Industry,3/1/2009,3/1/2011,1/1/2014,Child,15459,Burkina Faso | Gabon | Ghana | Kenya | Malawi |Mozambique | United Republic of Tanzania,Results reported in peer-reviewed journal,11/17/2011,22007715,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Malaria,Phase 2,2,NMRC-M3V-D/Ad- PfCA Prime/Boost,Inactive / no longer in development,Other: plasmid DNA & viral vector,Protein: specify,CPS | AMA-1,None,NCT00873431,Completed,U.S. Army Medical Research & Materiel Command,Government,5/1/2009,11/1/2016,11/1/2017,Adult,26,United States of America,Results reported in peer-reviewed journal,2/14/2013,23457473,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Malaria,Phase 1,1,BSAM-2,Inactive / no longer in development,Recombinant subunit (non VLP),Protein: specify,"BSAM-2 is a mixture of two MSP1 42 proteins, MSP1 42-FVO & MSP142-3D7; & two AMA1 proteins, AMA1-FVO & AMA1-3D7, mixed in a 1:1:1:1 ratio",Novel other: specify,NCT00890019,Completed,National Institute of Allergy & Infectious Diseases (NIAID),Government,4/23/2009,7/18/2012,7/18/2012,Adult,400,United States of America | Mali,Results reported in peer-reviewed journal,10/4/2012,23056238,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Malaria,Phase 1,1,ChAd63/MVA ME-TRAP,Active candidate / in development,Recombinant viral vector,Protein: specify,"TRAP + ME epitopes (CS, LSA1, LSA3, STARP, EXP1, pb9)",None,NCT00890760,Completed,University of Oxford,Academic,7/1/2007,8/1/2011,9/1/2011,Adult,54,United Kingdom of Great Britain & Northern Ireland,Results reported in peer-reviewed journal,3/1/2012,22275401,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Malaria,Phase 2,2,ChAd63/MVA ME-TRAP,Active candidate / in development,Recombinant viral vector,Protein: specify,"TRAP + ME epitopes (CS, LSA1, LSA3, STARP, EXP1, pb9)",None,NCT00891176,Completed,University of Oxford,Academic,3/1/2009,2/1/2010,2/1/2011,Adult,55,United Kingdom of Great Britain & Northern Ireland,Results reported in peer-reviewed journal,11/28/2013,24284865,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Malaria,Phase 2,2,AMA1-C1,Inactive / no longer in development,Recombinant subunit (non VLP),Protein: specify,AMA | C1,Novel other: specify,NCT00985465,Completed,University of Oxford,Academic,1/1/2010,9/1/2010,9/1/2010,Adult,8,United Kingdom of Great Britain & Northern Ireland,Results reported in peer-reviewed journal,7/22/2011,21799809,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Malaria,Phase 1,1,PfSPZ Vaccine,Inactive / no longer in development,Inactivated whole target organism,,,None,NCT01018459,Completed,Sanaria,Industry,4/1/2009,7/1/2010,9/1/2010,Adult,80,United States of America,Results reported in peer-reviewed journal,10/28/2011,21903775,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Malaria,Phase 2,2,ChAd63/MVA MSP1,Inactive / no longer in development,Recombinant viral vector,Protein: specify,MSP-1,None,NCT01025336,Completed,University of Oxford,Academic,11/1/2009,9/1/2010,9/1/2010,Adult,16,United Kingdom of Great Britain & Northern Ireland,Results reported in peer-reviewed journal,8/23/2011,21862998,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Malaria,Phase 1,1,Adenovirus (Ad35) vectored CS,Inactive / no longer in development,Recombinant viral vector,Protein: specify,CSP,None,NCT01026246,Completed,National Institute of Allergy & Infectious Diseases (NIAID),Government,4/1/2010,12/1/2011,12/1/2011,Adult,48,Burkina Faso,Results reported in peer-reviewed journal,11/11/2013,24244339,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Malaria,Phase 1,1,EBA175 RII,Inactive / no longer in development,Recombinant subunit (non VLP),Protein: specify,"EBA175 RII, non-glycosylated",None,NCT01030822,Completed,National Institute of Allergy & Infectious Diseases (NIAID),Government,6/1/2010,3/1/2012,3/1/2012,Adult,60,Ghana,Results reported in peer-reviewed journal,9/19/2016,27644034,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Malaria,Phase 1,1,ChAd63 AMA1/MVA AMA1,Inactive / no longer in development,Recombinant viral vector,Protein: specify,AMA-1,None,NCT01103687,Completed,University of Oxford,Academic,3/1/2010,10/1/2010,10/1/2010,Adult,16,United Kingdom of Great Britain & Northern Ireland,Results reported in peer-reviewed journal,2/21/2012,22363582,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Malaria,Phase 2,2,ChAd63/MVA ME-TRAP,Active candidate / in development,Recombinant viral vector,Protein: specify,"TRAP + ME epitopes (CS, LSA1, LSA3, STARP, EXP1, pb9)",None,NCT01151189,Completed,University of Oxford,Academic,6/1/2010,3/1/2011,3/1/2011,Adult,52,United Kingdom of Great Britain & Northern Ireland,Results reported in peer-reviewed journal,10/23/2012,23089736,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Malaria,Phase 3,3,"RTS,S/AS01",Active candidate / in development,Recombinant subunit (non VLP),Protein: specify,CSP,Novel other: specify,NCT01153893,Completed,GSK,Industry,7/1/2010,5/1/2013,5/1/2013,Child,200,Kenya,Results reported in peer-reviewed journal,7/7/2016,27394191,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Malaria,Phase 2,2,VMP001/AS01,Inactive / no longer in development,Recombinant subunit (non VLP),Protein: specify,CSP,Novel other: specify,NCT01169077,Completed,U.S. Army Medical Research & Materiel Command,Government,7/1/2010,5/1/2011,12/1/2011,Adult,48,United States of America,Results reported in peer-reviewed journal,2/26/2016,26919472,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Malaria,Phase 1,1,polyepitope DNA EP1300,Inactive / no longer in development,Other: DNA vaccine,Protein: specify,CSP | SSP2 | TRAP | LSA-1 | EXP-1,Novel other: specify,NCT01181856,Completed,National Institute of Allergy & Infectious Diseases (NIAID),Government,8/1/2010,7/1/2012,7/1/2012,Adult,39,United States of America,Results reported in peer-reviewed journal,11/4/2016,27697302,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Malaria,Phase 2,2,"RTS,S/AS01",Active candidate / in development,Recombinant subunit (non VLP),Protein: specify,CSP,Novel other: specify,NCT01262872,Completed,GSK,Industry,1/1/2011,4/1/2014,12/1/2014,Child,480,Malawi,Results reported in registry,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Malaria,Phase 3,3,"RTS,S/AS01",Active candidate / in development,Recombinant subunit (non VLP),Protein: specify,CSP,Novel other: specify,NCT01341704,Completed,GSK,Industry,5/1/2011,4/1/2012,4/1/2012,Child,327,Nigeria,Results reported in both peer-reviewed journal & registry,11/12/2014,25077418,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Malaria,Phase 2,2,MSP3-LSP,Unknown status,,,,Aluminum salts (alum),NCT01366534,Completed,Vac4All,Industry,5/1/2011,12/1/2011,3/1/2013,Child,800,Mali,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Malaria,Phase 1,1,ChAd63/AMA MVA/AMA1,Inactive / no longer in development,Recombinant viral vector,Protein: specify,AMA-1,Novel other: specify,NCT01369927,Completed,University of Oxford,Academic,6/1/2011,3/1/2013,3/1/2013,Adult,35,United Kingdom of Great Britain & Northern Ireland,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Malaria,Phase 1,1,ChAd63/MVA ME-TRAP,Active candidate / in development,Recombinant viral vector,Protein: specify,"TRAP + ME epitopes (CS, LSA1, LSA3, STARP, EXP1, pb9)",None,NCT01373281,Completed,University of Oxford,Academic,7/1/2011,7/1/2013,7/1/2013,Adult,39,United Kingdom of Great Britain & Northern Ireland,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Malaria,Phase 2,2,"Adenovirus (Ad35) vectored CS & RTS,S-AS01 in heterologous prime-boost regimen",Inactive / no longer in development,Recombinant viral vector,Protein: specify,CSP,Novel other: specify,NCT01373879,Completed,GSK,Industry,8/1/2011,2/1/2012,7/1/2012,Adult,68,United States of America,Results reported in both peer-reviewed journal & registry,7/6/2015,26148007,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Malaria,Phase 1,1,ChAd63/MVA ME-TRAP,Active candidate / in development,Recombinant viral vector,Protein: specify,"TRAP + ME epitopes (CS, LSA1, LSA3, STARP, EXP1, pb9)",None,NCT01375907,Completed,University of Oxford,Academic,6/1/2010,12/1/2011,12/1/2011,Child | Adult,52,Gambia,Results reported in peer-reviewed journal,3/19/2013,23526949,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Malaria,Phase 1,1,ChAd63/MVA ME-TRAP,Active candidate / in development,Recombinant viral vector,Protein: specify,"TRAP + ME epitopes (CS, LSA1, LSA3, STARP, EXP1, pb9)",None,NCT01399424,Completed,University of Oxford,Academic,6/1/2010,5/1/2011,5/1/2011,Adult,30,Kenya,Results reported in peer-reviewed journal,3/19/2013,23526949,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Malaria,Phase 2,2,Adenovirus (Ad26) vectored CS; Adenovirus (Ad35) vectored CS,Inactive / no longer in development,Recombinant viral vector,Protein: specify,CSP,None,NCT01414504,Completed,Crucell Holland BV,Industry,6/1/2011,5/1/2012,5/1/2012,Adult,36,United States of America,Interim results reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Malaria,Phase 1,1,Pfs25-EPA,Inactive / no longer in development,Recombinant subunit (non VLP),Protein: specify,Pfs25-EPA,Novel other: specify,NCT01436422,Completed,National Institute of Allergy & Infectious Diseases (NIAID),Government,8/1/2011,8/1/2013,8/1/2013,Adult,30,United States of America,Interim results reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Malaria,Phase 1,1,PfSPZ Vaccine,Active candidate / in development,Inactivated whole target organism,,,None,NCT01444001,Completed,Sanaria,Industry,9/14/2011,6/5/2013,6/5/2013,Adult,64,United States of America,Results reported in peer-reviewed journal,8/8/2013,23929949,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Malaria,Phase 1,1,CSVAC,Active candidate / in development,Recombinant viral vector,Protein: specify,CS,None,NCT01459198,Completed,University of Oxford,Academic,12/1/2011,10/1/2012,10/1/2012,Adult,24,Ireland,Results reported in peer-reviewed journal,12/18/2014,25522180,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Malaria,Phase 1,1,ChAd63/MVA ME-TRAP,Active candidate / in development,Recombinant viral vector,Protein: specify,"TRAP + ME epitopes (CS, LSA1, LSA3, STARP, EXP1, pb9)",None,NCT01477580,Completed,University of Oxford,Academic,10/1/2011,3/1/2013,3/1/2013,Child,72,Gambia,Results reported in peer-reviewed journal,8/24/2016,27109630,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Malaria,Phase 1,1,PfCelTOS FMP012,Active candidate / in development,Recombinant subunit (non VLP),Protein: specify,CelTOS (cell-traversal protein for ookinetes & sporozoites),Novel other: specify,NCT01550289,Completed,"Office of the Surgeon General, Department of the Army, USAMRMC",Government,2/1/2012,10/1/2012,12/1/2012,Adult,30,United States of America,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Malaria,Phase 2,2,PfPEBS,Active candidate / in development,Other: synthetic protein,Protein: specify,PfPEBS,Novel other: specify,NCT01619462,Unknown,Vac4All,Industry,5/1/2012,5/1/2013,8/1/2013,Adult,36,Switzerland,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Malaria,Phase 2,2,ChAd63/MVA (monovalent CS or ME-TRAP) in prime boost regimen,Inactive / no longer in development,Recombinant viral vector,Protein: specify,CS | ME-TRAP,None,NCT01644565,Completed,University of Oxford,Academic,4/1/2012,11/1/2012,11/1/2012,Adult,30,United Kingdom of Great Britain & Northern Ireland,Results reported in peer-reviewed journal,4/1/2015,25336730,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Malaria,Phase 2b,2,ChAd63/MVA ME-TRAP,Active candidate / in development,Recombinant viral vector,Protein: specify,"TRAP + ME epitopes (CS, LSA1, LSA3, STARP, EXP1, pb9)",None,NCT01646398,Completed,University of Oxford,Academic,11/1/2012,8/1/2014,9/1/2014,Child,730,Burkina Faso,Results reported in peer-reviewed journal,8/24/2016,27109630,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Malaria,Phase 2b,2,ChAd63/MVA ME-TRAP,Active candidate / in development,Recombinant viral vector,Protein: specify,"TRAP + ME epitopes (CS, LSA1, LSA3, STARP, EXP1, pb9)",None,NCT01669096,Completed,University of Oxford,Academic,8/1/2012,2/1/2013,2/1/2013,Adult,120,Senegal,Results reported in peer-reviewed journal,12/15/2016,27978537,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Malaria,Phase 2b,2,ChAd63/MVA ME-TRAP,Active candidate / in development,Recombinant viral vector,Protein: specify,"TRAP + ME epitopes (CS, LSA1, LSA3, STARP, EXP1, pb9)",None,NCT01683773,Completed,University of Oxford,Academic,3/1/2012,8/1/2012,8/1/2012,Adult,120,Kenya,Results reported in peer-reviewed journal,5/6/2015,25947165,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Malaria,Phase 1,1,ChAd63/MVA ME-TRAP,Active candidate / in development,Recombinant viral vector,Protein: specify,"TRAP + ME epitopes (CS, LSA1, LSA3, STARP, EXP1, pb9)",Novel other: specify,NCT01696422,Completed,University of Oxford,Academic,8/1/2012,12/1/2014,12/1/2014,Adult,23,United Kingdom of Great Britain & Northern Ireland,Results reported in peer-reviewed journal,10/27/2017,28941620,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Malaria,Phase 2,2,"ChAd63/MVA (multivalent CS, ME-TRAP or AMA-1) in prime-boost regimen",Inactive / no longer in development,Recombinant viral vector,Protein: specify,CS | ME-TRAP | AMA-1,None,NCT01755598,Completed,University of Oxford,Academic,1/1/2013,10/1/2013,10/1/2013,Adult,48,United Kingdom of Great Britain & Northern Ireland,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Malaria,Phase 1,1,ChAd63/MVA PvDBP,Active candidate / in development,Recombinant viral vector,Protein: specify,PvDBP_RII,None,NCT01847781,Completed,University of Oxford,Academic,4/1/2013,7/1/2014,7/1/2014,Adult,24,United Kingdom of Great Britain & Northern Ireland,Results not yet reported,6/15/2017,28614791,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Malaria,Phase 2,2,"RTS,S/AS01",Active candidate / in development,Recombinant subunit (non VLP),Protein: specify,CSP,Novel other: specify,NCT01867463,Completed,GSK,Industry,5/1/2013,3/1/2014,12/1/2014,Adult,64,United States of America,Results reported in peer-reviewed journal,9/1/2016,27296848,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Malaria,Phase 1,1,Pfs25-EPA,Active candidate / in development,Other: Pfs25 conjugated with EPA,,Pfs25,None,NCT01883609,Completed,National Institute of Allergy & Infectious Diseases (NIAID),Government,3/27/2013,12/22/2015,12/19/2016,Adult,350,United States of America | Mali,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Malaria,Phase 2,2,"RTS,S/AS01 + ChAd63 & MVA encoding ME-TRAP",Inactive / no longer in development,Recombinant subunit VLP (non-fusion),Protein: specify,ME-TRAP,Novel other: specify,NCT01905215,Completed,University of Oxford,Academic,9/1/2013,8/1/2014,8/1/2014,Adult,48,United Kingdom of Great Britain & Northern Ireland,Results reported in peer-reviewed journal,9/1/2016,27307573,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Malaria,Phase 1,1,P27A,Active candidate / in development,Other: synthetic peptide,Protein: specify,P27A,Novel other: specify,NCT01960686,Completed,Centre Hospitalier Universitaire Vaudois (CHUV),Academic,3/5/2014,7/1/2015,7/17/2015,Adult,56,Switzerland | Tanzania,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Malaria,Phase 1,1,PfSPZ Vaccine,Active candidate / in development,Inactivated whole target organism,,,None,NCT02013245,Completed,Sanaria,Industry,10/29/2013,8/20/2015,8/20/2015,Adult,450,Mali,Results reported in peer-reviewed journal,2/16/2017,28216244,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Malaria,Phase 2,2,Pfs25-VLP/Alhydrogel Fraunhofer,Active candidate / in development,Other: Pfs25 genetically fused to alfalfa mosiac virus coat protein,,Pfs25,Novel other: specify,NCT02017899,Completed,Fraunhofer USA,Industry,10/1/2013,8/1/2014,1/1/2015,Adult,44,United States of America,Results reported in registry,,,clinicaltrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Malaria,Phase 1,1,pfAMA1-DiCo,Active candidate / in development,Recombinant subunit (non VLP),Protein: specify,AMA1-DiCo,Novel other: specify,NCT02021968,Completed,Inserm,Government,1/6/2014,3/1/2015,7/27/2015,Adult,66,France | Burkina Faso,Results reported in peer-reviewed journal,10/27/2017,28947345,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Malaria,Phase 1,1,PfSPZ Vaccine,Active candidate / in development,Inactivated whole target organism,,,None,NCT02034500,Completed,Sanaria,Industry,12/12/2013,5/1/2015,9/8/2016,Adult,40,United States of America,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Malaria,Phase 2,2,PvCS N+C+R/PvCS N+C,Unknown status,,,,Novel other: specify,NCT02097472,Unknown,Malaria Vaccine & Drug Development Center,Industry,5/1/2014,5/1/2015,8/1/2015,Adult,32,Colombia,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Malaria,Phase 1,1,ChAd63/MVA ME-TRAP,Active candidate / in development,Recombinant viral vector,Protein: specify,"TRAP + ME epitopes (CS, LSA1, LSA3, STARP, EXP1, pb9)",None,NCT02099994,Completed,University of Oxford,Academic,2/1/2014,11/1/2015,11/1/2015,Child,65,Gambia,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Malaria,Phase 1,1,PfSPZ Vaccine,Active candidate / in development,Inactivated whole target organism,,,None,NCT02145000,Completed,Sanaria,Industry,4/1/2014,7/1/2015,8/1/2015,Adult,67,United Republic of Tanzania,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Malaria,Phase 1,1,PfCelTOS FMP012,Active candidate / in development,Recombinant subunit (non VLP),Protein: specify,CelTOS (cell-traversal protein for ookinetes & sporozoites),Novel other: specify,NCT02193087,"Open, not recruiting","Office of the Surgeon General, Department of the Army, USAMRMC",Government,8/1/2014,8/1/2019,9/1/2019,Adult,36,United States of America,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Malaria,Phase 1,1,ChAd63 RH5 +/- MVA RH5,Active candidate / in development,Recombinant viral vector,Protein: specify,RH5,None,NCT02207920,Completed,University of Oxford,Academic,8/1/2014,10/1/2015,10/1/2015,Adult,26,United Kingdom of Great Britain & Northern Ireland,Interim results reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Malaria,Phase 1,1,PfSPZ Vaccine,Active candidate / in development,Inactivated whole target organism,,,None,NCT02237209,Completed,Sanaria,Industry,6/1/2014,4/1/2015,6/1/2015,Adult,67,United States of America,Results reported in peer-reviewed journal,1/12/2017,28097230,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Malaria,Phase 2,2,"ChAd63/MVA (ME-TRAP) co-administered with RTS,S/AS01",Inactive / no longer in development,Recombinant viral vector,Protein: specify,ME-TRAP,Novel other: specify,NCT02269423,Completed,University of Oxford,Academic,1/1/2015,10/1/2015,10/1/2015,Adult,48,United Kingdom of Great Britain & Northern Ireland,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Malaria,Phase 1,1,"Pfs25-EPA + Pfs230-EPA / Alhydrogel LMIV, NIAID, NIH",Active candidate / in development,"Other: Pfs25M or Pf230D1M conjugated to EPA, respectively",,"Pfs25M, Pfs230D1M",Novel other: specify,NCT02362217,"Open, not recruiting",National Institute of Allergy & Infectious Diseases (NIAID),Government,12/10/2014,3/31/2016,9/30/2017,Adult,54,United States of America | Mali,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Malaria,Phase 1,1,PfSPZ Vaccine,Active candidate / in development,Inactivated whole target organism,,,None,NCT02431767,Completed,Sanaria,Industry,3/1/2015,9/1/2015,2/1/2016,Adult,33,Equitorial Guinea,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Malaria,Phase 1,1,FMP010,Inactive / no longer in development,Recombinant subunit (non VLP),Protein: specify,MSP-1,Novel other: specify,NCT02485912,Completed,U.S. Army Medical Research & Materiel Command,Government,4/1/2008,12/1/2008,6/1/2009,Adult,30,Kenya,Results reported in peer-reviewed journal,1/23/2013,23342996,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Malaria,Phase 1,1,ChAd63 Pfs25/MVA Pfs25,Active candidate / in development,Other: Pfs25 fused to IMX313,,Pfs25,None,NCT02547649,"Open, recruiting",University of Oxford,Academic,10/1/2015,3/1/2017,3/1/2017,Adult,24,United Kingdom of Great Britain & Northern Ireland,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Malaria,Phase 1,1,R21,Active candidate / in development,Recombinant subunit (non VLP),Protein: specify,CSP less- HepBsA,Novel other: specify,NCT02593071,"Open, recruiting",University of Oxford,Academic,9/1/2015,3/1/2017,3/1/2017,Adult,24,United Kingdom of Great Britain & Northern Ireland,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Malaria,Phase 1,1,R21,Active candidate / in development,Recombinant subunit (non VLP),Protein: specify,CSP less- HepBsA,Novel other: specify,NCT02623725,"Open, recruiting",University of Oxford,Academic,11/1/2015,3/1/2017,3/1/2017,Adult,20,United Kingdom of Great Britain & Northern Ireland,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Malaria,Phase 2,2,PfSPZ Vaccine,Active candidate / in development,Inactivated whole target organism,,,None,NCT02627456,"Open, recruiting",Sanaria,Industry,1/1/2016,3/1/2017,6/1/2017,Adult,84,United States of America,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Malaria,Phase 1,1,PfSPZ Vaccine,Active candidate / in development,Inactivated whole target organism,,,None,NCT02637583,Completed,Sanaria,Industry,12/1/2015,8/1/2016,3/1/2017,Child | Adult,99,United Republic of Tanzania,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Malaria,Phase 1,1,PfSPZ Vaccine,Active candidate / in development,Inactivated whole target organism,,,None,NCT02647489,"Open, not recruiting",Sanaria,Industry,10/8/2015,7/31/2017,7/31/2017,Adult,500,Mali,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Malaria,Phase 1,1,PAMVAC,Active candidate / in development,,Protein: specify,VAR2CSA fragment,Novel other: specify,NCT02676895,"Open, recruiting",University Hospital Tuebingen,Academic,5/9/2016,8/1/2017,12/1/2017,Adult,66,Germany | Benin,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Malaria,Phase 1,1,PRIMVAC,Active candidate / in development,,Protein: specify,VAR2CSA fragment,Novel other: specify,NCT02684383,"Open, recruiting",Inserm,Government,5/9/2016,6/30/2018,3/31/2019,Adult,68,France | Burkina Faso,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Malaria,Phase 1,1,PfSPZ Vaccine,Active candidate / in development,Inactivated whole target organism,,,None,NCT02687373,"Open, recruiting",National Institute of Allergy & Infectious Diseases (NIAID),Government,4/7/2016,4/1/2017,10/3/2017,Adult,112,Burkina Faso,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Malaria,Phase 2,2,PfSPZ Vaccine,Active candidate / in development,Inactivated whole target organism,,,None,NCT02717494,"Open, recruiting",Sanaria,Industry,7/1/2016,12/1/2017,11/1/2018,Child,572,Kenya,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Malaria,Phase 3,3,"RTS,S/AS01",Active candidate / in development,Recombinant subunit (non VLP),Protein: specify,CSP,Novel other: specify,NCT02719379,Not yet open,GSK,Industry,1/1/2017,8/1/2017,3/1/2020,Child,700,Ghana,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Malaria,Phase 1,1,PfSPZ Vaccine,Active candidate / in development,Inactivated whole target organism,,,None,NCT02878330,"Open, recruiting",Sanaria,Industry,11/1/2016,7/1/2017,8/1/2017,Child | Adult,135,Equatorial Guinea,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Malaria,Phase 2,2,R21 with ME-TRAP combined,Active candidate / in development,Recombinant viral vector,Protein: specify,2 components: adjuv R21 + ChAd-MVA vectored ME-TRAP,Novel other: specify,NCT02927145,"Open, recruiting",University of Oxford,Academic,8/1/2016,3/1/2017,10/1/2017,Adult,48,United Kingdom of Great Britain & Northern Ireland,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Malaria,Phase 1,1,R21,Active candidate / in development,Recombinant subunit (non VLP),Protein: specify,CSP less- HepBsA,Novel other: specify,NCT02934178,"Open, recruiting",University of Oxford,Academic,8/1/2016,2/1/2017,5/1/2017,Adult,24,Burkina Faso,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Malaria,Phase 2,2,RH5.1/ ASO1,Active candidate / in development,,,,Novel other: specify,NCT02942277,"Open, recruiting",University of Oxford,Academic,9/1/2016,5/1/2017,1/1/2018,Adult,78,United Kingdom of Great Britain & Northern Ireland,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Malaria,Phase 1,1,"Pfs25-EPA + Pfs230-EPA / AS01 LMIV, NIAID, NIH",Active candidate / in development,"Other: Pfs25M or Pf230D1M conjugated to EPA, respectively",,"Pfs25M, Pfs230D1M",Novel other: specify,NCT02958540,"Open, recruiting",National Institute of Allergy & Infectious Diseases (NIAID),Government,10/6/2016,4/30/2018,4/30/2018,Adult,900,United States of America | Mali,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Malaria,Phase 2,2,"RTS,S/AS01",Active candidate / in development,Recombinant subunit (non VLP),Protein: specify,CSP,Novel other: specify,NCT03031912,Not yet open,University of Oxford,Academic,2/1/2017,3/1/2018,3/1/2018,Adult,190,Thailand,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Malaria,Phase 1,1,ChAd63-METRAP,Active candidate / in development,,,ME-TRAP,,NCT03141138,"Open, recruiting",University of Oxford,Academic,3/28/2017,9/1/2017,9/1/2017,Adult,15,United Kingdom of Great Britain & Northern Ireland,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Malaria,Phase 2,2,Pb(PfCS@UIS4)-infected mosquitoes,Active candidate / in development,Other: Genetically Modified Plasmodium Berghei,Other: specify,Whole parasite with CS protein,None,NCT03175380,"Open, not recruiting",Radboud University,Academic,5/29/2017,7/1/2018,7/1/2018,Adult,30,Netherlands,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Malaria,Phase 2,2,"RTS,S/AS01E, RTS,S/AS01B",Active candidate / in development,Recombinant subunit (non VLP),Protein: specify,CSP,Novel other: specify,NCT03255278,"Open, not recruiting",GSK,Industry,5/23/2017,7/6/2018,9/3/2018,Adult,150,United States of America,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Malaria,Phase 1,1,PfSPZ-GA1,Active candidate / in development,Inactivated whole target organism,,,None,NCT03276962,"Open, recruiting",Sanaria,Industry,5/30/2017,6/1/2018,10/1/2018,Adult,67,Netherlands,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Malaria,Phase 2,2,"ChAdOx1, ChAdOx1/MVA LS2",Active candidate / in development,Recombinant viral vector,Protein: specify,LS2 (LSA1 & LSAP2),None,NCT03313037,"Open, recruiting",University of Oxford,Academic,7/3/2017,9/1/2018,9/1/2018,Adult,31,United Kingdom of Great Britain & Northern Ireland,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Malaria,Phase 2,2,"RTS,S/AS01",Active candidate / in development,Recombinant subunit (non VLP),Protein: specify,CSP,Novel other: specify,NCT03342898,"Open, recruiting",GSK,Industry,9/28/2017,4/15/2020,11/25/2022,Child,1500,Ghana,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Malaria,Phase 1,1,"D-CA/ChAd65-CA,D-CAT/ChAd63-CAT",Active candidate / in development,Other: prime with DNA vaccine & boost with recombinant viral vector,,,None,PACTR201203000306280,Not yet open,U.S. Army Medical Research & Materiel Command,Government,11/20/2017,12/30/2018,11/1/2019,Adult,52,United States of America,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Malaria,Phase 2b,2,GMZ2,Active candidate / in development,Recombinant subunit (non VLP),Protein: specify,"GLURP, MSP3",Novel other: specify,RPCEC00000182,Completed,Statens Serum Institut,Government,11/1/2010,3/30/2014,3/30/2014,Child,1840,Gabon | Uganda | Burkina Faso | Ghana,Results reported in peer-reviewed journal,7/28/2016,27477844,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Malaria,Phase 1,1,SE36,Active candidate / in development,Recombinant subunit (non VLP),Protein: specify,N-terminal domain of serine repeat antigen (SERA5),Aluminum salts (alum),,Completed,"Nobelpharma Co Ltd, Japan",Industry,6/24/2015,2/3/2017,2/8/2017,Child,108,Burkina Faso,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 3 | Phase 4,3.5,PCV7 (Prevnar 7),Registered,Subunit conjugate,Conjugate: specify antigen & carrier,"4, 6B, 9V, 14, 18C, 19F & 23F",None,ACTRN12607000387426,Completed,Individual Professor C Raina MacIntyre,Other,16/05/2005,Unspecified,Unspecified,Senior,315,Australia,Results reported in peer-reviewed journal,4/23/2014,24760002,https://www.ncbi.nlm.nih.gov/pubmed/?term=ACTRN12607000387426,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 3,3,PCV10 (Synflorix ),Registered,Subunit conjugate,Conjugate: specify antigen & carrier,"1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F & 23F",None,ACTRN12609000515291,Completed,Royal Children's Hospital,Government,1/6/2009,Unspecified,Unspecified,Child,100,Australia,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 3 | Phase 4,3.5,PCV13 (Prevnar 13) | PCV10 (Synflorix),Registered,Subunit conjugate,Conjugate: specify antigen & carrier CRM197,"1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F & 23F",None,ACTRN12610000544077,"Open, recruiting",University Menzies School of Health Research,Academic,29/08/2011,Unspecified,Unspecified,Child,425,Australia,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 2|Phase 3,2.5,PCV13 (Prevnar 13),Registered,Subunit conjugate,Conjugate: specify antigen & carrier,"1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F & 23F",None,ACTRN12613000264785,"Open, recruiting",Individual Te-Yu Hung,Other,6/3/2013,Unspecified,Unspecified,Child,100,Australia,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 1,1,PCV13 (Prevnar 13),Registered,Subunit conjugate,Conjugate: specify antigen & carrier,"1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F & 23F",Novel other: specify,ACTRN12613000368730,Not yet open,Individual Associate Professor Mimi Tang,Other,16/04/2013,Unspecified,Unspecified,Child,30,Australia,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 2,2,PCV 13 (Prevnar 13) |dTpa | MCV4,Active candidate / registered,Subunit conjugate,Conjugate: specify antigen & carrier CRM197,"1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F & 23F",None,ACTRN12613000536763,Completed,"Children's Hospital, Westmead",Academic,8/7/2013,Unspecified,Unspecified,Adult,227,Australia,Results reported in peer-reviewed journal,11/21/2016,27780630,https://www.ncbi.nlm.nih.gov/pubmed/?term=ACTRN12613000536763,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 1,1,PCV13 (Prevnar 13),Registered,Subunit conjugate,Conjugate: specify antigen & carrier CRM197,"1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F & 23F",None,ACTRN12614001003662,"Open, recruiting",Hunter Medical Research Institute,Other,1/6/2016,Unspecified,Unspecified,Adult,100,Australia,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 3,3,PPV-23 (Pneumovax 23),Registered,Polysaccharides,,"1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F & 33F",None,ACTRN12615000536561,"Open, recruiting",University of Newcastle,Academic,23/02/2016,12/31/2017,Unspecified,Adult,4500,Australia,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 1|Phase 2,1.5,PCV10 (Nucovac),Registered,Subunit conjugate,Conjugate: specify antigen & carrier,"1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F & 23F",Yes,CTRI/2013/05/003711,Completed,Panacea Biotec Ld,Industry,4/6/2013,Unspecified,Unspecified,Adult,48,India,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 1,1,PCV10 (SIILPCV10),Registered,Subunit conjugate,Conjugate: specify antigen & carrier,"1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F & 23F",None,CTRI/2013/09/003961,Completed,Serum Institute of India,Other,18/06/2014,Unspecified,Unspecified,Adult,34,India,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 1,1,PCV10 (Nucovac),Registered,Subunit conjugate,Conjugate: specify antigen & carrier,"1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F & 23F",Yes,CTRI/2014/04/004543,Completed,Panacea Biotec Ld,Industry,19/04/2014,Unspecified,Unspecified,Child,72,India,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 2,2,PCV10 (SIILPCV10),Registered,Subunit conjugate,Conjugate: specify antigen & carrier,"1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F & 23F",None,CTRI/2015/12/006456,Completed,Serum Institute of India,Other,7/1/2016,Unspecified,Unspecified,Child,112,India,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 1,1,PCV14 (LBVE014),Active candidate / in development,Subunit conjugate,Conjugate: specify antigen & carrier,,None,CTRI/2017/06/008776,"Open, not recruiting",Biological E Limited,Industry,12/6/2017,7/12/2017,7/12/2017,Adult,24,India,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 4,4,PCV13 (Prevnar 13) + 2-PE,Active candidate / registered,Subunit conjugate,Conjugate: specify antigen & carrier,"1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F & 23F",None,CTRI/2017/08/009492,Not yet open,Pfizer,Industry,21/11/2017,12/21/2018,12/21/2018,Child,300,India,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 4,4,PCV7 (Prevnar 7),Registered,Subunit conjugate,Conjugate: specify antigen & carrier,"4, 6B, 9V, 14, 18C, 19F & 23F",None,EUCTR2017-001529-41-Outside-EU/EEA,Unknown,Pfizer,Industry,Unspecified,Unspecified,Unspecified,Child,100,Russian Federation,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 2,2,PCV7 (Prevnar 7) | PPV-23 (Pneumovax 23),Registered,Subunit conjugate,Conjugate: specify antigen & carrier,"4, 6B, 9V, 14, 18C, 19F & 23F",None,IRCT201110116660N3,Completed,Mazandaran University of Medical Sciences,Academic,27/07/2011,Unspecified,Unspecified,"Child, Adult",50,Iran,Results reported in peer-reviewed journal,1/11/2017,PMC5412244,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5412244/,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 2,2,PCV13 (Prevnar 13),Registered,Subunit conjugate,Conjugate: specify antigen & carrier,"1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F & 23F",None,JPRN-UMIN000010576,"Open, recruiting",National Cancer Center Hospital,Academic,23/04/2013,Unspecified,Unspecified,"Child, Adult",73,Japan,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 1,1,PCV7 (Prevnar 7),Registered,Subunit conjugate,Conjugate: specify antigen & carrier,"4, 6B, 9V, 14, 18C, 19F & 23F",None,NCT00000829,Completed,NIAID,Government | Industry,Unspecified,10/1/1999,Unspecified,Child,60,United States | Puerto Rico,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 3,3,PCV7 (Prevnar 7) | MMRV (ProQuad),Registered,Subunit conjugate,Conjugate: specify antigen & carrier,"4, 6B, 9V, 14, 18C, 19F & 23F",None,NCT00109343,Completed,Merck Sharp & Dohme Corp.,Industry,1/3/2006,9/1/2007,9/1/2007,Child,1027,United States,Results reported in both peer-reviewed journal & registry,12/12/2014,25219563,https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT00109343,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 3,3,PCV11,Active candidate / in development,Subunit conjugate,Conjugate: specify antigen & carrier,"1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, 23F",None,NCT00119743,Terminated,GlaxoSmithKline,Industry,1/10/2000,6/1/2004,6/1/2004,Child,5000,Czech Republic | Slovakia,Results reported in peer-reviewed journal,3/1/2007,17258357,https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT00119743,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 3,3,PPV-23 (Pneumovax 23),Registered,Polysaccharides,,"1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F & 33F",None,NCT00127153,Completed,Merck Sharp & Dohme Corp.,Industry,1/3/2005,5/1/2005,5/1/2005,Adult,130,Japan,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 2,2,PCV9 (PNCRM9),Active candidate / in development,Subunit conjugate,Conjugate: specify antigen & carrier,"1, 4, 5, 6B, 9V, 14, 18C, 19F & 23F",None,NCT00133549,Completed,NIAID,Government,1/11/2000,12/1/2002,12/1/2002,Senior,180,United States,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 1|Phase 2,1.5,PCV13 (Prevnar 13) | PPV-23 (Pneumovax 23),Registered,Subunit conjugate,Conjugate: specify antigen & carrier CRM197,"1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F & 23F",None,NCT00137605,Completed,CIHR Canadian HIV Trials Network,Other | Industry,1/9/2004,10/1/2007,Unknown,Adult,79,Canada,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 1|Phase 2,1.5,PCV7 (Prevnar 7),Registered,Subunit conjugate,Conjugate: specify antigen & carrier,"4, 6B, 9V, 14, 18C, 19F & 23F",None,NCT00142389,Completed,Johns Hopkins Bloomberg School of Public Health,Academic | Government | Industry,1/8/2004,12/1/2006,Unspecified,Adult,680,Bangladesh,Results reported in peer-reviewed journal,4/1/2013,23300160,https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT00142389,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 2,2,PCV7 (Prevnar 7) | PPV-23 (Pneumovax 23),Active candidate / registered,Subunit conjugate,Conjugate: specify antigen & carrier,"4, 6B, 9V, 14, 18C, 19F & 23F",None,NCT00148824,Completed,French National Agency for Research on AIDS & Viral Hepatitis,Other | Industry,1/2/2003,1/1/2006,Unspecified,Adult,212,France,Results reported in peer-reviewed journal,4/15/2010,20210645,https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT00148824,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 1,1,PCV7 (Prevnar 7) | PPV-23 (Pneumovax 23),Registered,Subunit conjugate,Conjugate: specify antigen & carrier,"4, 6B, 9V, 14, 18C, 19F & 23F",None,NCT00153543,Completed,CDC,Government,1/5/2002,6/1/2003,Unspecified,Adult,90,United States,Results reported in peer-reviewed journal,15/07/2009,,https://academic.oup.com/cid/article/49/2/241/404324/Immunogenicity-and-Reactogenicity-of-Pneumococcal,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 1,1,PCV7 (Prevnar 7) | PPV-23 (Pneumovax 23) | Tetanus-diphtheria toxoids (Td),Active candidate / registered,Subunit conjugate,Conjugate: specify antigen & carrier,"4, 6B, 9V, 14, 18C, 19F & 23F",None,NCT00164411,Completed,CDC,Other | Academic,1/1/2004,3/1/2005,Unspecified,Adult,30,United States,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 1|Phase 2,1.5,PCV7 (Prevnar 7),Registered,Subunit conjugate,Conjugate: specify antigen & carrier,"4, 6B, 9V, 14, 18C, 19F & 23F",None,NCT00169234,Completed,Kaiser Permanente,Other | Government,1/5/2003,2/1/2005,2/1/2005,Senior,220,United States,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 2,2,PCV11,Active candidate / in development,Subunit conjugate,Conjugate: specify antigen & carrier,"1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, 23F",None,NCT00169481,Completed,GlaxoSmithKline,Industry,1/10/2004,5/1/2005,5/1/2005,Child,689,Germany,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 3,3,PCV11,Active candidate / in development,Subunit conjugate,Conjugate: specify antigen & carrier,"1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, 23F",None,NCT00169507,Completed,GlaxoSmithKline,Industry,1/3/2005,4/1/2005,4/1/2005,Child,100,Slovakia,Results reported in both peer-reviewed journal & registry,3/1/2007,17258358,https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT00169507,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 3,3,PCV7 (Prevnar7) | DTaP-IPV-HBV/Hib combination vaccine | Infanrix hexa,Active candidate / registered,Subunit conjugate,Conjugate: specify antigen & carrier,"4, 6B, 9V, 14, 18C, 19F & 23F",None,NCT00169728,Completed,"Heinrich-Heine University, Duesseldorf",Academic | Industry,1/9/2003,10/1/2006,6/1/2006,Child,53,Germany,Results reported in peer-reviewed journal,3/15/2007,17090650,https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT00169728,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 2,2,PCV 7 (Prevnar7) | PPV-23 (Pneumovax 23),Registered,Subunit conjugate,Conjugate: specify antigen & carrier,"4, 6B, 9V, 14, 18C, 19F & 23F",None,NCT00170612,Completed,University of Melbourne,Academic | Government,1/11/2005,8/1/2008,1/1/2008,Child,552,Fiji | Australia,Results reported in peer-reviewed journal,4/19/2010,20199764,https://www.ncbi.nlm.nih.gov/pubmed/20199764,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 3,3,PCV7 (Prevnar 7),Registered,Subunit conjugate,Conjugate: specify antigen & carrier,"4, 6B, 9V, 14, 18C, 19F & 23F",None,NCT00189020,Completed,UMC Utrecht,Other,1/6/2005,2/1/2008,2/1/2008,Child,1005,Netherlands,Results reported in peer-reviewed journal,7/8/2009,19584345,https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT00189020,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 2,2,PCV9,Active candidate / in development,Subunit conjugate,Conjugate: specify antigen & carrier,"1, 4, 5, 6B, 9V, 14, 18C, 19F & 23F",None,NCT00197769,Completed,Public Health England,Academic,1/9/2000,1/1/2004,Unspecified,Child,null,United Kingdom,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 2,2,PCV7 (Prevnar 7) | PPV-23 (Pneumovax 23),Registered,Subunit conjugate,Conjugate: specify antigen & carrier,"4, 6B, 9V, 14, 18C, 19F & 23F",None,NCT00197821,Completed,Public Health England,Academic,1/1/2004,12/1/2008,12/1/2008,Adult,611,United Kingdom,Results reported in peer-reviewed journal,11/1/2009,19814624,https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT00197821,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 1|Phase 2,1.5,PCV13 (Prevnar 13),Registered,Subunit conjugate,Conjugate: specify antigen & carrier CRM197,"1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F & 23F",None,NCT00205803,Completed,Pfizer,Industry,1/9/2004,1/5/2007,Unspecified,Child,249,United States,Results reported in both peer-reviewed journal & registry,5/1/2010,20435707,https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT00205803,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 3,3,PCV7 (Prevnar 7),Registered,Subunit conjugate,Conjugate: specify antigen & carrier,"4, 6B, 9V, 14, 18C, 19F & 23F",None,NCT00213265,Unknown,The Hospital for Sick Children,Academic,1/7/2002,Unspecified,Unspecified,"Child, Adult",150,Canada,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 2,2,PCV7 (Prevnar 7),Registered,Subunit conjugate,Conjugate: specify antigen & carrier,"4, 6B, 9V, 14, 18C, 19F & 23F",None,NCT00219401,Completed,Papua New Guinea Institute of Medical Research,Academic,1/5/2005,5/1/2010,5/1/2009,Child,318,Papua New Guinea,Results reported in peer-reviewed journal,12/1/2013,23451070,https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT00219401,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 2,2,PCV13 (Prevnar 13),Registered,Subunit conjugate,Conjugate: specify antigen & carrier CRM197,"1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F & 23F",None,NCT00269672,Completed,Pfizer,Industry,1/9/2005,2/1/2007,2/1/2007,Senior,915,South Africa,Results reported in peer-reviewed journal,5/1/2014,PMC4896606,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4896606/,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 2,2,PPV-23 (Pneumovax 23),Registered,Polysaccharides,,"1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F & 33F",None,NCT00307008,Completed,GlaxoSmithKline,Industry,1/10/2003,2/1/2005,2/1/2005,Senior,1198,Sweden | Finland,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 3,3,PCV10 (Synflorix ),Registered,Subunit conjugate,Conjugate: specify antigen & carrier,"1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F & 23F",None,NCT00307034,Completed,GlaxoSmithKline,Industry,1/1/2006,1/1/2007,1/1/2007,Child,351,Japan,Results reported in registry,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 2,2,PCV11,Active candidate / in development,Subunit conjugate,Conjugate: specify antigen & carrier,"1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, 23F",None,NCT00307528,Completed,GlaxoSmithKline,Industry,1/1/2004,3/1/2007,3/1/2007,Senior,146,Belgium,Results reported in peer-reviewed journal,1/15/2015,24176494,https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT00307528,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 3,3,PCV10 (Synflorix ),Registered,Subunit conjugate,Conjugate: specify antigen & carrier,"1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F & 23F",None,NCT00307541,Completed,GlaxoSmithKline,Industry,1/10/2005,4/1/2006,Unspecified,Child,120,Germany | United States,Results reported in peer-reviewed journal,1/1/2012,21909049,https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT00333450,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 3,3,PCV10 (Synflorix ),Registered,Subunit conjugate,Conjugate: specify antigen & carrier,"1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F & 23F",None,NCT00307554,Completed,GlaxoSmithKline,Industry,1/11/2005,6/1/2006,Unspecified,Child,1600,Finland | France | Poland,Results reported in peer-reviewed journal,4/1/2009,19325447,https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT00307554,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 2,2,PPV-23 (Pneumovax 23) | PCV10 (Synflorix ),Registered,Polysaccharides,,"1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F & 33F",None,NCT00307567,Completed,GlaxoSmithKline,Industry,1/11/2005,3/1/2006,Unspecified,Child,689,Germany,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 3,3,PPV-23 (Pneumovax 23),Registered,Polysaccharides,,"1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F & 33F",None,NCT00310349,Unknown,University of Melbourne,Other,1/3/2006,1/1/2009,Unspecified,"Child, Adult",210,Australia,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 2,2,PCV13 (Prevnar 13) | GM-CSF,Active candidate / registered,Subunit conjugate,Conjugate: specify antigen & carrier CRM197,"1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F & 23F",None,NCT00323557,Completed,M.D. Anderson Cancer Center,Academic | Industry,1/6/2004,5/1/2011,5/1/2011,"Child, Adult",39,United States,Results reported in both peer-reviewed journal & registry,7/15/2008,18470901,https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT00323557,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 2,2,PCV11,Active candidate / in development,Subunit conjugate,Conjugate: specify antigen & carrier,"1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, 23F",None,NCT00327522,Completed,GlaxoSmithKline,Industry,1/6/2006,Unspecified,Unspecified,Adult,10,Belgium,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 1,1,PCV11,Active candidate / in development,Subunit conjugate,Conjugate: specify antigen & carrier,"1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, 23F",None,NCT00327665,Completed,GlaxoSmithKline,Industry,1/5/2006,1/8/2007,1/1/2007,Senior,335,Belgium | Finland | Sweden,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 3,3,PCV10 (Synflorix ),Registered,Subunit conjugate,Conjugate: specify antigen & carrier,"1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F & 23F",None,NCT00333450,Completed,GlaxoSmithKline,Industry,1/8/2006,12/1/2006,Unspecified,Child,120,Germany,Results reported in peer-reviewed journal,1/1/2012,21909049,https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT00333450,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 3,3,PCV10 (Synflorix ),Registered,Subunit conjugate,Conjugate: specify antigen & carrier,"1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F & 23F",None,NCT00334334,Completed,GlaxoSmithKline,Industry,1/6/2006,8/1/2007,7/1/2007,Child,1572,Germany | Spain | Poland,Results reported in peer-reviewed journal,4/1/2009,19325447,https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT00334334,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 2,2,PCV10 (Synflorix ) | Infanrix,Registered,Subunit conjugate,Conjugate: specify antigen & carrier,"1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F & 23F",None,NCT00338351,Completed,GlaxoSmithKline,Industry,1/4/2006,10/1/2006,Unspecified,Child,240,Chile,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 3,3,PCV10 (Synflorix ),Registered,Subunit conjugate,Conjugate: specify antigen & carrier,"1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F & 23F",None,NCT00344318,Completed,GlaxoSmithKline,Industry,1/8/2006,10/1/2007,4/1/2007,Child,806,Japan,Results reported in peer-reviewed journal,4/1/2009,19325447,https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT00344318,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 3,3,PCV10 (Synflorix ),Registered,Subunit conjugate,Conjugate: specify antigen & carrier,"1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F & 23F",None,NCT00345358,Completed,GlaxoSmithKline,Industry,1/9/2006,11/1/2007,11/1/2007,Child,600,Finland | Czech Republic,Results reported in peer-reviewed journal,8/1/2011,21540760,https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT00345358,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 3,3,PCV13 (Prevnar 13),Registered,Subunit conjugate,Conjugate: specify antigen & carrier CRM197,"1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F & 23F",None,NCT00366340,Completed,Pfizer,Industry,1/10/2006,8/1/2008,8/1/2008,Child,604,Germany,Results reported in both peer-reviewed journal & registry,8/1/2011,21704105,https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT00366340,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 3,3,PCV13 (Prevnar 13),Registered,Subunit conjugate,Conjugate: specify antigen & carrier CRM197,"1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F & 23F",Licensed other: specify,NCT00366548,Completed,Pfizer,Industry,1/11/2006,6/1/2008,6/1/2008,Child,500,Poland,Results reported in both peer-reviewed journal & registry,2/1/2015,25126854,https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT00366548,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 3,3,PCV13 (Prevnar 13),Registered,Subunit conjugate,Conjugate: specify antigen & carrier CRM197,"1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F & 23F",None,NCT00366678,Completed,Pfizer,Industry,1/10/2006,11/1/2008,11/1/2008,Child,613,France,Results reported in registry,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 3,3,PCV13 (Prevnar 13),Registered,Subunit conjugate,Conjugate: specify antigen & carrier CRM197,"1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F & 23F",None,NCT00366899,Completed,Pfizer,Industry,1/10/2006,7/1/2008,7/1/2008,Child,605,Italy,Results reported in both peer-reviewed journal & registry,10/1/2013,23965217,https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT00366899,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 3,3,PCV13 (Prevnar 13),Registered,Subunit conjugate,Conjugate: specify antigen & carrier CRM197,"1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F & 23F",None,NCT00368966,Completed,Pfizer,Industry,1/10/2006,7/1/2008,7/1/2008,Child,619,Spain,Results reported in both peer-reviewed journal & registry,10/1/2013,23965217,https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT00368966,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 3,3,PCV10 (Synflorix ),Registered,Subunit conjugate,Conjugate: specify antigen & carrier,"1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F & 23F",None,NCT00370227,Completed,GlaxoSmithKline,Industry,1/10/2006,3/1/2007,Unspecified,Child,390,Finland,Results reported in peer-reviewed journal,6/1/2010,20508478,https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT00370227,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 3,3,PCV10 (Synflorix ),Registered,Subunit conjugate,Conjugate: specify antigen & carrier,"1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F & 23F",None,NCT00370396,Completed,GlaxoSmithKline,Industry,1/9/2006,11/1/2007,6/1/2007,Child,1200,Finland | France | Poland,Results reported in peer-reviewed journal,4/1/2009,19325447,https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT00370396,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 3,3,PCV13 (Prevnar 13),Registered,Subunit conjugate,Conjugate: specify antigen & carrier CRM197,"1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F & 23F",None,NCT00373958,Completed,Pfizer,Industry,1/9/2006,6/1/2008,6/1/2008,Child,666,United States,Results reported in both peer-reviewed journal & registry,9/1/2010,20732948,https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT00373958,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 3,3,PCV 7 (PncCRM & PncOMPC),Active candidate / registered,Subunit conjugate,Conjugate: specify antigen & carrier to CRM197 or OMPC,"4, 6B, 9V, 14, 18C, 19F & 23F",None,NCT00378417,Completed,"National Institute for Health & Welfare, Finland",Other | Industry,1/3/1995,3/1/1999,Unspecified,Child,3075,Finland,Results reported in peer-reviewed journal,5/13/2013,23658394,https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT00378417,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 2,2,Influenza vaccination|Pneumococcal polysaccharide vaccination,Active candidate / in development,,,,,NCT00380679,Unknown,Louisiana State University Health Sciences Center in New Orleans,Other | Government,1/12/2005,3/1/2006,Unspecified,Adult,null,United States,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 3,3,PCV13 (Prevnar 13),Registered,Subunit conjugate,Conjugate: specify antigen & carrier CRM197,"1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F & 23F",None,NCT00384059,Completed,Pfizer,Industry,1/10/2006,10/1/2008,10/1/2008,Child,286,United Kingdom,Results reported in both peer-reviewed journal & registry,12/1/2010,21155091,https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT00384059,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 3,3,PCV10 (Synflorix ),Registered,Subunit conjugate,Conjugate: specify antigen & carrier,"1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F & 23F",None,NCT00390910,Completed,GlaxoSmithKline,Industry,1/10/2006,5/1/2008,5/1/2008,Child,286,Greece | Spain,Results reported in peer-reviewed journal,8/1/2011,21727108,https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT00390910,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 3,3,PCV13 (Prevnar 13),Registered,Subunit conjugate,Conjugate: specify antigen & carrier CRM197,"1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F & 23F",None,NCT00427895,Completed,Pfizer,Industry,1/3/2007,8/1/2011,8/1/2011,Adult,2141,United States,Results reported in registry,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 3,3,PCV13 (Prevnar 13),Registered,Subunit conjugate,Conjugate: specify antigen & carrier CRM197,"1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F & 23F",None,NCT00444457,Completed,Pfizer,Industry,1/5/2007,6/1/2009,6/1/2009,Child,1712,United States,Results reported in both peer-reviewed journal & registry,4/1/2013,23104129,https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT00444457,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 3,3,PCV13 (Prevnar 13),Registered,Subunit conjugate,Conjugate: specify antigen & carrier CRM197,"1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F & 23F",None,NCT00452452,Completed,Pfizer,Industry,1/7/2007,3/1/2008,3/1/2008,Child,355,Poland,Results reported in registry,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 3,3,PCV13 (Prevnar 13),Registered,Subunit conjugate,Conjugate: specify antigen & carrier CRM197,"1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F & 23F",None,NCT00452790,Completed,Pfizer,Industry,1/6/2007,2/1/2010,10/1/2009,Child,708,India,Results reported in registry,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 3,3,PCV7 (Prevnar 7) | PPV-23 (Pneumovax 23),Registered,Subunit conjugate,Conjugate: specify antigen & carrier,"4, 6B, 9V, 14, 18C, 19F & 23F",None,NCT00457977,Completed,University of Minnesota,Academic | Government,1/3/2007,5/1/2011,5/1/2011,Adult,181,United States,Results reported in both peer-reviewed journal & registry,9/15/2009,19556517,https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT00457977,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 3,3,PCV10 (Synflorix ) | Infanrix hexa | Infanrix IPV Hib | Infanrix penta|: Infanrix IPV | Meningitec | NeisVac-C | Menitorix,Registered,Subunit conjugate,Conjugate: specify antigen & carrier,"1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F & 23F",None,NCT00463437,Completed,GlaxoSmithKline,Industry,1/4/2007,6/1/2008,1/1/2008,Child,1437,Greece | Spain,Results reported in both peer-reviewed journal & registry,1/4/2009,19325447,https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT00463437,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 3,3,PCV13 (Prevnar 13),Registered,Subunit conjugate,Conjugate: specify antigen & carrier CRM197,"1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F & 23F",None,NCT00464945,Completed,Pfizer,Industry,1/6/2007,9/1/2008,9/1/2008,Child,269,Poland,Results reported in both peer-reviewed journal & registry,4/5/2011,2133503,https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT00464945,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 3,3,PCV10 (Synflorix ),Registered,Subunit conjugate,Conjugate: specify antigen & carrier,"1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F & 23F",None,NCT00466947,Completed,GlaxoSmithKline,Industry,1/6/2007,7/1/2011,8/1/2010,Child,23802,Argentina | Colombia | Panama,Results reported in both peer-reviewed journal & registry,6/3/2014,24892763,https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT00466947,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 3,3,PCV13 (Prevnar 13),Registered,Subunit conjugate,Conjugate: specify antigen & carrier CRM197,"1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F & 23F",None,NCT00474539,Completed,Pfizer,Industry,1/7/2007,3/1/2009,3/1/2009,Child,449,Spain,Results reported in both peer-reviewed journal & registry,10/1/2013,23965217,https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT00474539,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 3,3,PCV13 (Prevnar 13),Registered,Subunit conjugate,Conjugate: specify antigen & carrier CRM197,"1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F & 23F",None,NCT00475033,Completed,Pfizer,Industry,1/6/2007,5/1/2009,5/1/2009,Child,603,Canada,Results reported in registry,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 1,1,PPV-23 (Pneumovax 23),Registered,Polysaccharides,,"1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F & 33F",None,NCT00479323,Completed,NIAID,Government,1/6/2007,8/1/2008,8/1/2008,Adult,250,United States,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 1,1,PCV7 (Prevnar 7),Registered,Subunit conjugate,Conjugate: specify antigen & carrier,"4, 6B, 9V, 14, 18C, 19F & 23F",None,NCT00488826,Completed,Pfizer,Industry,1/10/2005,5/1/2007,Unspecified,Child,800,China,Results reported in registry,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 3,3,PCV10 (Synflorix ),Registered,Subunit conjugate,Conjugate: specify antigen & carrier,"1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F & 23F",None,NCT00489554,Completed,GlaxoSmithKline,Industry,1/7/2007,3/1/2008,3/1/2008,Child,230,Mexico,Results reported in both peer-reviewed journal & registry,11/1/2011,22048109,https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT00489554,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 3,3,PCV13 (Prevnar 13) | TIV,Active candidate / registered,Subunit conjugate,Conjugate: specify antigen & carrier CRM197,"1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F & 23F",None,NCT00492557,Completed,Pfizer,Industry,1/9/2007,2/1/2008,2/1/2008,Senior,1185,"Netherlands, Belgium, Hungary",Results reported in both peer-reviewed journal & registry,7/18/2011,,http://www.sciencedirect.com/science/article/pii/S0264410X11007420,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 3,3,PCV10 (Synflorix ) | Infanrix Hexa | Meningococcal vaccine GSK134612 | Paracetamol,Active candidate / registered,Subunit conjugate,Conjugate: specify antigen & carrier,"1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F & 23F",None,NCT00496015,Completed,GlaxoSmithKline,Industry,2/7/2007,2/17/2009,3/25/2008,Child,750,Czech Republic,Results reported in peer-reviewed journal,17/10/2009,19837254,https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT00370318,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 3,3,PPV-23 (Pneumovax 23),Registered,Polysaccharides,,"1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F & 33F",None,NCT00496093,Completed,Merck Sharp & Dohme Corp.,Industry,1/10/2005,1/1/2006,1/1/2006,Adult,133,India,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 3,3,PCV13 (Prevnar 13),Registered,Subunit conjugate,Conjugate: specify antigen & carrier CRM197,"1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F & 23F",None,NCT00500266,Completed,Pfizer,Industry,1/5/2008,5/1/2009,4/1/2009,Senior,1053,United States | Germany | Sweden,Results reported in registry,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 3,3,PCV13 (Prevnar 13),Registered,Subunit conjugate,Conjugate: specify antigen & carrier CRM197,"1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F & 23F",None,NCT00500357,Completed,Pfizer,Industry,1/11/2007,1/1/2010,1/1/2010,Senior,105,South Africa,Results reported in registry,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 3,3,PCV13 (Prevnar 13),Registered,Subunit conjugate,Conjugate: specify antigen & carrier CRM197,"1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F & 23F",None,NCT00508742,Completed,Pfizer,Industry,1/12/2007,8/1/2011,8/1/2011,Child,1866,Israel,Results reported in both peer-reviewed journal & registry,10/1/2013,23804191,https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT00508742,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 2,2,PCV10 (Synflorix ),Registered,Subunit conjugate,Conjugate: specify antigen & carrier,"1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F & 23F",None,NCT00513409,Completed,GlaxoSmithKline,Industry,1/8/2007,8/1/2008,2/1/2008,Child,163,Chile,Results reported in both peer-reviewed journal & registry,5/1/2011,21441782,https://www.ncbi.nlm.nih.gov/pubmed/21441782?dopt=Abstract,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 3,3,PCV13 (Prevnar 13) | TIV,Active candidate / registered,Subunit conjugate,Conjugate: specify antigen & carrier CRM197,"1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F & 23F",None,NCT00521586,Completed,Pfizer,Industry,1/9/2007,12/1/2013,12/1/2013,Adult,1116,United States,Results reported in both peer-reviewed journal & registry,8/1/2012,22739693,https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT00521586,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 3,3,PPV-23 (Pneumovax 23) | ZOSTAVAX,Active candidate / registered,Polysaccharides,,"1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F & 33F",None,NCT00535730,Completed,Merck Sharp & Dohme Corp.,Industry,1/6/2007,2/1/2008,2/1/2008,Adult,473,United States,Results reported in both peer-reviewed journal & registry,11/1/2010,20980796,https://www.ncbi.nlm.nih.gov/pubmed/20980796?dopt=Abstract,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 3,3,PCV13 (Prevnar 13),Registered,Subunit conjugate,Conjugate: specify antigen & carrier CRM197,"1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F & 23F",None,NCT00546572,Completed,Pfizer,Industry,1/11/2007,7/1/2010,7/1/2010,Senior,938,United States | Sweden,Results reported in registry,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 3,3,PCV10 (Synflorix ),Registered,Subunit conjugate,Conjugate: specify antigen & carrier,"1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F & 23F",None,NCT00547248,Completed,GlaxoSmithKline,Industry,1/10/2007,10/1/2008,5/1/2008,Child,756,Philippines | Poland,Results reported in peer-reviewed journal,1/1/2011,20980933,https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT00547248,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 3,3,PPV-23 (Pneumovax 23),Registered,Polysaccharides,,"1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F & 33F",None,NCT00560950,Completed,Merck Sharp & Dohme Corp.,Industry,1/7/2007,5/1/2008,5/1/2008,Adult,143,United States,Results reported in both peer-reviewed journal & registry,2/15/2010,2008869,https://www.ncbi.nlm.nih.gov/pubmed/20088694?dopt=Abstract,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 3,3,PCV13 (Prevnar 13),Registered,Subunit conjugate,Conjugate: specify antigen & carrier CRM197,"1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F & 23F",None,NCT00562354,Completed,Pfizer,Industry,1/10/2007,12/1/2007,12/1/2007,Adult,271,Japan,Results reported in both peer-reviewed journal & registry,12/1/2014,25424792,https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT00562354,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 1|Phase 2,1.5,PCV13 (Prevnar 13) | CPG 7909,Active candidate / registered,Subunit conjugate,Conjugate: specify antigen & carrier CRM197,"1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F & 23F",Novel other: specify,NCT00562939,Completed,University of Aarhus,Academic,1/1/2008,1/1/2009,1/1/2009,Adult,97,Denmark,Results reported in both peer-reviewed journal & registry,7/1/2010,20504165,https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT00562939,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 3,3,PCV13 (Prevnar 13),Registered,Subunit conjugate,Conjugate: specify antigen & carrier CRM197,"1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F & 23F",None,NCT00574548,Completed,Pfizer,Industry,1/11/2007,2/1/2010,2/1/2010,Adult,720,United States,Results reported in both peer-reviewed journal & registry,4/25/2014,24606865,https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT00574548,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 3,3,PCV13 (Prevnar 13),Registered,Subunit conjugate,Conjugate: specify antigen & carrier CRM197,"1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F & 23F",None,NCT00574795,Completed,Pfizer,Industry,1/9/2007,8/1/2008,8/1/2008,Child,193,Japan,Results reported in both peer-reviewed journal & registry,9/1/2013,23538524,https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT00574795,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 1,1,PPV-23 (Pneumovax 23),Registered,Polysaccharides,,"1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F & 33F",None,NCT00589394,Completed,Mayo Clinic,Other,1/7/2007,1/1/2010,12/1/2008,Adult,100,United States,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 3,3,PPV-23 (Pneumovax 23),Registered,Polysaccharides,,"1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F & 33F",None,NCT00594347,Completed,Sanofi,Industry,1/11/2007,4/1/2009,3/1/2008,Child,339,Thailand,Results reported in peer-reviewed journal,7/1/2014,PMC4186054,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4186054/,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 3,3,PCV10 (Synflorix ),Registered,Subunit conjugate,Conjugate: specify antigen & carrier,"1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F & 23F",None,NCT00611663,Completed,GlaxoSmithKline,Industry,1/1/2008,3/1/2009,11/1/2008,Child,245,Greece | Spain,Results reported in both peer-reviewed journal & registry,8/1/2011,21727108,https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT00609492,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 2|Phase 3,2.5,PCV13 (Prevnar 13) | PPV-23 (Pneumovax 23),Registered,Subunit conjugate,Conjugate: specify antigen & carrier CRM197,"1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F & 23F",None,NCT00617344,Completed,Hopitaux de Paris,Academic,1/5/2008,4/1/2016,12/1/2014,Adult,47,France | Monaco,Results reported in peer-reviewed journal,5/9/2017,28784280,https://www.ncbi.nlm.nih.gov/pubmed/28784280,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 1|Phase 2,1.5,PCV9 (PNCRM9),Active candidate / in development,Subunit conjugate,Conjugate: specify antigen & carrier,"1, 4, 5, 6B, 9V, 14, 18C, 19F & 23F",None,NCT00617760,Completed,National Institute on Deafness & Other Communication Disorders (NIDCD),Government,1/10/2000,12/1/2004,12/1/2004,Adult,153,United States,Results reported in peer-reviewed journal,12/5/2014,25444821,https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT00617682,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 3,3,PCV7 (Prevnar 7) | MenC-TT,Active candidate / registered,Subunit conjugate,Conjugate: specify antigen & carrier,"4, 6B, 9V, 14, 18C, 19F & 23F",None,NCT00618605,Completed,Pfizer,Industry,1/3/2008,12/1/2009,8/1/2009,Child,330,Germany,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 3,3,PCV13 (Prevnar 13) | PPV-23 (Pneumovax 23),Registered,Subunit conjugate,Conjugate: specify antigen & carrier CRM197,"1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F & 23F",None,NCT00624819,Completed,Uniformed Services University of the Health Sciences,Other | Government,1/12/2002,7/1/2013,7/1/2013,Adult,275,United States,Results reported in peer-reviewed journal,10/1/2010,20795819,https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT00622843,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 3,3,PCV10 (Synflorix ),Registered,Subunit conjugate,Conjugate: specify antigen & carrier,"1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F & 23F",None,NCT00652275,Completed,GlaxoSmithKline,Industry,1/3/2008,11/1/2011,11/1/2011,Child,524,Poland,Results reported in peer-reviewed journal,3/4/2017,27736293,https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT00624819,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 3,3,PCV10 (Synflorix ) | Pediacel | Infanrix,Registered,Subunit conjugate,Conjugate: specify antigen & carrier,"1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F & 23F",None,NCT00653627,Completed,GlaxoSmithKline,Industry,1/4/2008,5/1/2009,5/1/2009,Child,780,Netherlands,Results reported in peer-reviewed journal,2/1/2013,23118268,https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT00652951,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 3,3,PCV13 (Prevnar 13),Registered,Subunit conjugate,Conjugate: specify antigen & carrier CRM197,"1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F & 23F",None,NCT00666380,Completed,Institute of Child Health,Other,1/6/2006,3/1/2008,Unspecified,"Child, Adult",30,United Kingdom,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 3,3,PCV13 (Prevnar 13),Registered,Subunit conjugate,Conjugate: specify antigen & carrier CRM197,"1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F & 23F",None,NCT00678301,Completed,Pfizer,Industry,1/4/2008,9/1/2009,9/1/2009,Child,354,Brazil,Results reported in registry,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 3,3,PCV10 (Synflorix ) | Zilbrix™ Hib | Polio Sabin,Registered,Subunit conjugate,Conjugate: specify antigen & carrier,"1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F & 23F",None,NCT00679159,Completed,GlaxoSmithKline,Industry,1/6/2008,12/1/2009,11/1/2009,Child,365,Mali | Nigeria,Results reported in peer-reviewed journal,11/23/2011,22112189,https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT00678301,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 3,3,PCV10 (Synflorix ),Registered,Subunit conjugate,Conjugate: specify antigen & carrier,"1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F & 23F",None,NCT00686075,Completed,GlaxoSmithKline,Industry,1/6/2008,5/1/2009,5/1/2009,Child,503,"Korea, Republic of",Results reported in both peer-reviewed journal & registry,12/1/2011,21817957,https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT00680914,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 3,3,PCV13 (Prevnar 13),Registered,Subunit conjugate,Conjugate: specify antigen & carrier CRM197,"1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F & 23F",None,NCT00689351,Completed,Pfizer,Industry,1/6/2008,11/1/2009,3/1/2009,Child,168,Taiwan,Results reported in both peer-reviewed journal & registry,3/9/2012,22198517,https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT00688870,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 2,2,PCV13 (Prevnar 13),Registered,Subunit conjugate,Conjugate: specify antigen & carrier CRM197,"1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F & 23F",None,NCT00695877,Completed,Pfizer,Industry,1/6/2008,12/1/2009,12/1/2009,Child,180,"Korea, Republic of",Results reported in both peer-reviewed journal & registry,3/1/2013,23011012,https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT00689351,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 1,1,dPly or dPly + PhtD (GSK2189242A),Active candidate / in development,Subunit conjugate,Protein: specify,PlyD1 + PhtD,Aluminum salts (alum),NCT00707967,Completed,GlaxoSmithKline,Industry,30/06/2008,1/15/2009,1/15/2009,Adult,157,Belgium,Results reported in peer-reviewed journal,11/28/2014,24607003,https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT00707798,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 3,3,PCV13 (Prevnar 13),Registered,Subunit conjugate,Conjugate: specify antigen & carrier CRM197,"1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F & 23F",None,NCT00712803,Completed,Pfizer,Industry,1/7/2008,5/1/2010,5/1/2010,Child,225,Mexico,Results reported in both peer-reviewed journal & registry,10/1/2013,2396521,https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT00708682,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 3,3,PPV-23 (Pneumovax 23),Registered,Polysaccharides,,"1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F & 33F",None,NCT00718237,Completed,Menzies School of Health Research,Academic,1/6/2006,7/1/2011,2/1/2011,"Child, Adult",227,Australia,Results reported in peer-reviewed journal,11/27/2015,26529076,https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT00714064,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 2,2,PPV-23 (Pneumovax 23) | TIV,Active candidate / registered,Polysaccharides,,"1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F & 33F",None,NCT00743652,Completed,Memorial Sloan Kettering Cancer Center,Academic,1/8/2008,8/1/2012,8/1/2012,Senior,126,United States,Results reported in registry,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 3,3,PCV13 (Prevnar 13),Registered,Subunit conjugate,Conjugate: specify antigen & carrier CRM197,"1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F & 23F",None,NCT00749034,Completed,Pfizer,Industry,1/1/2009,9/1/2010,9/1/2010,Child,373,United States,Results reported in registry,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 1,1,PhtD + dPly | PCV8,Active candidate / in development,Subunit conjugate,Protein: specify,dPly + PhtD,Licensed other: specify,NCT00757926,Completed,GlaxoSmithKline,Industry,19/09/2008,28/05/2009,28/05/2009,Senior,168,Sweden,Results reported in peer-reviewed journal,5/1/2014,24599529,https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT00756067,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 3,3,PCV10 (Synflorix) | Meningococcal vaccine GSK134612,Active candidate / registered,Subunit conjugate,Conjugate: specify antigen & carrier,"1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F & 23F",None,NCT00761631,Completed,GlaxoSmithKline,Industry,1/10/2008,11/1/2009,6/1/2009,Child,363,Mexico | Taiwan,Results reported in peer-reviewed journal,1/1/2013,23076383,https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT00758264,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 3,3,PCV13 (Prevnar 13),Registered,Subunit conjugate,Conjugate: specify antigen & carrier CRM197,"1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F & 23F",None,NCT00767416,Completed,Pfizer,Industry,1/12/2008,7/1/2010,7/1/2010,Child,1200,United States,Results reported in both peer-reviewed journal & registry,12/1/2011,21983216,https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT00761631,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 3,3,PCV13 (Prevnar 13) | Pentacel,Registered,Subunit conjugate,Conjugate: specify antigen & carrier CRM197,"1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F & 23F",None,NCT00779779,Completed,Sanofi,Industry,1/10/2003,11/1/2006,5/1/2006,Child,1167,United States,Results reported in registry,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 3,3,PCV10 (Synflorix ),Registered,Subunit conjugate,Conjugate: specify antigen & carrier,"1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F & 23F",None,NCT00800670,Completed,GlaxoSmithKline,Industry,1/12/2008,7/1/2009,7/1/2009,Child,172,Slovakia | Sweden,Results reported in peer-reviewed journal,9/1/2011,21572373,https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT00792909,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 3,3,PCV10 (Synflorix ),Registered,Subunit conjugate,Conjugate: specify antigen & carrier,"1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F & 23F",None,NCT00814489,Completed,GlaxoSmithKline,Industry,1/1/2009,11/1/2009,11/1/2009,Child,466,Malaysia | Singapore,Results reported in both peer-reviewed journal & registry,10/2/2014,25278086,https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT00808444,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 1,1,PhtD + dPly + PD (GSK2231395A) | Engerix-B,Active candidate / in development,Subunit conjugate,Protein: specify,PhtD + dPly + PD,Licensed other: specify,NCT00814710,Completed,GlaxoSmithKline,Industry,1/1/2009,6/1/2010,6/1/2010,Adult,40,Sweden,Results reported in both peer-reviewed journal & registry,1/1/2014,,https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT00814489,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 3,3,PCV10 (Synflorix ) | Tritanrix-HebB/Hib,Registered,Subunit conjugate,Conjugate: specify antigen & carrier,"1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F & 23F",None,NCT00824655,Completed,GlaxoSmithKline,Industry,1/3/2009,11/1/2009,11/1/2009,Child,360,India,Results reported in both peer-reviewed journal & registry,5/1/2012,22634448,https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT00814710,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 3,3,PCV13 (Prevnar 13),Registered,Subunit conjugate,Conjugate: specify antigen & carrier CRM197,"1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F & 23F",None,NCT00824850,Completed,Pfizer,Industry,1/3/2009,6/1/2010,6/1/2010,Child,234,Sweden,Results reported in registry,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 2,2,PCV13 (Prevnar 13),Registered,Subunit conjugate,Conjugate: specify antigen & carrier CRM197,"1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F & 23F",None,NCT00829010,Completed,Pfizer,Industry,1/1/2010,9/1/2010,9/1/2010,Child,75,United States,Results reported in both peer-reviewed journal & registry,9/1/2013,24008739,https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT00824850,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 3,3,PCV10 (Synflorix ),Registered,Subunit conjugate,Conjugate: specify antigen & carrier,"1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F & 23F",None,NCT00831012,Completed,GlaxoSmithKline,Industry,1/2/2009,8/1/2012,5/1/2011,Child,489,South Africa,Results reported in both peer-reviewed journal & registry,1/1/2017,28079828,https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT00829010,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 3,3,PCV10 (Synflorix ),Registered,Subunit conjugate,Conjugate: specify antigen & carrier,"1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F & 23F",None,NCT00842530,Completed,GlaxoSmithKline,Industry,1/2/2009,1/1/2012,1/1/2012,Child,6181,Finland,Results reported in peer-reviewed journal,1/19/2013,23158882,https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT00861380,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 1,1,PhtD + dPly + PD (GSK2231395A),Active candidate / in development,Subunit conjugate,Protein: specify,PhtD + dPly + PD,Licensed other: specify,NCT00853749,Terminated,GlaxoSmithKline,Industry,1/3/2009,4/1/2009,4/1/2009,Adult,30,Canada | Belgium,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 3,3,PCV13 (Prevnar 13),Registered,Subunit conjugate,Conjugate: specify antigen & carrier CRM197,"1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F & 23F",None,NCT00861380,Completed,Pfizer,Industry,1/5/2009,8/1/2010,8/1/2010,Child,89,Iceland,Results reported in registry,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 3,3,PCV10 (Synflorix ),Registered,Subunit conjugate,Conjugate: specify antigen & carrier,"1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F & 23F",None,NCT00865566,Completed,GlaxoSmithKline,Industry,1/5/2009,10/1/2013,1/1/2012,Child,41188,Finland,Results reported in peer-reviewed journal,19/01/2013,23158882,https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT00861380,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 1,1,PcsB + StkP + PsaA (IC47),Active candidate / in development,Subunit conjugate,Protein: specify,"PcsB, StkP & PsaA",Aluminum salts (alum),NCT00875524,Completed,Valneva Austria GmbH,Other | Industry,1/3/2009,2/1/2010,2/1/2010,Adult,32,Germany,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 3,3,PCV10 (Synflorix) | PCV (Prevenar) |Menitorix|Meningitec|NeisVac|Infanrix hexa| Infanrix penta|Infanrix IPV/Hib|Infanrix IPV,Registered,Subunit conjugate,Conjugate: specify antigen & carrier,"1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F & 23F",None,NCT00896064,Completed,GlaxoSmithKline,Industry,1/5/2009,11/1/2012,10/1/2012,Child,582,Germany | Poland | Spain,Results reported in both peer-reviewed journal & registry,7/5/2016,27145999,https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT00891176,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 2,2,dPly + PhtD (GSK2189242A),Active candidate / in development,Subunit conjugate,Protein: specify,PlyD1 + PhtD,Aluminum salts (alum),NCT00900978,Completed,GlaxoSmithKline,Industry,1/5/2009,8/1/2009,8/1/2009,Adult,43,Belgium,Results reported in peer-reviewed journal,11/28/2014,24607003,https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT00707798,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 1|Phase 2,1.5,PCV7 (Prevnar 7),Registered,Subunit conjugate,Conjugate: specify antigen & carrier,"4, 6B, 9V, 14, 18C, 19F & 23F",None,NCT00901654,Unknown,German-Jordanian University,Academic | Industry,1/5/2009,10/1/2010,8/1/2010,Child,377,Jordan,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 3,3,PCV10 (Synflorix ),Registered,Subunit conjugate,Conjugate: specify antigen & carrier,"1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F & 23F",None,NCT00911144,Completed,GlaxoSmithKline,Industry,1/6/2009,10/1/2009,10/1/2009,Child,52,Germany,Results reported in both peer-reviewed journal & registry,1/1/2012,21909049,https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT00907777,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 3,3,PCV10 (Synflorix ),Registered,Subunit conjugate,Conjugate: specify antigen & carrier,"1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F & 23F",None,NCT00918580,Completed,GlaxoSmithKline,Industry,1/6/2009,1/1/2010,1/1/2010,Child,450,"Korea, Republic of",Results reported in both peer-reviewed journal & registry,01/012/2011,21817957,https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT00911144,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 3,3,PCV13 (Prevnar 13),Registered,Subunit conjugate,Conjugate: specify antigen & carrier CRM197,"1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F & 23F",None,NCT00919178,Completed,Pfizer,Industry,1/11/2009,3/1/2013,3/1/2013,Child,158,United States | United Kingdom | Egypt | France | Italy | Lebanon | Saudi Arabia,Results reported in registry,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 3,3,PCV10 (Synflorix ),Registered,Subunit conjugate,Conjugate: specify antigen & carrier,"1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F & 23F",None,NCT00953056,Completed,GlaxoSmithKline,Industry,1/8/2009,10/1/2010,9/1/2010,Child,467,Czech Republic,Results reported in peer-reviewed journal,4/12/2013,23391599,https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT00950833,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 3,3,PCV13 (Prevnar 13),Registered,Subunit conjugate,Conjugate: specify antigen & carrier CRM197,"1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F & 23F",None,NCT00963235,Completed,Pfizer,Industry,1/3/2010,4/1/2013,4/1/2013,"Child, Adult",303,Romania | South Africa,Results reported in both peer-reviewed journal & registry,1/17/2015,25888646,https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT00962780,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 3,3,PCV13 (Prevnar 13),Registered,Subunit conjugate,Conjugate: specify antigen & carrier CRM197,"1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F & 23F",None,NCT00969228,Completed,Pfizer,Industry,1/11/2009,5/1/2012,5/1/2012,Adult,331,United States,Results reported in both peer-reviewed journal & registry,7/1/2015,25395187,https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT00963235,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 3,3,PCV13 (Prevnar 13) | PPV-23 (Pneumovax 23),Registered,Subunit conjugate,Conjugate: specify antigen & carrier CRM197,"1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F & 23F",None,NCT00981669,Completed,Pfizer,Industry,1/1/2010,5/1/2013,5/1/2013,"Child, Adult",251,United States | Belgium | Canada | Czech Republic | France | Germany | Netherlands | Poland | Spain | Sweden,Results reported in registry,8/1/2015,25870329,https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT00980655,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 3,3,PCV10 (Synflorix ),Registered,Subunit conjugate,Conjugate: specify antigen & carrier,"1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F & 23F",None,NCT00985751,Completed,GlaxoSmithKline,Industry,1/11/2009,7/1/2010,6/1/2010,Child,210,Mali,Results reported in peer-reviewed journal,2/1/2013,23291945,https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT00985465,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 2,2,dPly + PhtD (GSK2189242A),Active candidate / in development,Subunit conjugate,Protein: specify,PlyD1 + PhtD,Aluminum salts (alum),NCT00993447,Completed,GlaxoSmithKline,Industry,1/11/2009,3/1/2011,10/1/2010,Child,257,Czech Republic,Results reported in peer-reviewed journal,23/05/2014,24699466,https://www.ncbi.nlm.nih.gov/pubmed/24699466,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 3,3,PCV13 (Prevnar 13) | PPV-23 (Pneumovax 23),Registered,Subunit conjugate,Conjugate: specify antigen & carrier CRM197,"1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F & 23F",None,NCT01017536,Unknown,Hospital Universitari Son Dureta,Academic,1/12/2007,4/1/2010,4/1/2008,Adult,220,Spain,Results reported in peer-reviewed journal,6/15/2010,20299956,https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT00999739,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 3,3,PCV13 (Prevnar 13) | PPV-23 (Pneumovax 23),Registered,Subunit conjugate,Conjugate: specify antigen & carrier CRM197,"1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F & 23F",None,NCT01026779,Completed,Pfizer,Industry,1/12/2009,10/1/2010,10/1/2010,Adult,962,United States,Results reported in registry,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 3,3,PCV13 (Prevnar 13),Registered,Subunit conjugate,Conjugate: specify antigen & carrier CRM197,"1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F & 23F",None,NCT01027845,Completed,Pfizer,Industry,1/4/2010,11/1/2010,11/1/2010,"Child, Adult",263,France,Results reported in registry,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 3,3,PCV10 (Synflorix ),Registered,Subunit conjugate,Conjugate: specify antigen & carrier,"1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F & 23F",None,NCT01040325,Completed,GlaxoSmithKline,Industry,1/12/2009,9/1/2011,8/1/2010,Child,360,Japan,Results reported in peer-reviewed journal,12/1/2015,25830489,https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT01027845,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 3,3,PCV10 (Synflorix ),Registered,Subunit conjugate,Conjugate: specify antigen & carrier,"1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F & 23F",None,NCT01049282,Completed,GlaxoSmithKline,Industry,1/4/2010,8/1/2011,8/1/2011,Child,282,India,Results reported in both peer-reviewed journal & registry,9/1/2014,25008901,https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT01030822,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 1,1,Salmonella Typhi-vectored pneumonia vaccine,Active candidate / in development,"Live, attenuated target organism",Protein: specify,PspA,None,NCT01060748,Completed,Arizona State University,Academic,1/8/2009,7/1/2011,7/1/2011,Adult,60,United States,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 3,3,PCV10 (Synflorix ),Registered,Subunit conjugate,Conjugate: specify antigen & carrier,"1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F & 23F",None,NCT01142765,Completed,GlaxoSmithKline,Industry,1/7/2010,2/1/2011,2/1/2011,Child,238,Singapore,Results reported in both peer-reviewed journal & registry,10/1/2014,25278086,https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT01119625,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 3,3,PCV10 (Synflorix ),Registered,Subunit conjugate,Conjugate: specify antigen & carrier,"1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F & 23F",None,NCT01159990,Completed,GlaxoSmithKline,Industry,1/2/2011,7/1/2011,7/1/2011,Child,300,Vietnam,Results reported in both peer-reviewed journal & registry,2/21/2013,23432812,https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT01153841,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 3,3,PCV10 (Synflorix ),Registered,Subunit conjugate,Conjugate: specify antigen & carrier,"1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F & 23F",None,NCT01162590,Completed,GlaxoSmithKline,Industry,1/10/2010,2/1/2011,2/1/2011,Child,105,Nigeria,Results reported in both peer-reviewed journal & registry,12/4/2013,24356787,https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT01153893,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 3,3,PCV10 (Synflorix ),Registered,Subunit conjugate,Conjugate: specify antigen & carrier,"1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F & 23F",None,NCT01194180,Completed,GlaxoSmithKline,Industry,1/6/2011,5/1/2013,1/1/2013,Child,300,Burkina Faso,Results reported in peer-reviewed journal,12/27/2016,28030521,https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT01175083,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 3,3,PCV13 (Prevnar 13) | DTaP,Registered,Subunit conjugate,Conjugate: specify antigen & carrier CRM197,"1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F & 23F",None,NCT01215188,Completed,Pfizer,Industry,1/9/2010,11/1/2011,11/1/2011,Child,551,Japan,Results reported in registry,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 2,2,dPly + PhtD (GSK2189242A),Active candidate / in development,Subunit conjugate,Protein: specify,PlyD1 + PhtD,Aluminum salts (alum),NCT01222338,Completed,GlaxoSmithKline,Industry,1/9/2010,10/1/2012,11/1/2011,Child,576,Czech Republic| Germany | Poland | Sweden,Results reported in registry,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 1,1,PCV15 (V114),Active candidate / in development,Subunit conjugate,Conjugate: specify antigen & carrier CRM197,"1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F , 22F, 23F & 33F",Aluminum salts (alum),NCT01224639,Completed,Merck Sharp & Dohme Corp.,Industry,1/9/2009,1/1/2011,4/1/2010,"Child, Adult",150,United States,Results reported in peer-reviewed journal,4/23/2015,25741971,https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT01215175,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 2,2,PCV15 (V114),Active candidate / in development,Subunit conjugate,Conjugate: specify antigen & carrier CRM197,"1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F , 22F, 23F & 33F",None,NCT01231503,Completed,Merck Sharp & Dohme Corp.,Industry,1/10/2010,7/1/2012,7/1/2012,Child,1152,Canada | Finland | Puerto Rico | Spain | United States,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 2,2,dPly + PhtD (GSK2189242A),Active candidate / in development,Subunit conjugate,Protein: specify,PlyD1 + PhtD,Aluminum salts (alum),NCT01290419,Completed,GlaxoSmithKline,Industry,1/2/2011,3/1/2013,3/1/2013,Child,1320,Gambia,Results reported in both peer-reviewed journal & registry,5/2/2017,28389097,https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT01262872,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 2,2,PCV7 (Prevnar 7) | PPV-23 (Pneumovax 23),Registered,Subunit conjugate,Conjugate: specify antigen & carrier,"4, 6B, 9V, 14, 18C, 19F & 23F",None,NCT01432262,Completed,Papua New Guinea Institute of Medical Research,Academic,1/12/2009,9/1/2012,9/1/2011,Child,280,Papua New Guinea,Results reported in peer-reviewed journal,10/13/2017,29028802,https://www.ncbi.nlm.nih.gov/pubmed/29028802,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 3,3,PCV13 (Prevnar 13) | PPV-23 (Pneumovax 23),Registered,Subunit conjugate,Conjugate: specify antigen & carrier CRM197,"1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F & 23F",None,NCT01435135,Completed,University of Oxford,Academic,1/1/2012,8/1/2012,8/1/2012,Adult,4,United Kingdom,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 3,3,PCV13 (Prevnar 13),Registered,Subunit conjugate,Conjugate: specify antigen & carrier CRM197,"1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F & 23F",None,NCT01436396,Completed,Pfizer,Industry,1/7/2011,2/1/2011,12/1/2011,Adult,324,Mexico,Results reported in both peer-reviewed journal & registry,2/1/2015,25499011,https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT01432262,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 2,2,PCV13 (Prevnar 13) | PPV-23 (Pneumovax 23),Registered,Subunit conjugate,Conjugate: specify antigen & carrier CRM197,"1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F & 23F",None,NCT01444339,Withdrawn,NIAID,Government,Unspecified,8/1/2014,8/1/2014,"Child, Adult",0,Thailand,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 3,3,PCV13 (Prevnar 13) | PCV10 (Synflorix),Registered,Subunit conjugate,Conjugate: specify antigen & carrier CRM197,"1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F & 23F",None,NCT01444352,Completed,University of Oxford,Academic,1/4/2012,8/1/2013,8/1/2013,Child,178,United Kingdom,Results reported in peer-reviewed journal,12/1/2016,,discovery.ucl.ac.uk/.../Truck%20et%20al%20The%20Antibody%20Response%20Foll...,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 1,1,PhtD,Active candidate / in development,Subunit conjugate,Protein: specify,PhtD,Aluminum salts (alum),NCT01446926,Completed,Sanofi,Industry,1/2/2007,8/1/2007,8/1/2007,Adult,63,Switzerland,Results reported in peer-reviewed journal,12/14/2012,23131206,https://www.ncbi.nlm.nih.gov/pubmed/23131206?dopt=Abstract,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 1,1,PhtD + PcpA or PcpA,Active candidate / in development,Subunit conjugate,Protein: specify,PhtD + PcpA,Aluminum salts (alum),NCT01450280,Completed,Sanofi,Industry,1/2/2010,9/1/2010,9/1/2010,Adult,131,Switzerland,Results reported in peer-reviewed journal,12/14/2012,23123106,https://www.ncbi.nlm.nih.gov/pubmed/23123106?dopt=Abstract,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 1,1,PlyD1,Active candidate / in development,Subunit conjugate,Protein: specify,PlyD1,Aluminum salts (alum),NCT01450293,Completed,Sanofi,Industry,1/6/2010,1/1/2011,1/1/2011,Adult,100,Switzerland,Results reported in peer-reviewed journal,1/2/2013,23153437,https://www.ncbi.nlm.nih.gov/pubmed/23153437?dopt=Abstract,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 1,1,PlyD1 + PhtD + PcpA,Active candidate / in development,Subunit conjugate,Protein: specify,PlyD1 + PhtD + PcpA,Aluminum salts (alum),NCT01451086,Completed,Sanofi,Industry,1/9/2011,6/1/2013,3/1/2013,"Child, Adult",280,Bangladesh,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 3,3,PPV-23 (Pneumovax 23),Registered,Polysaccharides,,"1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F & 33F",None,NCT01479296,Completed,Jiangsu Province Centers for Disease Control & Prevention,Other | Industry,1/10/2011,8/1/2012,7/1/2012,"Child, Adult",1200,China,Results reported in peer-reviewed journal,3/1/2015,PMC4514320,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514320/,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 1,1,PCV10 (Synflorix ),Registered,Subunit conjugate,Conjugate: specify antigen & carrier,"1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F & 23F",None,NCT01502358,Completed,GlaxoSmithKline,Industry,12/12/2011,3/15/2012,3/15/2012,Child,61,Germany,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 2,2,PCV15 (V114),Active candidate / in development,Subunit conjugate,Conjugate: specify antigen & carrier CRM197,"1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F , 22F, 23F & 33F",None,NCT01537185,Completed,Merck Sharp & Dohme Corp.,Industry,1/3/2012,2/1/2013,9/1/2012,Adult,692,Canada | Israel | Norway | Poland | Spain | Sweden | United States,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 1,1,PCV13 (Prevnar 13),Registered,Subunit conjugate,Conjugate: specify antigen & carrier CRM197,"1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F & 23F",None,NCT01540474,Completed,Pfizer,Industry,1/10/2011,1/1/2012,1/1/2012,"Child, Adult",72,China,Results reported in peer-reviewed journal,12/1/2015,PMC4667767,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4667767/,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 1,1,PATH-wSP,Active candidate / in development,Inactivated whole target organism,,,Aluminum salts (alum),NCT01545375,Completed,PATH,Other,1/2/2012,4/1/2013,10/1/2012,Adult,42,United States,Results reported in registry,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 2,2,dPly + PhtD (GSK2189242A),Active candidate / in development,Subunit conjugate,Protein: specify,PlyD1 + PhtD,Aluminum salts (alum),NCT01578889,Completed,GlaxoSmithKline,Industry,1/5/2012,7/1/2016,7/1/2016,Child,1805,United States,Results reported in registry,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 2,2,PCV11 | PCV12,Active candidate / in development,Subunit conjugate,Conjugate: specify antigen & carrier,,None,NCT01623557,Completed,GlaxoSmithKline,Industry,1/7/2012,1/22/2014,4/25/2013,Child,953,Germany | Poland | Spain | Czech Republic,Results reported in registry,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 3,3,PCV13 (Prevnar 13) | PCV10 (Synflorix),Registered,Subunit conjugate,Conjugate: specify antigen & carrier CRM197,"1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F & 23F",None,NCT01641133,Unknown,Papua New Guinea Institute of Medical Research,Academic,1/11/2011,11/1/2016,4/1/2014,Child,200,Papua New Guinea,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 3,3,PCV10 (Synflorix ),Registered,Subunit conjugate,Conjugate: specify antigen & carrier,"1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F & 23F",None,NCT01650389,Completed,GlaxoSmithKline,Industry,1/9/2012,5/1/2014,7/1/2013,Child,457,Mexico,Results reported in registry,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 3,3,PCV13 (Prevnar 13),Registered,Subunit conjugate,Conjugate: specify antigen & carrier CRM197,"1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F & 23F",None,NCT01658696,Completed,Pfizer,Industry,1/6/2012,10/1/2012,10/1/2012,Senior,764,Japan,Results reported in registry,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 2,2,PCV13 (Prevnar 13),Registered,Subunit conjugate,Conjugate: specify antigen & carrier CRM197,"1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F & 23F",None,NCT01666925,Completed,NIAID,Other,10/10/2012,8/21/2015,8/21/2015,Adult,884,United States,Results reported in registry,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 3,3,PCV13 (Prevnar 13),Registered,Subunit conjugate,Conjugate: specify antigen & carrier CRM197,"1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F & 23F",None,NCT01704365,Completed,Pfizer,Industry,1/8/2012,4/1/2014,4/1/2014,Child,1674,China,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 3,3,PPV-23 (Pneumovax 23),Registered,Polysaccharides,,"1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F & 33F",None,NCT01739231,Completed,Merck Sharp & Dohme Corp.,Industry,1/6/2013,10/1/2013,10/1/2013,"Child, Adult",102,Russian Federation,Results reported in both peer-reviewed journal & registry,8/2/2016,27149114,https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT01734239,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 3,3,PCV10 (Synflorix ),Registered,Subunit conjugate,Conjugate: specify antigen & carrier,"1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F & 23F",None,NCT01764256,Completed,GlaxoSmithKline,Industry,1/6/2013,6/1/2015,6/1/2015,Child,52,Poland | Russian Federation,Results reported in registry,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 1,1,PspA + PhtD + PlyD1 (PPrV),Active candidate / in development,Subunit conjugate,Protein: specify,"PspA, PhtD & PlyD1",Aluminum salts (alum),NCT01767402,Completed,icddrb,Other | Industry,1/9/2011,2/1/2014,2/1/2014,"Child, Adult",280,Bangladesh,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 1,1,PhtD,Active candidate / in development,Subunit conjugate,Protein: specify,PhtD,Licensed other: specify,NCT01805921,Completed,GlaxoSmithKline,Industry,1/10/2003,11/1/2004,11/1/2004,Adult,150,Belgium,Results reported in peer-reviewed journal,1/15/2015,24176494,https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT01767402,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 2,2,PCV13 (Prevnar 13),Registered,Subunit conjugate,Conjugate: specify antigen & carrier CRM197,"1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F & 23F",None,NCT01861730,Completed,Karolinska University Hospital,Academic | Industry,1/5/2013,12/1/2013,11/1/2013,Adult,20,Sweden,Results reported in peer-reviewed journal,5/9/2017,28410816,https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT01847781,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 3,3,PCV13 (Prevnar 13),Registered,Subunit conjugate,Conjugate: specify antigen & carrier CRM197,"1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F & 23F",None,NCT01922284,Completed,Karolinska University Hospital,Academic,1/8/2013,12/1/2015,12/1/2015,Adult,134,Sweden,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 3,3,PCV13 (Prevnar 13) | Meningococcal vaccine GSK134612,Active candidate / registered,Subunit conjugate,Conjugate: specify antigen & carrier CRM197,"1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F & 23F",None,NCT01949909,"Open, not recruiting",GlaxoSmithKline,Industry,1/10/2013,2/1/2020,2/1/2020,Child,900,Australia | Canada | Czech Republic | Panama | South Africa | Turkey,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 3,3,PCV 13 (Prevnar 13) | PPV-23 (Pneumo23) | Methotrexate,Registered,Subunit conjugate,Conjugate: specify antigen & carrier CRM197,"1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F & 23F",None,NCT01953510,"Open, recruiting","University Hospital, Montpellier",Academic | Industry,1/9/2013,3/1/2018,4/1/2017,Adult,276,France | Monaco,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 2|Phase 3,2.5,PCV 13 (Prevnar 13) | PCV10 (Synflorix),Registered,Subunit conjugate,Conjugate: specify antigen & carrier CRM197,"1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F & 23F",None,NCT01960725,"Open, not recruiting",Murdoch Childrens Research Institute,Academic | Industry,30/09/2013,12/1/2016,5/1/2015,Child,1400,Vietnam,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 3,3,PCV13 (Prevnar 13),Registered,Subunit conjugate,Conjugate: specify antigen & carrier CRM197,"1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F & 23F",None,NCT01968083,Completed,Pfizer,Industry,1/1/2014,9/1/2014,9/1/2014,Child,500,Gambia,Results reported in both peer-reviewed journal & registry,31/05/2017,28479175,https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT01964716,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 1,1,GEN-004,Active candidate / in development,Recombinant subunit,Protein: specify,"3 recombinant T cell antigens : GB104: ABC transporter, substrate-binding protein / GB144: Maltose/maltodextrin binding protein, ABC transporter / GB152: Hypothetical protein",Aluminum salts (alum),NCT02014727,Completed,"Genocea Biosciences, Inc.",Industry,1/11/2013,2/1/2015,2/1/2015,Adult,90,United States,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 1|Phase 2,1.5,PCV15 (V114),Active candidate / in development,Subunit conjugate,Conjugate: specify antigen & carrier CRM197,"1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F , 22F, 23F & 33F",None,NCT02052154,Completed,Merck Sharp & Dohme Corp.,Industry,1/1/2014,7/1/2016,7/1/2016,"Child, Adult",341,United States,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 2,2,PCV13 (Prevnar 13) | PPV-23 (Pneumovax 23),Registered,Subunit conjugate,Conjugate: specify antigen & carrier CRM197,"1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F & 23F",None,NCT02062580,"Open, not recruiting",Hopitaux de Paris,Academic,1/3/2014,9/1/2019,2/1/2019,Adult,70,France,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 3,3,PCV13 (NBP606),Active candidate / in development,Subunit conjugate,Conjugate: specify antigen & carrier CRM197,"1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F & 23F",None,NCT02088892,Completed,"SK Chemicals Co.,Ltd.",Industry,1/12/2013,3/1/2015,10/1/2014,Adult,767,Unspecified,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 1|Phase 2,1.5,PATH-wSP,Active candidate / in development,Inactivated whole target organism,,,Aluminum salts (alum),NCT02109874,Completed,PATH,Other,1/4/2014,12/1/2015,12/1/2015,Adult,304,Kenya,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 2,2,GEN-004,Active candidate / in development,Recombinant subunit,Protein: specify,"3 recombinant T cell antigens : GB104: ABC transporter, substrate-binding protein / GB144: Maltose/maltodextrin binding protein, ABC transporter / GB152: Hypothetical protein",Aluminum salts (alum),NCT02132299,Completed,"Genocea Biosciences, Inc.",Industry,1/9/2014,4/1/2016,4/1/2016,Adult,98,United Kingdom,Results reported in peer-reviewed journal,6/20/2016,,https://www.genocea.com/assets/Hetherington_GEN-004-002_ASM-ICAAC-2016_poster_presented_20Jun2016-1.pdf,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 3,3,PCV13 (Prevnar 13),Registered,Subunit conjugate,Conjugate: specify antigen & carrier CRM197,"1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F & 23F",None,NCT02141204,Completed,University of Siena,Academic,1/12/2011,10/1/2013,10/1/2013,Adult,50,Italy,Results reported in peer-reviewed journal,6/3/2016,27258647,https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT02123433,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 3,3,PCV13 (NBP606),Active candidate / in development,Subunit conjugate,Conjugate: specify antigen & carrier,"1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F & 23F",None,NCT02225587,"Open, recruiting","SK Chemicals Co.,Ltd.",Industry,1/9/2014,12/1/2016,6/1/2016,Child,534,"Korea, Republic of",Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 3,3,PCV13 (Prevnar 13) | PPV-23 (Pneumovax 23),Registered,Subunit conjugate,Conjugate: specify antigen & carrier CRM197,"1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F & 23F",None,NCT02240875,Completed,Merck Sharp & Dohme Corp.,Industry,1/8/2014,7/1/2015,7/1/2015,Adult,400,United States,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 2,2,PCV13 (Prevnar 13) | PPV-23 (Pneumovax 23),Registered,Subunit conjugate,Conjugate: specify antigen & carrier CRM197,"1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F & 23F",None,NCT02274415,"Open, recruiting",Centre Hospitalier Universitaire de Saint Etienne,Academic | Industry,1/4/2015,12/1/2020,12/1/2020,Adult,150,France,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 2,2,PCV13 (Prevnar 13) | PPV-23 (Pneumovax 23),Registered,Subunit conjugate,Conjugate: specify antigen & carrier CRM197,"1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F & 23F",None,NCT02286895,"Open, not recruiting",Hopitaux de Paris,Academic,1/9/2013,3/1/2018,5/1/2016,Adult,180,France,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 2,2,PCV13 (Prevnar 13) | PPV-23 (Pneumovax 23),Registered,Subunit conjugate,Conjugate: specify antigen & carrier CRM197,"1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F & 23F",None,NCT02287480,"Open, not recruiting",Hopitaux de Paris,Academic,1/12/2014,5/1/2018,6/1/2016,Adult,60,Unspecified,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 3,3,PPV-23 (Pneumovax 23),Registered,Polysaccharides,,"1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F & 33F",None,NCT02290340,Completed,"Walvax Biotechnology Co., Ltd.",Academic | Industry,1/9/2012,5/1/2013,12/1/2012,"Child, Adult",1660,China,Results reported in peer-reviewed journal,1/10/2015,PMC4635697,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4635697/,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 1|Phase 2,1.5,PCV10 (SIILPCV10),Registered,Subunit conjugate,Conjugate: specify antigen & carrier,"1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F & 23F",None,NCT02325050,Completed,PATH,Other,1/1/2015,4/1/2016,4/1/2016,"Child, Adult",346,Gambia,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 3,3,PCV10 (Synflorix ),Registered,Subunit conjugate,Conjugate: specify antigen & carrier,"1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F & 23F",None,NCT02472548,Completed,GlaxoSmithKline,Industry,1/6/2015,5/1/2016,1/1/2016,Child,320,Bangladesh,Results reported in registry,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 2,2,PPV13 (Prevnar13) |DTaP/IPV/Hib vaccine|Rotavirus vaccine|4-component Meningococcal B vaccine|Meningococcal C/Hib vaccine (MenC/Hib vaccine)|Measles/Mumps/Rubella Vaccine (MMR vaccine),Active candidate / registered,Subunit conjugate,Conjugate: specify antigen & carrier CRM197,"1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F & 23F",None,NCT02501421,"Open, not recruiting",University of Oxford,Academic,1/8/2015,12/1/2017,12/1/2017,Child,189,United Kingdom,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 3,3,PCV13,Registered,Subunit conjugate,Conjugate: specify antigen & carrier,"1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F & 23F",None,NCT02508376,"Open, not recruiting",Jiangsu Province Centers for Disease Control & Prevention,Other | Industry,1/6/2016,12/1/2017,12/1/2017,Child,900,China,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 1|Phase 2,1.5,PCV15 (V114),Active candidate / in development,Subunit conjugate,Conjugate: specify antigen & carrier CRM197,"1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F , 22F, 23F & 33F",None,NCT02542462,Completed,Merck Sharp & Dohme Corp.,Industry,15/09/2015,4/14/2017,4/14/2017,"Child, Adult",338,United States,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 1,1,PCV13,Registered,Subunit conjugate,Conjugate: specify antigen & carrier,"1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F & 23F",None,NCT02564575,Unknown,Beijing Chaoyang District Centre for Disease Control & Prevention,Other,1/11/2015,12/1/2016,12/1/2016,"Child, Adult",120,Unspecified,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 2,2,PCV15 (V114),Active candidate / in development,Subunit conjugate,Conjugate: specify antigen & carrier CRM197,"1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F , 22F, 23F & 33F",None,NCT02568215,Completed,Merck Sharp & Dohme Corp.,Industry,1/10/2015,1/1/2016,1/1/2016,Adult,690,United States,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 1,1,PspA + PlyD1 (PnuBioVax),Active candidate / in development,Subunit conjugate,Protein: specify,PspA + Ply,Aluminum salts (alum),NCT02598388,Completed,ImmunoBiology Limited,Industry,1/10/2015,9/1/2016,9/1/2016,Adult,36,United Kingdom,Results reported in peer-reviewed journal,6/26/2016,,http://www.immbio.com/uploads/documents/PnuBioVax_Phase_I_Clinical_trial_results.pdf,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 2,2,PCV15 (V114),Active candidate / in development,Subunit conjugate,Conjugate: specify antigen & carrier CRM197,"1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F , 22F, 23F & 33F",None,NCT02600975,Completed,Merck Sharp & Dohme Corp.,Industry,1/10/2015,1/1/2016,1/1/2016,Senior,253,United States,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 3,3,PCV13 (Prevnar 13),Registered,Subunit conjugate,Conjugate: specify antigen & carrier CRM197,"1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F & 23F",None,NCT02658253,"Open, recruiting","Medical Research Council Unit, The Gambia",Other,1/3/2016,12/1/2018,12/1/2017,Adult,600,Gambia,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 4,4,PCV13 (Prevnar 13) | PPV-23 (Pneumovax 23),Registered,Subunit conjugate,Conjugate: specify antigen & carrier CRM197,"1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F & 23F",None,NCT02661464,"Open, recruiting",Jena University Hospital,Government,27/09/2017,8/1/2020,8/1/2020,Adult,132,Germany,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 2,2,PPV-23 (Pneumovax 23) | PCV10 (Synflorix),Registered,Polysaccharides,,"1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F & 33F",None,NCT02741128,"Open, recruiting",Westat,Academic | Government,1/3/2016,5/1/2019,5/1/2019,"Child, Adult",345,Brazil,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 1,1,PPV-23 (Pneumovax 23),Registered,Polysaccharides,,"1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F & 33F",None,NCT02753413,Completed,Mayo Clinic,Other,1/4/2016,7/1/2018,7/1/2017,Adult,260,United States,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 3,3,PCV13,Registered,Subunit conjugate,Conjugate: specify antigen & carrier,"1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F & 23F",None,NCT02788045,Not yet open,"Walvax Biotechnology Co., Ltd.",Industry,1/4/2016,6/1/2017,6/1/2017,Child,2760,Unspecified,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 2,2,PPV-23 (Pneumovax 23) | Act-HIB,Active candidate / registered,Polysaccharides,,"1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F & 33F",None,NCT02860650,Completed,Uppsala University,Academic,1/1/2001,1/1/2010,1/1/2008,"Child, Adult",85,Sweden,Results reported in peer-reviewed journal,2/7/2017,28069358,https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT02806284,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 1,1,PCV13 (LBVE013) | PCV14 (LBVE014),Active candidate / in development,Subunit conjugate,Conjugate: specify antigen & carrier,,None,NCT02926430,Completed,LG Life Sciences,Industry,1/9/2016,3/1/2017,12/1/2016,Adult,63,"Korea, Republic of",Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 3,3,PCV13 (NBP606),Active candidate / in development,Subunit conjugate,Conjugate: specify antigen & carrier,"1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F & 23F",None,NCT02943902,"Open, recruiting","SK Chemicals Co.,Ltd.",Industry,1/10/2015,2/1/2018,10/1/2017,Child,534,"Korea, Republic of",Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 3,3,PCV 13 (Prevnar 13) | PCV10 (Synflorix),Registered,Subunit conjugate,Conjugate: specify antigen & carrier CRM197,"1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F & 23F",None,NCT02968849,"Open, recruiting","University of Witwatersrand, South Africa",Academic,9/1/2017,12/1/2018,6/1/2018,Child,600,South Africa,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 1,1,Multivalent PCV,Active candidate / in development,Subunit conjugate,Conjugate: specify antigen & carrier,,None,NCT02992197,Completed,Pfizer,Industry,1/11/2016,8/1/2017,8/1/2017,Adult,66,United States,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 2,2,PCV15 (V114),Active candidate / in development,Subunit conjugate,Conjugate: specify antigen & carrier CRM197,"1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F , 22F, 23F & 33F",None,NCT03026972,"Open, not recruiting",Merck Sharp & Dohme Corp.,Industry,21/03/2017,10/18/2018,10/18/2018,Child,1050,United States | Canada | Denmark | Finland | Israel | Spain,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 2,2,PCV13 (Prevnar 13) | PPV-23 (Pneumovax 23),Registered,Subunit conjugate,Conjugate: specify antigen & carrier CRM197,"1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F & 23F",None,NCT03110952,Not yet open,Hopitaux de Paris,Academic,1/5/2017,5/1/2021,11/1/2020,Adult,120,France,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 2,2,PCV13 (Prevnar 13) | PPV-23 (Pneumovax 23) | Rituximab,Registered,Subunit conjugate,Conjugate: specify antigen & carrier CRM197,"1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F & 23F",None,NCT03138096,Not yet open,Hopitaux de Paris,Government,1/5/2017,11/1/2020,11/1/2020,Adult,120,France,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 2|Phase 3,2.5,PCV 13 (Prevnar 13) | PCV10 (Synflorix),Registered,Subunit conjugate,Conjugate: specify antigen & carrier CRM197,"1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F & 23F",None,NCT03159975,"Open, recruiting",Murdoch Childrens Research Institute,Other,8/3/2017,3/30/2021,8/30/2020,Child,2500,Vietnam,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 1,1,Bioconjugate PV | PPV-23 (Pneumovax 23),Active candidate / registered,Subunit conjugate,Conjugate: specify antigen & carrier CRM197,"1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F & 23F",None,NTC00981669,"Open, recruiting",LimmaTech Biologics AG,Industry,7/9/2017,5/1/2018,5/1/2018,Adult,70,Germany,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 2,2,Multivalent PCV | PCV13 (Prevnar 13) | PPV-23 (Pneumovax 23),Active candidate / registered,Subunit conjugate,Conjugate: specify antigen & carrier CRM197,"1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F & 23F",None,PACTR2008060000892906,"Open, recruiting",Pfizer,Industry,10/10/2017,12/21/2018,12/21/2018,Adult,440,United States,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 1,1,Multivalent PCV | PPV-23 (Pnemovax 23) | DTaP,Active candidate / registered,Subunit conjugate,Conjugate: specify antigen & carrier CRM197,"1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F & 23F",None,PACTR2010060002033537,"Open, recruiting",Pfizer,Industry,12/10/2017,5/28/2019,5/28/2019,Adult,506,United States,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 1,1,PCV7 (Prevnar 7) | PPV-23 (Pneumovax 23),Registered,Subunit conjugate,Conjugate: specify antigen & carrier,"4, 6B, 9V, 14, 18C, 19F & 23F",None,,Completed,Hospital das Clínicas da Faculdade de Medicina da USP,Academic,1/1/2011,Unspecified,Unspecified,Adult,330,Brazil,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 1,1,PCV7 (VCN7-T),Active candidate / in development,Subunit conjugate,Conjugate: specify antigen & carrier tetanus toxoid,"4, 6B, 9V, 14, 18C, 19F & 23F",None,,Completed,Biomolecular Chemistry Center (CQB),Other,17/06/2012,Unspecified,Unspecified,Adult,40,Cuba,Results reported in peer-reviewed journal,10/1/2015,26947279,https://www.ncbi.nlm.nih.gov/pubmed/?term=RPCEC00000133,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 1,1,PCV7 (VCN7-T),Active candidate / in development,Subunit conjugate,Conjugate: specify antigen & carrier Tetanus toxoid,"4, 6B, 9V, 14, 18C, 19F & 23F",None,,Completed,Biomolecular Chemistry Center (CQB),Other,1/5/2013,Unspecified,Unspecified,Child,45,Cuba,Results reported in peer-reviewed journal,9/15/2014,25068497,https://www.ncbi.nlm.nih.gov/pubmed/?term=RPCEC00000173,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 2|Phase 3,2.5,PCV7 (VCN7-T),Active candidate / in development,Subunit conjugate,Conjugate: specify antigen & carrier tetanus toxoid,"4, 6B, 9V, 14, 18C, 19F & 23F",None,,Completed,Biomolecular Chemistry Center (CQB),Other,9/6/2014,Unspecified,Unspecified,Child,1140,Cuba,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 1|Phase 2,1.5,PCV7 (VCN7-T),Active candidate / in development,Subunit conjugate,Conjugate: specify antigen & carrier tetanus toxoid,"4, 6B, 9V, 14, 18C, 19F & 23F",None,,Not yet open,Finlay Institute,Other,24/05/2017,4/28/2017,Unspecified,Child,880,Cuba,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Pneumococcal Infections,Phase 3,3,PCV13 (GBP411),Active candidate / in development,Subunit conjugate,Conjugate: specify antigen & carrier,"1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F & 23F",None,,Not yet open,"SK Chemicals Co.,Ltd.",Industry,14/04/2017,4/23/2018,Unspecified,Child,100,Tailand,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Rotavirus,Phase 1,1,RV3-BB,Active candidate / in development,"Live, attenuated target organism",Whole Virus,,,ACTRN12610000525088,Completed,Murdoch Children's Reseach Institute,Academic,25/6/2010,,,"Child, Adult",60,Australia,Results reported in peer-reviewed journal,16/04/2013,https://doi.org/10.1016/j.vaccine.2013.04.008,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Rotavirus,Phase 2,2,RV3-BB,Active candidate / in development,"Live, attenuated target organism",Whole Virus,,,ACTRN12611001212943,Completed,Murdoch Children's Reseach Institute,Academic,24/11/2011,,,Child,93,New Zealand,Results reported in peer-reviewed journal,1/12/2015,26318715,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Rotavirus,Phase 2,2,RV3-BB,Active candidate / in development,"Live, attenuated target organism",Whole Virus,,,ACTRN12612001282875,Completed,Murdoch Children's Reseach Institute,Academic,12/12/2012,,,Child,1647,Indonesia,Results reported in peer-reviewed journal,1/12/2015,26318715,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Rotavirus,Phase 1,1,Hexavalent BRV Vaccine,Active candidate / in development,"Live, attenuated target organism",Whole Virus,,,ChiCTR-PIR-16008824,"Open, recruiting",Hebei Center for Disease Control & Prevention,Government,12/7/2017,,,"Child, Adult",200,China,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Rotavirus,Phase 2,2,Rotasiil,Registered,"Live, attenuated target organism",Whole Virus,,,CTRI/2009/091/000821,Completed,Serum Institute of India Pvt. Ltd.,Industry,21/10/2009,21/12/2010,21/12/2010,Adult,114,India,Results reported in peer-reviewed journal,11/8/2014,https://doi.org/10.1016/j.vaccine.2014.03.003,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Rotavirus,Phase 2,2,Rotasiil,Registered,"Live, attenuated target organism",Whole Virus,,,CTRI/2010/091/003064,Completed,Serum Institute of India Pvt. Ltd.,Industry,10/1/2011,10/6/2011,,Child,60,India,Results reported in peer-reviewed journal,11/8/2014,https://doi.org/10.1016/j.vaccine.2014.03.003,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Rotavirus,Phase 2,2,BRV-TV,Active candidate / in development,"Live, attenuated target organism",Whole Virus,,,CTRI/2012/07/002820,Completed,Shantha Biotechnics Limited,Industry,23/7/2012,,,Adult,120,India,Results reported in peer-reviewed journal,1/8/2014,25091664,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Rotavirus,Phase 3,3,ROTAVAC,Registered,"Live, attenuated target organism",Whole Virus,,,CTRI/2014/04/004548,"Open, recruiting",Bharat Biotech International Limited,Industry,17/4/2014,,,Child,900,India,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Rotavirus,Phase 3,3,ROTAVAC,Registered,"Live, attenuated target organism",Whole Virus,,,CTRI/2014/05/004592,Completed,Bharat Biotech International Limited,Industry,13/5/2014,,,Child,1356,India,Results reported in peer-reviewed journal,16/5/2017,PMC5435614,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Rotavirus,Phase 3,3,BRV-TV,Active candidate / in development,"Live, attenuated target organism",Whole Virus,,,CTRI/2014/08/004893,Completed,Shantha Biotechnics Limited,Industry,20/8/2014,,,Child,1182,India,Results reported in peer-reviewed journal,16/6/2017,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Rotavirus,Phase 3,3,ROTAVAC,Registered,"Live, attenuated target organism",Whole Virus,,,CTRI/2015/02/005577,"Open, recruiting",Bharat Biotech International Limited,Industry,25/2/2016,1/2/2018,1/2/2018,Child,1975,India | Vietnam,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Rotavirus,Phase 3,3,Rotasiil,Registered,"Live, attenuated target organism",Whole Virus,,,CTRI/2015/07/006034,Completed,Serum Institute of India Pvt. Ltd.,Industry,7/20/2015,1/10/2016,1/10/2016,Child,1500,India,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Rotavirus,Phase 1,1,LBRV-PV (Liquid formulation of Rotasiil),Active candidate / in development,"Live, attenuated target organism",Whole Virus,,,CTRI/2015/11/006384,"Open, not recruiting",Serum Institute of India Pvt. Ltd.,Industry,26/11/2015,1/3/2016,1/3/2016,Child,20,India,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Rotavirus,Phase 3,3,Rotarix,Registered,"Live, attenuated target organism",Whole Virus,,,EUCTR2006-003239-61-FI,Completed,GlaxoSmithKline,Industry,21/7/2006,24/8/2007,24/8/2007,Child,1200,Finland,Results reported in registry,,,https://www.clinicaltrialsregister.eu/,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Rotavirus,Phase 3,3,Rotarix,Registered,"Live, attenuated target organism",Whole Virus,,,EUCTR2012-005200-18-Outside-EU/EEA,"Open, not recruiting",GlaxoSmithKline,Industry,13/5/2015,,,Child,3333,China,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Rotavirus,Phase 3,3,Rotarix,Registered,"Live, attenuated target organism",Whole Virus,,,NCT00139347,Completed,GlaxoSmithKline,Industry,1/12/2003,1/3/2007,1/3/2007,Child,6360,Argentina | Brazil | Colombia | Dominican Republic | Honduras | Panama,Results reported in both peer-reviewed journal & registry,1/6/2011,21378594,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Rotavirus,Phase 3,3,Rotarix,Registered,"Live, attenuated target organism",Whole Virus,,,NCT00197210,Completed,GlaxoSmithKline,Industry,1/12/2003,1/7/2007,1/7/2007,Child,10708,Singapore,Results reported in peer-reviewed journal,9/10/2009,19679216,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Rotavirus,Phase 3,3,Rotarix,Registered,"Live, attenuated target organism",Whole Virus,,,NCT00241644,Completed,GlaxoSmithKline,Industry,1/10/2005,1/6/2008,1/6/2008,Child,2089,Malawi | South Africa,Results reported in both peer-reviewed journal & registry,13/9/2012,22974466,clinicaltrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Rotavirus,Phase 2,2,Rotarix,Registered,"Live, attenuated target organism",Whole Virus,,,NCT00263666,Completed,GlaxoSmithKline,Industry,1/3/2005,1/2/2008,1/2/2008,Child,100,South Africa,Results reported in both peer-reviewed journal & registry,5/1/2006,16394298,https://clinicaltrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Rotavirus,Phase 3,3,Rotarix,Registered,"Live, attenuated target organism",Whole Virus,,,NCT00329745,Completed,GlaxoSmithKline,Industry,1/1/2007,1/7/2008,1/7/2008,Child,8687,Singapore,Results reported in registry,,,https://clinicaltrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Rotavirus,Phase 3,3,Rotarix,Registered,"Live, attenuated target organism",Whole Virus,,,NCT00334607,Completed,GlaxoSmithKline,Industry,1/6/2007,1/2/2007,1/6/2007,Child,484,USA,Results reported in peer-reviewed journal,1/11/2008,18977955,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Rotavirus,Phase 3,3,Rotarix,Registered,"Live, attenuated target organism",Whole Virus,,,NCT00345956,Completed,GlaxoSmithKline,Industry,1/9/2006,1/3/2007,1/3/2007,Child,375,Vietnam,Results reported in peer-reviewed journal,3/3/2011,21256876,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Rotavirus,Phase 3,3,RotaTeq,Registered,"Live, attenuated target organism",Whole Virus,,,NCT00362648,Completed,Merck Sharp & Dohme Corp.,Industry,1/3/2007,1/3/2009,1/3/2009,Child,7504,Ghana | Kenya | Mali,Results reported in peer-reviewed journal,21/8/2010,20692030,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Rotavirus,Phase 3,3,Rotarix,Registered,"Live, attenuated target organism",Whole Virus,,,NCT00363545,Completed,GlaxoSmithKline,Industry,1/9/2006,1/4/2007,1/4/2007,Child,1270,Panama,Results reported in registry,,,https://clinicaltrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Rotavirus,Phase 3,3,Rotarix,Registered,"Live, attenuated target organism",Whole Virus,,,NCT00382772,Completed,GlaxoSmithKline,Industry,1/11/2006,1/4/2007,1/8/2007,Child,1200,Finland,Results reported in peer-reviewed journal,1/3/2011,21238572,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Rotavirus,Phase 3,3,Rotarix,Registered,"Live, attenuated target organism",Whole Virus,,,NCT00396630,Completed,GlaxoSmithKline,Industry,1/1/2007,1/1/2008,1/2/2008,Child,200,Dominican Republic,Results reported in peer-reviewed journal,28/11/2011,22008819,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Rotavirus,Phase 3,3,Rotarix,Registered,"Live, attenuated target organism",Whole Virus,,,NCT00420316,Completed,GlaxoSmithKline,Industry,1/2/2007,1/8/2007,1/8/2007,Child,2601,Finland,Results reported in registry,,,https://clinicaltrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Rotavirus,Phase 3,3,Rotarix,Registered,"Live, attenuated target organism",Whole Virus,,,NCT00420745,Completed,GlaxoSmithKline,Industry,1/1/2007,1/3/2008,1/3/2008,Child,1009,France | Poland | Portugal | Spain,Results reported in peer-reviewed journal,1/5/2012,22228231,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Rotavirus,Phase 2,2,Rotarix,Registered,"Live, attenuated target organism",Whole Virus,,,NCT00432380,Completed,GlaxoSmithKline,Industry,1/3/2007,1/9/2007,1/9/2007,Child,375,Philippines,Results reported in peer-reviewed journal,3/3/2011,21256876,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Rotavirus,Phase 2,2,ROTAVAC,Registered,"Live, attenuated target organism",Whole Virus,,,NCT00439660,Completed,Bharat Biotech International Limited,Industry,1/12/2006,1/11/2008,1/11/2008,Child,540,India,Results reported in peer-reviewed journal,1/7/2006,16735085,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Rotavirus,Phase 3,3,Rotarix,Registered,"Live, attenuated target organism",Whole Virus,,,NCT00480324,Completed,GlaxoSmithKline,Industry,1/6/2007,1/3/2009,1/11/2009,Child,765,Japan,Results reported in both peer-reviewed journal & registry,26/8/2011,21640780,https://clinicaltrials.gov/,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Rotavirus,Phase 3,3,RotaTeq,Registered,"Live, attenuated target organism",Whole Virus,,,NCT00496054,Completed,Merck Sharp & Dohme Corp.,Industry,1/5/2008,1/10/2008,1/10/2008,Child,110,India,Results reported in both peer-reviewed journal & registry,1/1/2013,23442588,https://clinicaltrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Rotavirus,Phase 3,3,RotaTeq,Registered,"Live, attenuated target organism",Whole Virus,,,NCT00731471,Completed,Merck Sharp & Dohme Corp.,Industry,1/8/2008,1/8/2009,1/8/2009,Child,762,Japan,Results reported in both peer-reviewed journal & registry,1/8/2013,23732903,https://clinicaltrials.gov/,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Rotavirus,Phase 4,4,Rotarix,Registered,"Live, attenuated target organism",Whole Virus,,,NCT00740090,Completed,"International Centre for Diarrhoeal Disease Research, Bangladesh",Other,1/9/2008,1/3/2011,1/3/2011,Child,4550,Bangladesh,Results reported in both peer-reviewed journal & registry,18/4/2017,28419095,clinicaltrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Rotavirus,Phase 4,4,RotaTeq,Registered,"Live, attenuated target organism",Whole Virus,,,NCT00741039,Completed,"University Hostpital, Brest",Academic,1/5/2007,1/12/2010,1/6/2011,Child,7204,France,Results reported in peer-reviewed journal,1/5/2011,21443962,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Rotavirus,Phase 2,2,BRV-TV,Active candidate / in development,"Live, attenuated target organism",Whole Virus,,,NCT00758264,Withdrawn,Shantha Biotechnics Limited,Other | Industry,1/9/2009,,,N/A,N/A,N/A,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Rotavirus,Phase 4,4,Rotarix,Registered,"Live, attenuated target organism",Whole Virus,,,NCT00788151,Completed,GlaxoSmithKline,Industry,1/11/2008,1/8/2009,1/8/2009,Child,522,Sri Lanka,Results reported in both peer-reviewed journal & registry,1/8/2014,25424932,https://clinicaltrials.gov/,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Rotavirus,Phase 1,1,RotaTeq,Registered,"Live, attenuated target organism",Whole Virus,,,NCT00839254,Withdrawn,Merck Sharp & Dohme Corp.,Industry,1/1/2009,1/1/2010,1/1/2010,Adult,66,N/A,Results reported in both peer-reviewed journal & registry,8/5/2014,25424929,https://clinicaltrials.gov/,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Rotavirus,Phase 2,2,RotaTeq,Registered,"Live, attenuated target organism",Whole Virus,,,NCT00880893,Completed,National Institute of Allergy & Infectious Diseases,Government,1/12/2004,1/1/2014,1/1/2014,Child,202,Botswana | Tanzania | Zambia | Zimbabwe,Results reported in peer-reviewed journal,1/5/2009,19332437,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Rotavirus,Phase 1,1,RotaTeq,Registered,"Live, attenuated target organism",Whole Virus,,,NCT00953927,Completed,Merck Sharp & Dohme Corp.,Industry,1/9/2010,1/3/2010,1/3/2010,"Child, Adult",144,China,Results reported in registry,,,https://clinicaltrials.gov/,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Rotavirus,Phase 4,4,Rotarix,Registered,"Live, attenuated target organism",Whole Virus,,,NCT00980655,Completed,GlaxoSmithKline,Industry,1/8/2009,1/7/2010,1/7/2010,Child,684,South Korea,Results reported in both peer-reviewed journal & registry,1/6/2012,22699440,https://clinicaltrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Rotavirus,Phase 1,1,"Attenuated Pentavalent Rotavirus Vaccine (Serotypes G1, G2, G3, G4, G9)",Active candidate / in development,"Live, attenuated target organism",Whole Virus,,,NCT00984763,Completed,Butantan Institute,Other,1/4/2009,1/4/2010,1/6/2010,Adult,80,Brazil,Results reported in both peer-reviewed journal & registry,,,clinicaltrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Rotavirus,Phase 4,4,Rotarix,Registered,"Live, attenuated target organism",Whole Virus,,,NCT00997607,Completed,Seattle Children's Hospital,Academic,1/12/2009,1/5/2012,1/7/2017,Child,15,USA,Results reported in both peer-reviewed journal & registry,,,clinicaltrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Rotavirus,Phase 4,4,RotaTeq,Registered,"Live, attenuated target organism",Whole Virus,,,NCT01033409,"Open, not recruiting",Lifespan,Industry,1/7/2009,1/6/2017,1/6/2017,Child,560,USA,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Rotavirus,Phase 2,2,BRV-TV,Active candidate / in development,"Live, attenuated target organism",Whole Virus,,,NCT01072786,Unknown,Shantha Biotechnics Limited,Industry,1/7/2010,1/11/2010,1/12/2010,Child,90,India,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Rotavirus,Phase 1,1,Rotarix,Registered,"Live, attenuated target organism",Whole Virus,,,NCT01095224,Completed,GlaxoSmithKline,Industry,1/3/2010,1/4/2010,1/4/2010,Child,50,China,Results reported in peer-reviewed journal,1/8/2013,23807360,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Rotavirus,Phase 1,1,BRV-TV,Active candidate / in development,"Live, attenuated target organism",Whole Virus,,,NCT01098474,Completed,Shantha Biotechnics Limited,Industry,1/4/2010,1/5/2010,1/5/2010,Adult,20,India,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Rotavirus,Phase 1,1,Rotarix,Registered,"Live, attenuated target organism",Whole Virus,,,NCT01119521,Completed,GlaxoSmithKline,Industry,1/4/2010,1/6/2010,1/6/2010,Child,50,China,Results reported in peer-reviewed journal,1/8/2013,23807360,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Rotavirus,Phase 1,1,Rotarix,Registered,"Live, attenuated target organism",Whole Virus,,,NCT01175083,Completed,GlaxoSmithKline,Industry,1/3/2010,31/3/2010,31/3/2010,Adult,52,China,Results reported in peer-reviewed journal,1/8/2013,23807360,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Rotavirus,Phase 3,3,Rotarix,Registered,"Live, attenuated target organism",Whole Virus,,,NCT01187433,Completed,GlaxoSmithKline,Industry,1/8/2010,1/5/2012,1/5/2012,Child,3340,China,Results reported in peer-reviewed journal,1/8/2013,23807360,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Rotavirus,Phase 4,4,Rotarix,Registered,"Live, attenuated target organism",Whole Virus,,,NCT01204658,Completed,GlaxoSmithKline,Industry,1/11/2010,1/4/2011,1/4/2011,Child,15,Taiwan,Results reported in both peer-reviewed journal & registry,1/9/2013,24079716,https://clinicaltrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Rotavirus,Phase 4,4,Rotarix,Registered,"Live, attenuated target organism",Whole Virus,,,NCT01215175,Completed,PATH,Product Development Partner,1/4/2011,1/9/2012,1/6/2013,Child,1140,Pakistan,Results reported in peer-reviewed journal,2/6/2015,26035743,clinicaltrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Rotavirus,Phase 4,4,Rotarix / RotaTeq,Registered,"Live, attenuated target organism",Whole Virus,,,NCT01323972,Completed,National Institute of Allergy & Infectious Diseases,Government,1/3/2011,1/10/2013,1/3/2014,Child,1384,USA,Results reported in both peer-reviewed journal & registry,1/2/2016,26823540,clinicaltrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Rotavirus,Phase 3,3,ROTAVAC,Registered,"Live, attenuated target organism",Whole Virus,,,NCT01340820,Completed,Bharat Biotech International Limited,Industry | Other,1/3/2011,12/1/2012,1/4/2014,Child,6800,India,Results reported in peer-reviewed journal,12/6/2014,24629994,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Rotavirus,Phase 3,3,Rotarix,Registered,"Live, attenuated target organism",Whole Virus,,,NCT01378312,Completed,University of Vermont,Academic,1/5/2011,1/10/2014,1/11/2014,Child,700,Bangladesh,Results reported in peer-reviewed journal,1/4/2015,25711607,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Rotavirus,Phase 1,1,Rotavin-M1,Registered,"Live, attenuated target organism",Whole Virus,,,NCT01379430,Completed,"National Institute of Hygiene & Epidemiology, Vietnam",Government,1/8/2009,1/10/2009,1/10/2009,Adult,29,Vietnam,Results reported in peer-reviewed journal,27/4/2012,22520120,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Rotavirus,Phase 2,2,Rotavin-M1,Registered,"Live, attenuated target organism",Whole Virus,,,NCT01382095,Completed,"National Institute of Hygiene & Epidemiology, Vietnam",Government,1/10/2009,1/3/2010,1/4/2010,Child,200,Vietnam,Results reported in peer-reviewed journal,27/4/2012,22520120,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Rotavirus,Phase 3,3,Rotavin-M1,Registered,"Live, attenuated target organism",Whole Virus,,,NCT01511250,Completed,GlaxoSmithKline,Industry,1/5/2010,1/9/2011,1/10/2011,Child,799,Vietnam,Results reported in peer-reviewed journal,20/11/2009,19931712,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Rotavirus,Phase 4,4,Rotarix,Registered,"Live, attenuated target organism",Whole Virus,,,NCT01600092,Completed,PATH,Product Development Partner,1/9/2012,1/2/2013,1/2/2013,Child,456,Ghana,Results reported in both peer-reviewed journal & registry,27/4/2016,23599316,clinicaltrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Rotavirus,Phase 3,3,RotaTeq,Registered,"Live, attenuated target organism",Whole Virus,,,NCT01616693,Completed,Merck Sharp & Dohme Corp.,Industry,1/4/2013,1/3/2014,1/3/2014,Child,1020,"Canada, Czech Republic, Denmark, Finland, Israel, Mexico, Poland, Spain, Sweden, USA",Results reported in both peer-reviewed journal & registry,1/4/2017,28141698,https://clinicaltrials.gov/,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Rotavirus,Phase 4,4,Rotarix,Registered,"Live, attenuated target organism",Whole Virus,,Novel other: specify,NCT01635647,Completed,PATH,Product Development Partner,1/7/2012,1/7/2013,1/7/2013,Child,620,India,Results reported in both peer-reviewed journal & registry,,,clinicaltrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Rotavirus,Phase 3,3,Trivalent Genetic Reassortment Vaccine,Active candidate / in development,,,,,NCT01746108,Completed,"Lanzhou Institute of Biological Products, China",Industry,1/8/2012,1/6/2014,1/12/2014,Child,10020,China,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Rotavirus,Phase 1,1,Monovalent P2-VP8 Subunit Rotavirus Vaccine,Inactive / no longer in development,"Subunit (e.g., toxoid, carbohydrate) from target organism",,,Aluminum salts (alum),NCT01782300,Completed,PATH,Product Development Partner,1/12/2012,1/6/2013,1/9/2013,Adult,48,USA,Results reported in peer-reviewed journal,,26065919,clinicaltrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Rotavirus,Phase 3,3,Rotarix,Registered,"Live, attenuated target organism",Whole Virus,,,NCT01852266,Completed,"International Centre for Diarrhoeal Disease Research, Bangladesh",Other,1/7/2010,1/4/2011,1/12/2011,"Child, Adult",300,Bangladesh,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Rotavirus,Phase 4,4,RotaTeq,Registered,"Live, attenuated target organism",Whole Virus,,,NCT01967134,Completed,Dennis Clements,Other | Industry,1/2/2014,1/12/2015,1/5/2016,Child,66,United States,Results reported in registry,,,https://clinicaltrials.gov/,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Rotavirus,Phase 3,3,RotaTeq,Registered,"Live, attenuated target organism",Whole Virus,,,NCT02066428,Completed,Merck Sharp & Dohme Corp.,Industry,1/5/2014,1/6/2015,1/6/2015,Child,4040,China,Results reported in registry,,,https://clinicaltrials.gov/,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Rotavirus,Phase 2,2,Monovalent P2-VP8 Subunit Rotavirus Vaccine,Inactive / no longer in development,"Subunit (e.g., toxoid, carbohydrate) from target organism",,,Aluminum salts (alum),NCT02114268,Completed,PATH,Product Development Partner,1/3/2014,1/11/2015,1/11/2015,Child,204,South Africa,Results reported in peer-reviewed journal,17/8/2017,28483414,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Rotavirus,Phase 3,3,Rotasiil,Registered,"Live, attenuated target organism",Whole Virus,,,NCT02165267,Completed,Serum Institute of India Pvt. Ltd.,Industry,1/5/2014,1/3/2016,1/3/2017,Child,7500,India,Results not yet reported,,,clinicaltrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Rotavirus,Phase 3,3,Rotarix,Registered,"Live, attenuated target organism",Whole Virus,,,NCT02174978,Not yet open,GlaxoSmithKline,Industry,23/11/2017,27/5/2018,27/5/2018,Child,308,Unspecified,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Rotavirus,Phase 3,3,Rotasiil,Registered,"Live, attenuated target organism",Whole Virus,,,NCT02178748,Completed,Epicentre,Other,1/6/2014,1/12/2015,1/12/2017,Child,7770,Niger,Results reported in peer-reviewed journal,23/3/2017,28328346,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Rotavirus,Phase 3,3,RotaTeq / Rotarix,Registered,"Live, attenuated target organism",Whole Virus,,,NCT02215707,Completed,"National Institute of Pediatrics, Mexico",Government,1/11/2013,1/10/2016,1/11/2016,Child,1498,Mexico,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Rotavirus,Phase 4,4,RotaTeq,Registered,"Live, attenuated target organism",Whole Virus,,,NCT02296463,Completed,PATH,Product Development Partner,1/10/2014,1/3/2015,1/3/2015,Child,605,Mali,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Rotavirus,Phase 4,4,Rotarix / RotaTeq,Registered,"Live, attenuated target organism",Whole Virus,,,NCT02556996,Completed,"Children's Hospital Medical Center, Cincinnati",Academic,6/24/2015,1/4/2017,1/7/2017,Child,100,USA,Results reported in peer-reviewed journal,1/9/2016,https://doi.org/10.1542/peds.2016-1952,clinicaltrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Rotavirus,Phase 3,3,"Rotasiil, Rotarix",Registered,"Live, attenuated target organism",Whole Virus,,,NCT02601716,Completed,Serum Institute of India Pvt. Ltd.,Industry,1/11/2015,1/12/2017,12/4/2017,Child,1500,India,Results reported in peer-reviewed journal,27/10/2017,https://doi.org/10.1016/j.vaccine.2017.09.014,clinicaltrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Rotavirus,Phase 2,2,Trivalent P2-VP8 subunit rotavirus vaccine,Active candidate / in development,"Subunit (e.g., toxoid, carbohydrate) from target organism",,,Aluminum salts (alum),NCT02670187,Completed,PATH,Product Development Partner,1/2/2016,1/10/2017,1/10/2017,Child,660,South Africa,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Rotavirus,Phase 2,2,Heat Stable Rotavirus (HSRV) Vaccine,Active candidate / in development,"Live, attenuated target organism",Whole Virus,,,NCT02756208,"Open, not recruiting",MSD Wellcome Trust Hilleman Laboratories Pvt. Ltd.,Industry,1/6/2016,1/3/2017,1/5/2017,"Child, Adult",100,Bangladesh,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Rotavirus,Phase 4,4,Rotarix,Registered,"Live, attenuated target organism",Whole Virus,,,NCT02927444,Completed,GlaxoSmithKline,Industry,9/16/2016,5/26/2017,5/26/2017,Child,292,Japan,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Rotavirus,Phase 3,3,Rotarix,Registered,"Live, attenuated target organism",Whole Virus,,,NCT02933281,"Open, recruiting",GlaxoSmithKline,Industry,10/8/2016,13/7/2016,16/11/2018,Child,1600,Costa Rica | Finland | Germany | Japan | South Korea | Taiwan | United States,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Rotavirus,Phase 4,4,Rotarix,Registered,"Live, attenuated target organism",Whole Virus,,,NCT02956837,Not yet open,Telethon Kids Institute,Other,1/12/2016,1/12/2020,1/12/2020,Child,1000,Unspecified,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Rotavirus,Phase 4,4,Rotarix,Registered,"Live, attenuated target organism",Whole Virus,,,NCT03038243,Not yet open,University of Vermont,Academic,1/3/2017,1/12/2017,1/12/2017,Child,220,Bangladesh,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Rotavirus,Phase 2,2,RotaSheild,Inactive / no longer in development,"Live, attenuated target organism",Whole Virus,,,RBR-2gv984,Completed,International Medica Foundation,Other,,,,Child,998,Ghana,Results reported in peer-reviewed journal,,23599316,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Rotavirus,Phase 1,1,"Attenuated Pentavalent Rotavirus Vaccine (Serotypes G1, G2, G3, G4, G9)",Active candidate / in development,"Live, attenuated target organism",Whole Virus,,,RPCEC00000133,Completed,Butantan Institute,Other,1/3/2009,1/6/2010,1/6/2010,Adult,80,Brazil,Results reported in both peer-reviewed journal & registry,4/2/2013,https://doi.org/10.1016/j.vaccine.2012.12.020,clinicaltrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Respiratory Syncytial Virus,Phase 1,1,MEDI-534 (PIV3/RSV F),Inactive / no longer in development,Recombinant viral vector,Protein: specify,PIV3 & RSV fusion (F),None,NCT00345670,Completed,MedImmune LLC,Industry,6/1/2006,5/1/2007,,Child,120,USA,Results reported in peer-reviewed journal,7/1/2009,https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT00345670,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Respiratory Syncytial Virus,Phase 1,1,MEDI-534 (PIV3/RSV F),Inactive / no longer in development,Recombinant viral vector,Protein: specify,PIV3 & RSV fusion (F),None,NCT00493285,Completed,MedImmune LLC,Industry,7/1/2007,11/1/2009,4/1/2010,Child,49,USA,Results reported in registry,,,clinicaltrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Respiratory Syncytial Virus,Phase 2,2,MEDI-534 (PIV3/RSV F),Inactive / no longer in development,Recombinant viral vector,Protein: specify,PIV3 & RSV fusion (F),None,NCT00688870,Completed,MedImmune LLC,Industry,6/1/2008,8/1/2012,8/1/2012,Child,1338,USA | Australia | Brazil | Canada | Finland | Germany | Israel | South Africa | Spain,Results reported in both peer-reviewed journal & registry,6/10/2013,https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT00686075,clinicaltrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Respiratory Syncytial Virus,Phase 2,2,MEDI-559 (RSV live-attenuated),Inactive / no longer in development,"Live, attenuated target organism",Protein: specify,All viral proteins,None,NCT00772928,Completed,MedImmune LLC,Industry,10/1/2008,12/1/2011,12/1/2011,Child,116,USA | Puerto Rico,Results reported in peer-reviewed journal,10/29/2013,https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT00767416,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Respiratory Syncytial Virus,Phase 1,1,RSV F Nanoparticle,Active candidate / in development,Recombinant subunit (non VLP),Protein: specify,RSV fusion (F),Aluminum salts (alum),NCT01336699,Completed,Novavax,Industry,12/1/2010,12/1/2011,12/1/2011,Adult,150,USA,Results reported in peer-reviewed journal,1/7/2013,https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT01290419,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Respiratory Syncytial Virus,Phase 1,1,RSV MEDI ΔM2-2,Inactive / no longer in development,"Live, attenuated target organism",Protein: specify,All viral proteins except M2-2,None,NCT01479972,Completed,NIAID,Government,8/1/2011,6/1/2015,8/1/2015,Adult | Child,60,USA,Results reported in peer-reviewed journal,11/4/2015,https://www.ncbi.nlm.nih.gov/pubmed/?term=A+gene+deletion+that+up-regulates+viral+gene+expression,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Respiratory Syncytial Virus,Phase 2,2,RSV F Nanoparticle,Active candidate / in development,Recombinant subunit (non VLP),Protein: specify,RSV fusion (F),Aluminum salts (alum),NCT01734239,Completed,Novavax,Industry,10/1/2012,4/1/2013,5/1/2013,Adult,330,USA,Results reported in peer-reviewed journal,2/1/2016,https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT01704365,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Respiratory Syncytial Virus,Phase 1,1,RSV F Nanoparticle,Inactive / no longer in development,Recombinant subunit (non VLP),Protein: specify,RSV fusion (F),None,NCT01738074,Completed,Novavax,Industry,10/1/2012,7/1/2013,3/1/2014,Adult | Senior,220,USA,Results reported in peer-reviewed journal,4/12/2017,https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT01709019,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Respiratory Syncytial Virus,Phase 1,1,RSV001 (PanAd3-RSV MVA-RSV),Inactive / no longer in development,Prime-boost: PanAd3-RSV/MVA-RSV,Protein: specify,"RSV fusion (F), Nucleoprotein (N), transcription processivity factor (M2-1)",None,NCT01825109,Completed,ReiThera Srl,Industry,5/1/2013,8/1/2015,8/1/2015,Adult | Senior,72,UK,Results reported in peer-reviewed journal,10/28/2015,https://www.ncbi.nlm.nih.gov/pubmed/26510727,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Respiratory Syncytial Virus,Phase 1,1,RSV cps2,Inactive / no longer in development,"Live, attenuated target organism",Protein: specify,All viral proteins,None,NCT01865487,Completed,NIAID,Government,10/1/2013,7/1/2015,,Child,50,USA,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Respiratory Syncytial Virus,Phase 1,1,RSV ΔNS2 Δ1313 I1314L,Active candidate / in development,"Live, attenuated target organism",Protein: specify,All viral proteins except NS2,None,NCT01922856,"Open, recruiting",NIAID,Government,6/1/2013,5/1/2017,,Child,75,USA,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Respiratory Syncytial Virus,Phase 1,1,GSK3003891A (RSV F),Active candidate / in development,Recombinant subunit (non VLP),Protein: specify,RSV fusion (F),Aluminum salts (alum),NCT01927159,Completed,GlaxoSmithKline,Industry,7/22/2013,4/9/2014,3/16/2015,Adult,128,Canada,Results reported in peer-reviewed journal,9/29/2016,https://academic.oup.com/jid/article/215/1/24/2631192/A-Randomized-Controlled-Observer-Blinded-Phase-1,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Respiratory Syncytial Virus,Phase 2,2,RSV F Nanoparticle,Active candidate / in development,Recombinant subunit (non VLP),Protein: specify,RSV fusion (F),Aluminum salts (alum),NCT01966900,Completed,Novavax,Industry,10/1/2013,4/1/2014,4/1/2014,Adult,720,USA,Results reported in peer-reviewed journal,6/27/2017,http://www.sciencedirect.com/science/article/pii/S0264410X17306813?via%3Dihub,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Respiratory Syncytial Virus,Phase 1,1,RSV cps2,Inactive / no longer in development,"Live, attenuated target organism",Protein: specify,All viral proteins,None,NCT01989533,Completed,NIAID,Government,9/1/2013,5/1/2015,5/1/2015,Child,51,USA,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Respiratory Syncytial Virus,Phase 1,1,RSV LID ΔM2-2,Active candidate / in development,"Live, attenuated target organism",Protein: specify,All viral proteins except M2-2,None,NCT02062385,Completed,NIAID,Government,9/1/2014,4/1/2015,4/1/2015,Child,3,USA,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Respiratory Syncytial Virus,Phase 1,1,MEDI8897 (Anti-RSV mAb),Active candidate / in development,Other: monoclonal antibody specific for RSV fusion (F),Other: specify,,None,NCT02121080,Completed,MedImmune LLC,Industry,4/1/2014,6/1/2015,6/1/2015,Adult,342,USA,Results reported in both peer-reviewed journal & registry,2/23/2017,https://www.ncbi.nlm.nih.gov/pubmed/?term=griffin+MEDI8897,clinicaltrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Respiratory Syncytial Virus,Phase 1,1,MEDI7510 (RSV sF + Adj),Inactive / no longer in development,Recombinant subunit (non VLP),Protein: specify,RSV fusion (F),Novel other: specify,NCT02123433,Completed,MedImmune LLC,Industry,4/1/2014,6/1/2015,6/1/2015,Adult | Senior,246,USA,Results reported in both peer-reviewed journal & registry,5/27/2016,https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT02115815,clinicaltrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Respiratory Syncytial Virus,Phase 1,1,REGN2222 (Anti-RSV mAb),Inactive / no longer in development,Other: monoclonal antibody specific for RSV fusion (F),Other: RSV F-specific neutralizing mAb,,None,NCT02133690,Completed,Regeneron Pharmaceuticals,Industry,5/1/2014,2/1/2015,2/1/2015,Adult,132,USA,Interim results reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Respiratory Syncytial Virus,Phase 1,1,RSV LID ΔM2-2,Active candidate / in development,"Live, attenuated target organism",Protein: specify,All viral proteins except M2-2,None,NCT02255227,Completed,NIAID,Government,9/1/2014,4/1/2015,4/1/2015,Child,29,USA,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Respiratory Syncytial Virus,Phase 2,2,RSV F Nanoparticle,Active candidate / in development,Recombinant subunit (non VLP),Protein: specify,RSV fusion (F),Aluminum salts (alum),NCT02267109,Completed,Novavax,Industry,9/1/2014,7/1/2016,7/1/2016,Adult,50,USA,Interim results reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Respiratory Syncytial Virus,Phase 2,2,RSV F Nanoparticle,Inactive / no longer in development,Recombinant subunit (non VLP),Protein: specify,RSV fusion (F),None,NCT02280408,Completed,Novavax,Industry,10/1/2014,3/1/2016,3/1/2016,Adult | Senior,1599,USA,Interim results reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Respiratory Syncytial Virus,Phase 1,1,MEDI7510 (RSV sF + Adj),Inactive / no longer in development,Recombinant subunit (non VLP),Protein: specify,RSV fusion (F),Novel other: specify,NCT02298179,Completed,MedImmune LLC,Industry,1/1/2015,2/1/2016,2/1/2016,Adult | Senior,363,USA,Results reported in peer-reviewed journal,9/5/2017,https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT02289820,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Respiratory Syncytial Virus,Phase 1,1,MEDI8897 (Anti-RSV mAb),Active candidate / in development,Other: monoclonal antibody specific for RSV fusion (F),Other: specify,,None,NCT02302066,Completed,MedImmune LLC,Industry,1/1/2015,9/1/2016,9/1/2016,Child,151,USA | Chile | South Africa,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Respiratory Syncytial Virus,Phase 1,1,RSV F Nanoparticle,Active candidate / in development,Recombinant subunit (non VLP),Protein: specify,RSV fusion (F),Aluminum salts (alum),NCT02304185,Completed,Novavax,Industry,11/1/2014,9/1/2015,4/1/2016,Child,32,Canada,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Respiratory Syncytial Virus,Phase 1,1,RSV F subunit vaccine,Inactive / no longer in development,Recombinant subunit (non VLP),Protein: specify,RSV fusion (F),Licensed other: specify,NCT02314923,Completed,GlaxoSmithKline,Industry,12/19/2014,3/27/2017,3/27/2017,Adult,288,Belgium,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Respiratory Syncytial Virus,Phase 3,3,REGN2222 (Anti-RSV mAb),Inactive / no longer in development,Other: monoclonal antibody specific for RSV fusion (F),Other: RSV F-specific neutralizing mAb,,None,NCT02344407,Completed,Regeneron Pharmaceuticals,Industry,6/1/2015,7/1/2017,9/1/2017,Child,1538,USA | Bulgaria | Australia | Canada | Chile | Denmark | Finland | Germany | Hungary | Netherlands | New Zealand | Panama |Puerto Rico | South Africa | Spain |Sweden | Turkey | Ukraine | UK,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Respiratory Syncytial Virus,Phase 2,2,GSK3003891A (RSV F),Active candidate / in development,Recombinant subunit (non VLP),Protein: specify,RSV fusion (F),Aluminum salts (alum),NCT02375256,Completed,GlaxoSmithKline,Industry,3/20/2015,7/2/2015,6/21/2016,Adult,507,USA | Australia | Czech Republic | Germany,Results reported in registry,,,clinicaltrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Respiratory Syncytial Virus,Phase 1,1,MVA-BN RSV (MVA-mBN294B),Active candidate / in development,Recombinant viral vector,Protein: specify,2 surface proteins & internal conserved protein,None,NCT02433652,Completed,Bavarian Nordic,Industry,8/1/2015,12/1/2015,5/1/2016,Adult,63,USA,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Respiratory Syncytial Virus,Phase 1,1,Ad35.RSV.FA2/Ad26.RSV.FA2,Inactive / no longer in development,Recombinant viral vector,Protein: specify,RSV fusion (F),None,NCT02464670,Completed,Crucell Holland BV,Industry,4/1/2015,6/1/2016,6/1/2016,Adult,54,USA,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Respiratory Syncytial Virus,Phase 1,1,DPX-RSV(A),Active candidate / in development,Recombinant subunit (non VLP),Protein: specify,Small Hydrophobic protein ectodomain,Novel other: specify,NCT02495246,"Open, not recruiting",Dalhousie University,Academic,5/1/2015,2/1/2017,6/1/2017,Adult,40,Canada,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Respiratory Syncytial Virus,Phase 1,1,GSK3389245A (ChAd155-RSV),Active candidate / in development,Recombinant viral vector,Protein: specify,"RSV Fusion (F), Nucleoprotein (N), transcription processivity factor (M2-1)",None,NCT02508194,"Open, not recruiting",GlaxoSmithKline,Industry,7/1/2015,4/1/2016,2/1/2017,Adult,73,UK,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Respiratory Syncytial Virus,Phase 2b,2,MEDI7510 (RSV sF + Adj),Inactive / no longer in development,Recombinant subunit (non VLP),Protein: specify,RSV fusion (F),Novel other: specify,NCT02532036,Withdrawn,MedImmune LLC,Industry,9/1/2015,9/1/2016,11/1/2016,Adult | Senior,2044,USA | Canada | Estonia |Chile | Latvia | Lithuania | South Africa,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Respiratory Syncytial Virus,Phase 1,1,Ad35.RSV.FA2/Ad26.RSV.FA2,Inactive / no longer in development,Recombinant viral vector,Protein: specify,RSV fusion (F),None,NCT02573181,Completed,Crucell Holland BV,Industry,9/1/2015,9/1/2016,9/1/2016,Adult,34,USA,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Respiratory Syncytial Virus,Phase 2,2,RSV F Nanoparticle,Inactive / no longer in development,Recombinant subunit VLP (non-fusion),Protein: specify,RSV fusion (F),None,NCT02608502,Completed,Novavax,Industry,10/1/2015,11/1/2016,11/1/2016,Adult | Senior,1330,USA,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Respiratory Syncytial Virus,Phase 1,1,RSV D46 cpΔM2-2,Active candidate / in development,"Live, attenuated target organism",Protein: specify,All viral proteins except M2-2,None,NCT02624947,"Open, recruiting",NIAID,Government,10/1/2015,5/1/2017,,Child,45,USA,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Respiratory Syncytial Virus,Phase 3,3,RSV F Nanoparticle,Inactive / no longer in development,Recombinant subunit (non VLP),Protein: specify,RSV fusion (F),None,NCT02628886,Completed,Novavax,Industry,11/1/2015,12/1/2016,12/1/2016,Adult | Senior,11850,USA,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Respiratory Syncytial Virus,Phase 3,3,RSV F Nanoparticle,Active candidate / in development,Recombinant subunit (non VLP),Protein: specify,RSV fusion (F),Aluminum salts (alum),NCT02646891,"Open, recruiting",Novavax,Industry,12/1/2015,5/1/2020,6/1/2020,Adult,8618,USA | Argentina | Australia | Chile | New Zealand | South Africa | Spain | United Kingdom,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Respiratory Syncytial Virus,Phase 2,2,GSK3003891A (RSV F),Active candidate / in development,Recombinant subunit (non VLP),Protein: specify,RSV fusion (F),None,NCT02795260,Completed,GlaxoSmithKline,Industry,4/1/2016,6/28/2016,6/28/2016,Adult,102,Belgium,Results reported in registry,,,clinicaltrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Respiratory Syncytial Virus,Phase 1,1,RSV LID ΔM2-2 1030s,Active candidate / in development,"Live, attenuated target organism",Protein: specify,All viral proteins except M2-2,None,NCT02828397,Completed,NIAID,Government,6/1/2016,7/7/2017,7/7/2017,Child,33,USA,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Respiratory Syncytial Virus,Phase 1,1,REGN2222 (Anti-RSV mAb),Inactive / no longer in development,Other: monoclonal antibody specific for RSV fusion (F),Other: RSV F-specific neutralizing mAb,,None,NCT02873260,Completed,Regeneron Pharmaceuticals,Industry,4/1/2016,6/1/2016,6/1/2016,Adult,28,USA,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Respiratory Syncytial Virus,Phase 1,1,VXA-RSV-f oral,Active candidate / in development,Recombinant viral vector,Protein: specify,RSV fusion (F),Novel other: specify,NCT02873286,"Open, recruiting",Vaxart,Industry,6/22/2016,9/9/2017,12/1/2017,Adult,66,USA,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Respiratory Syncytial Virus,Phase 1,1,MVA-BN-RSV (MVA-mBN294B),Active candidate / in development,Recombinant viral vector,Protein: specify,2 surface proteins & internal conserved protein,None,NCT02890381,Not yet open,Bavarian Nordic,Industry,9/1/2018,8/1/2019,8/1/2019,Adult | Senior,96,,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Respiratory Syncytial Virus,Phase 2,2,MVA-BN RSV (MVA-mBN294B),Active candidate / in development,Recombinant viral vector,Protein: specify,2 surface proteins & internal conserved protein,None,NCT02892812,"Open, not recruiting",Bavarian Nordic,Industry,9/1/2016,8/1/2018,8/1/2018,Adult | Senior,400,USA,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Respiratory Syncytial Virus,Phase 2b,2,MEDI8897 (Anti-RSV mAb),Active candidate / in development,Other: monoclonal antibody specific for RSV fusion (F),Other: specify,,None,NCT02911415,"Open, recruiting",MedImmune LLC,Industry,11/3/2016,11/1/2018,11/1/2018,Child,1500,USA | Bulgaria | Canada | Czech Republic | France | Hungary | Italy | Poland | South Africa | Spain | UK,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Respiratory Syncytial Virus,Phase 1,1,RSV LID cp ΔM2-2,Active candidate / in development,"Live, attenuated target organism",Protein: specify,All viral proteins except M2-2,None,NCT02915016,Completed,NIAID,Government,9/1/2016,4/24/2017,4/24/2017,Child,17,USA,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Respiratory Syncytial Virus,Phase 1,1,Ad26.RSV.preF,Active candidate / in development,Recombinant viral vector,Protein: specify,RSV fusion (F),None,NCT02941107,"Open, recruiting",Janssen Vaccines & Prevention B.V.,Industry,11/8/2016,2/22/2018,3/25/2019,Adult | Senior,72,USA,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Respiratory Syncytial Virus,Phase 2,2,GSK3389245A (ChAd155-RSV),Active candidate / in development,Recombinant viral vector,Protein: specify,"RSV Fusion (F), Nucleoprotein (N), transcription processivity factor (M2-1)",None,NCT02948127,"Open, recruiting",GlaxoSmithKline,Industry,1/11/2017,11/15/2018,9/12/2020,Child,96,USA | Spain | Italy,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Respiratory Syncytial Virus,Phase 1,1,RSV LID cp ΔM2-2,Active candidate / in development,"Live, attenuated target organism",Protein: specify,All viral proteins except M2-2,None,NCT02979535,"Open, not recruiting",NIAID,Government,9/1/2016,4/30/2017,4/30/2018,Child,8,USA,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Respiratory Syncytial Virus,Phase 1,1,RSV LID ΔM2-2,Active candidate / in development,"Live, attenuated target organism",Protein: specify,All viral proteins except M2-2,None,NCT02992119,"Open, not recruiting",NIAID,Government,8/1/2016,5/1/2017,,Child,33,USA,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Respiratory Syncytial Virus,Phase 2,2,GSK3003891A (RSV F),Active candidate / in development,Recombinant subunit (non VLP),Protein: specify,RSV fusion (F),None,NCT02992418,"Open, not recruiting",GlaxoSmithKline,Industry,11/10/2016,8/30/2017,3/7/2018,Adult,406,Belgium | Estonia | France |Germany,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Respiratory Syncytial Virus,Phase 1,1,SynGEM,Active candidate / in development,Recombinant bacterial vector,Protein: specify,RSV fusion (F),None,NCT02993757,"Open, not recruiting",Mucosis BV,Industry,10/1/2016,7/1/2017,12/1/2017,Adult,48,UK,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Respiratory Syncytial Virus,Phase 2,2,RSV F Nanoparticle,Active candidate / in development,Recombinant subunit (non VLP),Protein: specify,RSV fusion (F),Novel other: specify,NCT03084289,"Open, not recruiting",Novavax,Industry,1/1/2017,4/1/2017,7/1/2018,Adult | Senior,300,Australia,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Respiratory Syncytial Virus,Phase 1,1,RSV F DS-Cav1,Active candidate / in development,Recombinant subunit (non VLP),Protein: specify,RSV fusion (F),Aluminum salts (alum),NCT03102034,"Open, recruiting",NIAID,Government,2/22/2017,5/31/2018,5/31/2018,Adult,100,USA,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Respiratory Syncytial Virus,Phase 1,1,RSV D46/NS2/N/ΔM2-2-HindIII,Active candidate / in development,"Live, attenuated target organism",Protein: specify,All viral proteins except M2-2,None,NCT03161366,"Open, recruiting",NIAID,Government,4/1/2017,4/1/2019,4/1/2019,Child,33,USA,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Respiratory Syncytial Virus,Phase 1,1,RSV D46/NS2/N/ΔM2-2-HindIII,Active candidate / in development,"Live, attenuated target organism",Protein: specify,All viral proteins except M2-2,None,NCT03162614,"Open, recruiting",NIAID,Government,3/30/2017,4/1/2018,4/1/2018,Child,33,USA,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Respiratory Syncytial Virus,Phase 2,2,GSK3003891A (RSV F),Active candidate / in development,Recombinant subunit (non VLP),Protein: specify,RSV fusion (F),None,NCT03303976,Withdrawn,GlaxoSmithKline,Industry,7/10/2017,9/26/2019,1/20/2021,Adult,0,USA | Finland | Spain,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Respiratory Syncytial Virus,Phase 1,1,rBCG-N-hRSV,Active candidate / in development,Recombinant bacterial vector,Protein: specify,RSV nucleoprotein,None,NCT03313050,"Open, recruiting",Pontificia Universidad Catolica de Chile,Academic,6/27/2017,5/20/2018,5/20/2018,Adult,24,Chile,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Respiratory Syncytial Virus,Phase 1,1,RSV ΔNS2 Δ1313 I1314L,Active candidate / in development,"Live, attenuated target organism",Protein: specify,All viral proteins except M2-2,None,NCT03341637,"Open, recruiting",NIAID,Government,8/4/2017,5/1/2019,5/1/2019,Child,80,USA,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Respiratory Syncytial Virus,Phase 2,2,Ad26.RSV.preF,Active candidate / in development,Recombinant viral vector,Protein: specify,RSV fusion (F),None,Not registered,Not yet open,Janssen Vaccines & Prevention B.V.,Industry,10/16/2017,1/25/2019,1/25/2019,Child | Adult,48,Finland | UK,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Shigellosis,Phase 2,2,SC599,Inactive / no longer in development,"Live, attenuated target organism",Other: specify,LPS,None,EUCTR2004-001915-78-GB,Unknown,Institut Pasteur,Industry,6/12/2005,,,Adult,111,"FRA, GBR",Results not yet reported,,,ClinicalTrialsRegister.eu,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Shigellosis,Phase 1,1,Invaplex 50,Inactive / no longer in development,"Subunit (e.g., toxoid, carbohydrate) from target organism",Other: specify,"LPS, Ipas",None,NCT00082069,Completed,US Army Medical Research & Material Commad,Government,4/1/2004,11/1/2006,11/1/2006,Adult,32,USA,Results reported in peer-reviewed journal,8/23/2010,https://www.ncbi.nlm.nih.gov/pubmed/20619378,ClinicalTrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Shigellosis,Phase 2,2,SC599,Inactive / no longer in development,"Live, attenuated target organism",Other: specify,LPS,None,NCT00210288,Completed,Institut Pasteur,Industry,5/1/2005,9/1/2006,4/1/2007,Adult,111,"FRA, GBR",Results not yet reported,,,ClinicalTrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Shigellosis,Phase 3,3,S. Sonnei O-SP-rEPA & S. flexneri 2a O-SP-rEPA,Active candidate / in development,Subunit conjugate,Carbohydrate: specify,LPS,None,NCT00368316,Completed,NICHD,Government,1/1/2003,1/1/2008,2/1/2009,Child,2799,ISR,Results reported in both peer-reviewed journal & registry,3/2/2010,https://www.ncbi.nlm.nih.gov/pubmed/20056180,ClinicalTrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Shigellosis,Other: Phase 1/2,1.5,Invaplex 50,Inactive / no longer in development,"Subunit (e.g., toxoid, carbohydrate) from target organism",Other: specify,"LPS, Ipas",None,NCT00485134,Completed,US Army Medical Research & Material Commad,Government,5/1/2007,7/1/2009,9/1/2010,Adult,113,USA,Results reported in registry,,,ClinicalTrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Shigellosis,Phase 2b,2,CVD1208S,Inactive / no longer in development,"Live, attenuated target organism",Other: specify,LPS,None,NCT00866476,Withdrawn,University of Maryland,Academic,1/1/2010,2/1/2010,2/1/2010,Adult,20,USA,Results not yet reported,,,ClinicalTrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Shigellosis,Phase 2,2,CVD 1208S,Inactive / no longer in development,"Live, attenuated target organism",Other: specify,LPS,None,NCT00866619,Withdrawn,University of Maryland,Academic,1/1/2010,2/1/2010,2/1/2010,Adult,20,USA,Results not yet reported,,,ClinicalTrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Shigellosis,Phase 1,1,GVXN SD133,Active candidate / in development,Subunit conjugate,Carbohydrate: specify,LPS,Aluminum salts (alum),NCT01080716,Completed,GlycoVaxyn AG,Industry,2/1/2010,10/1/2010,10/1/2010,Adult,40,CHE,Results reported in peer-reviewed journal,8/6/2015,https://www.ncbi.nlm.nih.gov/pubmed/26162850,ClinicalTrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Shigellosis,Other: Phase 1/2,1.5,WRSS1,Active candidate / in development,"Live, attenuated target organism",Other: specify,"LPS, Ipas",None,NCT01091298,Completed,US Army Medical Research & Material Commad,Government,5/1/2010,12/1/2010,12/1/2010,Adult,40,THA,Results reported in peer-reviewed journal,7/5/2016,https://www.ncbi.nlm.nih.gov/pubmed/27146000,ClinicalTrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Shigellosis,Phase 1,1,WRSs2 & WRSs3,Active candidate / in development,"Live, attenuated target organism",Other: specify,"LPS, Ipas",None,NCT01351948,Completed,NIAID,Government,1/1/2013,5/1/2015,5/1/2015,Adult,90,USA,Results not yet reported,,,ClinicalTrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Shigellosis,Phase 1,1,O-SPC/rBRU,Inactive / no longer in development,Subunit conjugate,Conjugate: specify antigen & carrier,Synthetic O-specific polysaccharide fragment,None,NCT01374516,Completed,NICHD,Government,5/15/2011,4/24/2013,4/24/2013,Adult,60,ISR,Results not yet reported,,,ClinicalTrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Shigellosis,Phase 1,1,O-SPC/rBRU,Inactive / no longer in development,Subunit conjugate,Carbohydrate: specify,Synthetic O-specific polysaccharide fragment,None,NCT01424501,Withdrawn,NICHD,Government,7/16/2011,4/25/2012,4/25/2012,Adult,0,N/A,,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Shigellosis,Phase 1,1,Sf2aWC,Active candidate / in development,Inactivated whole target organism,Other: specify,LPS. Ipas,Novel other: specify,NCT01531322,Completed,PATH,Other,3/1/2011,12/1/2012,12/1/2012,Adult,82,USA,Results not yet reported,,,ClinicalTrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Shigellosis,Phase 1,1,CVD 1208S,Inactive / no longer in development,"Live, attenuated target organism",Other: specify,LPS,None,NCT01542632,Completed,University of Maryland,Academic,7/1/2011,9/1/2012,9/1/2012,Adult,26,USA,Results not yet reported,,,ClinicalTrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Shigellosis,Phase 2,2,WRSS1,Active candidate / in development,"Live, attenuated target organism",Other: specify,"LPS, Ipas",None,NCT01829490,Completed,PATH,Other,8/1/2013,4/1/2016,4/1/2016,"Child, Adult",103,BGD,Results not yet reported,,,ClinicalTrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Shigellosis,Phase 1,1,1790GAHB,Active candidate / in development,Other: naturally secreted outer membrane vesicle,Other: specify,LPS; lipoproteins,Aluminum salts (alum),NCT02037984,Completed,GlaxoSmithKline,Industry,2/1/2014,3/1/2015,3/1/2015,Adult,50,FRA,Results reported in peer-reviewed journal,8/4/2016,https://www.ncbi.nlm.nih.gov/pubmed/27490698,ClinicalTrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Shigellosis,Phase 1,1,1790GAHB,Active candidate / in development,Other: naturally secreted outer membrane vesicle,Other: specify,LPS; lipoproteins,Aluminum salts (alum),NCT02040831,Completed,GlaxoSmithKline,Industry,3/1/2014,4/1/2015,4/1/2015,Adult,52,GRB,Results reported in peer-reviewed journal,8/4/2016,https://www.ncbi.nlm.nih.gov/pubmed/27490698,ClinicalTrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Shigellosis,Phase 1,1,Flexyn2a,Active candidate / in development,Subunit conjugate,Carbohydrate: specify,LPS,Aluminum salts (alum),NCT02406729,Completed,LimmaTech Biologics AG,Industry,2/1/2015,5/1/2015,9/1/2015,Adult,30,USA,Results reported in peer-reviewed journal,12/5/2016,https://www.ncbi.nlm.nih.gov/pubmed/27581434,ClinicalTrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Shigellosis,Phase 1,1,InvaplexAR,Active candidate / in development,Recombinant subunit (non VLP),Other: specify,"LPS, IpaB, IpaC",None,NCT02465216,"Open, not recruiting",US Army Medical Research & Material Commad,Government,10/1/2015,3/1/2018,3/1/2019,Adult,40,USA,Results not yet reported,,,ClinicalTrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Shigellosis,Phase 2b,2,Flexyn2a,Active candidate / in development,Subunit conjugate,Carbohydrate: specify,LPS,Aluminum salts (alum),NCT02663700,Completed,LimmaTech Biologics AG,Industry,12/1/2015,9/1/2016,7/1/2017,Adult,67,USA,Results not yet reported,,,ClinicalTrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Shigellosis,Phase 2,2,1790GAHB,Active candidate / in development,Other: naturally secree,Other: specify,LPS; lipoproteins,Aluminum salts (alum),NCT02699099,Completed,GlaxoSmithKline,Industry,8/1/2016,3/10/2017,3/10/2017,Adult,72,KEN,Results not yet reported,,,ClinicalTrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Shigellosis,Phase 1,1,SF2a-TT15,Active candidate / in development,Subunit conjugate,Carbohydrate: specify,Synthetic O-specific polysaccharide fragment,None,NCT02859350,Not yet open,Institut Pasteur,Industry,6/1/2016,12/1/2016,5/1/2017,Adult,64,ISR,Results not yet reported,,,ClinicalTrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Shigellosis,Phase 1,1,WRSS1,Active candidate / in development,"Live, attenuated target organism",Other: specify,"LPS, Ipas",None,NCT02955160,"Open, not recruiting",PATH,Other,11/1/2016,12/1/2017,1/31/2018,Child,16,BGD,Results not yet reported,,,ClinicalTrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Shigellosis,Phase 2b,2,Sf2aWC,Active candidate / in development,Inactivated whole target organism,Other: specify,"LPS, Ipas",Novel other: specify,NCT03099291,Withdrawn,PATH,Other,8/1/2017,12/31/2018,12/31/2019,Adult,72,USA,Results not yet reported,,,ClinicalTrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Shigellosis,Phase 1,1,1790GAHB,Active candidate / in development,Other: naturally secreted outer membrane vesicle,Other: specify,LPS; lipoproteins,Aluminum salts (alum),NCT03152903,Completed,GlaxoSmithKline,Industry,3/16/2017,8/31/2017,8/31/2017,Adult,35,FRA,Results not yet reported,,,ClinicalTrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Shigellosis,Phase 1,1,SsWC,Inactive / no longer in development,Inactivated whole target organism,Other: specify,LPS,Novel other: specify,RBR-3p7577,Completed,Johns Hopkins University,Academic,,,,Adult,66,USA,Results reported in peer-reviewed journal,7/21/2005,https://www.ncbi.nlm.nih.gov/pubmed/16095766,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Tuberculosis,Phase 3,3,BCG,Registered,"Live, attenuated target organism",Other: specify,BCG,None,ACTRN12608000227392,Completed,Hospital The Mercy Hospital for Women,Academic,26/04/2008,1/4/2009,1/4/2009,Child,256,Australia,Results reported in peer-reviewed journal,11/3/2011,22071384,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Tuberculosis,Phase 3,3,BCG,Registered,"Live, attenuated target organism",Other: specify,BCG,None,CTRI/2014/03/004450,"Open, recruiting",JIPMER,Academic,11/2/2014,11/2/2017,11/2/2017,Child,2426,India,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Tuberculosis,Phase 4,4,BCG,Registered,"Live, attenuated target organism",Other: specify,BCG,None,EUCTR2011-005653-31-NL,Completed,"LUMC, Department Infection Disease",Academic,28/06/2012,31/12/2014,31/12/2014,Adult,25,Netherlands,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Tuberculosis,Phase 2,2,GSK TB vaccine 692342 (later M72),Active candidate / in development,Recombinant subunit (non VLP),Protein: specify,Mtb 32A & 39A,None,EUCTR2012-001820-36-EE,Completed,GlaxoSmithKline,Industry,15/10/2012,10/4/2014,10/4/2014,Adult,240,Estonia | China,Results reported in registry,,,ClinicalTrialsRegister.eu,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Tuberculosis,Phase 1,1,BCG,Registered,"Other: live, attenuated, cross-protecting organism",Other: specify,BCG,None,NCT00396370,Completed,NIAID,Government,1/12/2008,1/7/2012,1/7/2012,Adult,69,United States of America,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Tuberculosis,Phase 1,1,H1:LTK63,Inactive / no longer in development,Recombinant subunit (non VLP),Protein: specify,"Ag85B, ESAT-6",Novel other: specify,NCT00440544,Withdrawn,"St. George's, U. of London",Academic,1/1/2007,1/11/2007,1/2/2008,Adult,9,UK,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Tuberculosis,Phase 1,1,MVA85A,Active candidate / in development,Recombinant viral vector,Protein: specify,Ag85A,None,NCT00480558,Completed,University of Oxford,Academic,1/7/2007,1/1/2011,1/1/2011,Adult,48,South Africa,Results reported in peer-reviewed journal,1/26/2012,22281831,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Tuberculosis,Phase 1,1,RUTI,Active candidate / in development,Inactivated partial (split) target organism,Other: specify,"fragmented, detoxified whole organism in liposomes",None,NCT00546273,Completed,Archivel Farma,Industry,1/4/2007,1/6/2008,1/6/2008,Adult,24,Spain,Results reported in peer-reviewed journal,10/22/2009,19853680,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Tuberculosis,Phase 1,1,MVA85A,Active candidate / in development,Recombinant viral vector,Protein: specify,Ag85A,None,NCT00548444,Completed,University of Oxford,Academic,1/10/2007,1/1/2010,1/1/2010,Adult,12,UK,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Tuberculosis,Phase 2,2,GSK TB vaccine 692342 (later M72),Active candidate / in development,Recombinant subunit (non VLP),Protein: specify,Mtb 32A & 39A,None,NCT00600782,Completed,GlaxoSmithKline,Industry,1/2/2008,1/12/2008,1/12/2008,Adult,45,South Africa,Results reported in peer-reviewed journal,8/15/2013,23306546,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Tuberculosis,Phase 2,2,GSK TB vaccine 692342 (later M72),Active candidate / in development,Recombinant subunit (non VLP),Protein: specify,Mtb 32A & 39A,Novel other: specify,NCT00622843,Completed,GlaxoSmithKline,Industry,1/4/2008,1/4/2009,1/4/2009,Adult,181,Philippines,Results reported in peer-reviewed journal,10/20/2013,24142232,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Tuberculosis,Phase 1,1,BCG,Registered,"Live, attenuated target organism",Other: specify,BCG,None,NCT00653770,Completed,University of Oxford,Academic,1/8/2007,1/4/2010,1/4/2010,Adult,40,UK,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Tuberculosis,Phase 1,1,"FP85A, MVA85A",Active candidate / in development ,Recombinant viral vector,Protein: specify,Ag85A,None,NCT00654108,Completed,University of Oxford,Academic,1/9/2007,1/1/2010,1/1/2010,Adult,31,UK,Results reported in peer-reviewed journal,11/10/2012,23143773,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Tuberculosis,Phase 2,2,MVA85A,Active candidate / in development,Recombinant viral vector,Protein: specify,Ag85A,None,NCT00680914,Completed,University of Oxford,Academic,1/2/2008,1/12/2009,1/12/2009,Child,168,South Africa,Results reported in peer-reviewed journal,6/15/2011,21606542,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Tuberculosis,Phase 2,2,GSK TB vaccine 692342 (later M72),Active candidate / in development,Recombinant subunit (non VLP),Protein: specify,Mtb 32A & 39A,Novel other: specify,NCT00708682,Completed,GlaxoSmithKline,Industry,1/6/2008,1/5/2009,1/5/2009,Adult,37,Switzerland,Results reported in peer-reviewed journal,5/26/2014,24864125,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Tuberculosis,Phase 1,1,MVA85A,Active candidate / in development,Recombinant viral vector,Protein: specify,Ag85A,None,NCT00737503,Completed,University of Oxford,Academic,1/8/2008,1/1/2011,1/1/2011,Adult,24,Senegal,Results reported in peer-reviewed journal,6/28/2013,23840618,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Tuberculosis,Phase 1,1,VPM 1002 (rBCG),Active candidate / in development,Other: recombinant BCG,Other: specify,whole rBCG,None,NCT00756067,Completed,Vakzine Projekt Management GmbH,Industry,1/9/2008,1/12/2009,1/12/2009,Adult,80,Germany,Results reported in peer-reviewed journal,1/3/2013,23290835,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Tuberculosis,Phase 1,1,Ad5-Ag85A,Active candidate / in development,Recombinant viral vector,Protein: specify,Ag85A,None,NCT00808444,Completed,McMaster University,Academic,1/6/2009,1/12/2012,1/7/2013,Adult,48,Canada,Results reported in peer-reviewed journal,10/2/2013,24089406,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Tuberculosis,Phase 1,1,Ag85B-ESAT-6 (later H1),Inactive / no longer in development,Recombinant subunit (non VLP),Protein: specify,"Ag85B, ESAT-6",Novel other: specify,NCT00929396,Completed,Statens Serum Institut,Academic,1/10/2009,1/10/2011,1/10/2011,Adult,38,Netherlands,Results reported in peer-reviewed journal,10/30/2014,25454872,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Tuberculosis,Phase 1,1,Ag85B-ESAT-6 (later H1),Inactive / no longer in development,Recombinant subunit (non VLP),Protein: specify,"Ag85B, ESAT-6",Novel other: specify,NCT00936429,Completed,Statens Serum Institut,Academic,1/9/2007,1/6/2009,1/6/2009,Adult,20,Netherlands,Results reported in peer-reviewed journal,1/20/2011,21256189,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Tuberculosis,Phase 2,2,GSK TB vaccine 692342 (later M72),Active candidate / in development,Recombinant subunit (non VLP),Protein: specify,Mtb 32A & 39A,None,NCT00950833,Completed,GlaxoSmithKline,Industry,1/12/2009,1/9/2010,1/9/2010,Child,60,South Africa,Results reported in both peer-reviewed journal & registry,6/10/2015,26072017,ClinicalTrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Tuberculosis,Phase 2,2,MVA85A,Active candidate / in development,Recombinant viral vector,Protein: specify,Ag85A,None,NCT00955006,Completed,Aeras,Product Development Partner,1/7/2009,1/10/2012,1/10/2012,Child,2797,South Africa,Results reported in both peer-reviewed journal & registry,3/23/2013,23391465,ClinicalTrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Tuberculosis,Phase 2,2,"Aeras-402 (Ad35 + Ag85A, Ag85B, TB10.4)",Inactive / no longer in development,Recombinant viral vector,Protein: specify,"Ag85A, Ag85B, TB10.4",None,NCT01026038,Completed,Aeras,Product Development Partner,1/12/2009,1/3/2012,1/5/2012,Adult,26,South Africa,Results reported in both peer-reviewed journal & registry,2/17/2015,25698492,ClinicalTrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Tuberculosis,Phase 1,1,H1: IC31,Inactive / no longer in development,Recombinant subunit (non VLP),Protein: specify,"ESAT-6, Ag85B",Novel other: specify,NCT01064141,Completed,Statens Serum Institut,Academic,1/12/2008,1/4/2010,1/4/2010,Adult,39,Ethiopia,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Tuberculosis,Phase 2,2,GSK TB vaccine 692342 (later M72),Active candidate / in development,Recombinant subunit (non VLP),Protein: specify,Mtb 32A & 39A,None,NCT01110551,Completed,GlaxoSmithKline,Industry,1/7/2010,1/4/2011,1/3/2012,Child,302,Gambia,Results reported in peer-reviewed journal,8/9/2014,25305000,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Tuberculosis,Phase 1,1,VPM 1002 (rBCG),Active candidate / in development,Other: recombinant BCG,Other: specify,whole rBCG,None,NCT01134263,Completed,Vakzine Projekt Management GmbH,Industry,1/4/2010,1/12/2010,1/3/2011,Adult,24,South Africa,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Tuberculosis,Phase 1,1,BCG + isoniazid,Registered,"Live, attenuated target organism",Other: specify,BCG,None,NCT01136161,Completed,NIAID,Government,1/10/2010,1/7/2013,1/7/2013,Adult,82,South Africa,Results reported in peer-reviewed journal,6/30/2014,24814553,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Tuberculosis,Phase 2,2,RUTI,Active candidate / in development,Inactivated partial (split) target organism,Other: specify,"fragmented, detoxified whole organism in liposomes",None,NCT01148459,Completed,Archivel Farma,Industry,1/6/2010,1/5/2011,1/5/2011,Adult,95,South Africa,Results reported in peer-reviewed journal,2/26/2014,24586912,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Tuberculosis,Phase 2,2,MVA85A,Active candidate / in development,Recombinant viral vector,Protein: specify,Ag85A,None,NCT01157897,Completed,Aeras,Product Development Partner,1/7/2011,1/5/2014,1/9/2014,Adult,650,"Senegal, South Africa",Results reported in both peer-reviewed journal & registry,2/26/2015,25726088,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Tuberculosis,Phase 1,1,MVA85A,Active candidate / in development,Recombinant viral vector,Protein: specify,Ag85A,None,NCT01198366,Completed,University of Oxford,Academic,1/1/2010,1/1/2011,1/1/2011,Adult,24,UK,Results reported in peer-reviewed journal,12/21/2012,23266342,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Tuberculosis,Phase 1,1,MVA85A,Active candidate / in development,Recombinant viral vector,Protein: specify,Ag85A,None,NCT01199874,Completed,University of Oxford,Academic,1/5/2010,1/1/2012,1/1/2012,Adult,48,UK,Results reported in peer-reviewed journal,11/23/2013,24273174,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Tuberculosis,Phase 2,2,"Aeras-402 (Ad35 + Ag85A, Ag85B, TB10.4)",Inactive / no longer in development,Recombinant viral vector,Protein: specify,"Ag85A, Ag85B, TB10.4",None,NCT01200368,Completed,Aeras,Product Development Partner,1/9/2010,1/1/2014,1/4/2014,Child,487,Kenya | Mozambique | South Africa,Results reported in peer-reviewed journal,4/28/2015,25936724,ClinicalTrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Tuberculosis,Phase 2,2,V-5 immunitor,Active candidate / in development,Other: specify,Other: specify,Information not available,None,NCT01254422,Completed,Lisichansk Regional Tuberculosis Dispensary,Government,1/1/2010,1/12/2010,1/1/2011,Adult,123,Ukraine,Results reported in peer-reviewed journal,12/24/2010,21182457,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Tuberculosis,Phase 2,2,GSK TB vaccine 692342 (later M72),Active candidate / in development,Recombinant subunit (non VLP),Protein: specify,Mtb 32A & 39A,None,NCT01305109,Completed,GlaxoSmithKline,Industry,1/1/2011,1/7/2012,1/6/2015,Adult,240,India,Results reported in peer-reviewed journal,1/1/2016,26817879,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Tuberculosis,Phase 1,1,AERAS-422,Inactive / no longer in development,Recombinant viral vector,Protein: specify,"Ag85A, Ag85B, Rv3407, mutant perfringolysin",None,NCT01364883,Completed,Aeras,Product Development Partner,1/12/2010,1/2/2012,1/5/2012,Adult,24,US,Results reported in peer-reviewed journal,4/19/2016,27322481,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Tuberculosis,Phase 1,1,"Aeras-402 (Ad35 + Ag85A, Ag85B, TB10.4)",Inactive / no longer in development,Recombinant viral vector,Protein: specify,"Ag85A, Ag85B, TB10.4",None,NCT01397227,Completed,Aeras,Product Development Partner,1/2/2011,1/10/2011,1/3/2012,Adult,12,India,Results reported in peer-reviewed journal,1/30/2012,22296955,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Tuberculosis,Phase 2,2,GSK TB vaccine 692342 (later M72),Active candidate / in development,Recombinant subunit (non VLP),Protein: specify,Mtb 32A & 39A,None,NCT01434381,Completed,GlaxoSmithKline,Industry,1/11/2011,1/4/2014,1/4/2014,Adult,142,Estonia | China,Results reported in peer-reviewed journal,7/21/2016,27553419,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Tuberculosis,Phase 2,2,VPM 1002 (rBCG),Active candidate / in development,Other: recombinant BCG,Other: specify,whole rBCG,None,NCT01497769,Completed,Vakzine Projekt Management GmbH,Product Development Partner,1/11/2011,1/11/2012,1/11/2012,Child,48,South Africa,Results reported in peer-reviewed journal,12/14/2016,PMC5299117,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Tuberculosis,Phase 1,1,MVA85A,Active candidate / in development,Recombinant viral vector,Protein: specify,Ag85A,None,NCT01502969,Completed,University of Oxford,Academic,1/9/2011,1/10/2012,1/4/2013,Adult,24,UK,Results reported in peer-reviewed journal,8/20/2014,25151225,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Tuberculosis,Phase 1,1,ID93+GLA-SE,Active candidate / in development,Recombinant subunit (non VLP),Protein: specify,"Rv3619, Rv1813, Rv3620, & Rv2608",Novel other: specify,NCT01616459,Completed,Infectious Disease Research Institute,Product Development Partner,1/8/2012,1/5/2014,1/5/2014,Adult,60,United States of America,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Tuberculosis,Phase 2,2,MVA85A + BCG,Active candidate / in development,Recombinant viral vector,Protein: specify,Ag85A,None,NCT01666652,Completed,University of Cape Town,Academic,1/10/2012,1/5/2015,1/5/2015,Child,248,South Africa,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Tuberculosis,Phase 2,2,GSK TB vaccine 692342 (later M72),Active candidate / in development,Recombinant subunit (non VLP),Protein: specify,Mtb 32A & 39A,None,NCT01692886,Completed,GlaxoSmithKline,Industry,21/08/2012,6/12/2012,24/05/2013,Adult,20,Belgium,Results reported in registry,,,ClinicalTrialsRegister.eu,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Tuberculosis,Phase 1,1,"Aeras-402 (Ad35 + Ag85A, Ag85B, TB10.4)",Inactive / no longer in development,Recombinant viral vector,Protein: specify,"Ag85A, Ag85B, TB10.4",None,NCT01702857,Completed,University of Oxford,Academic,1/9/2012,1/8/2014,1/8/2014,Adult,40,UK,Results reported in peer-reviewed journal,11/3/2015,26529238,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Tuberculosis,Phase 2,2,M72+AS01E,Active candidate / in development,Recombinant subunit (non VLP),Protein: specify,Mtb 32A & 39A,Novel other: specify,NCT01765426,"Open, not recruiting",GlaxoSmithKline,Industry,1/8/2014,1/10/2018,1/10/2018,Adult,3506,Kenya | South Africa | Zambia,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Tuberculosis,Phase 1,1,ChAdOx1.85A / MVA85A,Active candidate / in development,Other: Simian adenovirus expressing antigen 85A,Protein: specify,Ag85A,None,NCT01857869,Completed,University of Oxford,Academic,1/7/2013,1/4/2016,1/4/2016,Adult,42,UK,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Tuberculosis,Phase 2,2,Aeras-404 (H4/IC31),Active candidate / in development,Recombinant subunit (non VLP),Protein: specify,"Ag85B, Tb10.4",Novel other: specify,NCT01868464,"Open, not recruiting",Aeras,Product Development Partner,1/7/2013,1/12/2017,1/2/2018,Child,229,South Africa,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Tuberculosis,Phase 2,2,H56:IC31,Active candidate / in development,Recombinant subunit (non VLP),Protein: specify,"Ag85B, ESAT-6, Rv2660c",Novel other: specify,NCT01879163,Completed,Aeras,Product Development Partner,1/8/2013,1/8/2015,1/11/2015,Adult,98,South Africa,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Tuberculosis,Phase 1,1,BCG (Tice),Registered,"Live, attenuated target organism",Other: specify,BCG,None,NCT01892618,"Open, not recruiting",NIAID,Government,1/6/2014,1/6/2016,1/6/2016,Adult,120,United States of America,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Tuberculosis,Phase 1,1,MVA85A-IMX313,Active candidate / in development,Recombinant viral vector,Protein: specify,Ag85A,Novel other: specify,NCT01893554,Completed,University of Oxford,Academic,1/7/2013,1/12/2014,1/12/2014,Adult,30,UK,Results reported in peer-reviewed journal,2/5/2016,26854906,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Tuberculosis,Phase 1,1,ID93+GLA-SE,Active candidate / in development,Recombinant subunit (non VLP),Protein: specify,"Rv3619, Rv1813, Rv3620, & Rv2608",Novel other: specify,NCT01933685,Completed,Infectious Disease Research Institute,Product Development Partner,1/9/2013,1/7/2015,1/7/2015,Adult,66,South Africa,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Tuberculosis,Phase 1,1,MVA85A,Active candidate / in development,Recombinant viral vector,Protein: specify,Ag85A,None,NCT01964716,Completed,University of Oxford,Academic,1/10/2013,1/1/2016,1/1/2016,Adult,37,UK,,5/13/2016,http://www.atsjournals.org/doi/pdf/10.1164/ajrccm-conference.2016.193.1_MeetingAbstracts.A5487,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Tuberculosis,Phase 1,1,Aeras-456 (H56:IC31),Active candidate / in development,Recombinant subunit (non VLP),Protein: specify,"Ag85B, ESAT-6",Novel other: specify,NCT01988636,Completed,Aeras,Product Development Partner,1/11/2011,1/12/2012,1/6/2013,Adult,25,South Africa,Results reported in peer-reviewed journal,6/19/2015,26095509,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Tuberculosis,Phase 3,3,Vaccae,Active candidate / in development,Other: inactivated non-tuberculous mycobacterium,Other: specify,whole NTM,None,NCT01995617,Unknown,AnHui Zhifei Longcom Biologic Pharmacy,Industry,1/10/2013,1/4/2017,1/6/2017,Child | Adult,10000,China,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Tuberculosis,Phase 1,1,"MTBVAC, BCG",Active candidate / in development,"Live, attenuated target organism",Other: specify,"Whole, attenuated Mtb",None,NCT02015091,Completed,"Biofabri, S.L.",Industry,1/1/2013,1/6/2014,1/11/2014,Adult,36,Switzerland,Results reported in both peer-reviewed journal & registry,,,ClinicalTrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Tuberculosis,Phase 2,2,BCG,Registered,"Live, attenuated target organism",Other: specify,BCG,None,NCT02074956,Completed,University of Cape Town,Academic,1/6/2010,1/4/2012,1/4/2012,Child,149,South Africa,Results reported in both peer-reviewed journal & registry,8/8/2014,25108027,ClinicalTrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Tuberculosis,Phase 1,1,DAR-901,Active candidate / in development,Other: inactivated non-tuberculous mycobacterium,Other: specify,whole NTM,None,NCT02075203,Completed,Dartmouth Hitchcock Medical Center,Academic,1/2/2014,1/3/2016,1/6/2016,Adult,77,United States of America,Results reported in peer-reviewed journal,5/12/2017,28498853,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Tuberculosis,Phase 1,1,Aeras-404 (H4/IC31),Active candidate / in development,Recombinant subunit (non VLP),Protein: specify,"Ag85B, Tb10.4",Novel other: specify,NCT02075983,Completed,Aeras,Product Development Partner,1/11/2007,1/5/2009,1/5/2009,Adult,64,Sweden,Results reported in peer-reviewed journal,2/17/2017,28216183,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Tuberculosis,Phase 1,1,Aeras-404 (H4/IC31),Active candidate / in development,Recombinant subunit (non VLP),Protein: specify,"Ag85B, Tb10.4",Novel other: specify,NCT02079207,Completed,Aeras,Product Development Partner,1/5/2008,1/10/2009,1/10/2009,Adult,60,Finland,Results reported in peer-reviewed journal,2/17/2017,28216183,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Tuberculosis,Phase 2,2,Aeras-404 (H4/IC31),Active candidate / in development,Recombinant subunit (non VLP),Protein: specify,"Ag85B, Tb10.4",Novel other: specify,NCT02083068,Completed,Aeras,Product Development Partner,1/2/2014,1/9/2017,1/12/2017,Child,990,South Africa,Results reported in peer-reviewed journal,7/9/2015,26048780,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Tuberculosis,Phase 3,3,BCG,Registered,"Live, attenuated target organism",Other: specify,BCG,None,NCT02109484,Completed,University of Oxford,Academic,1/3/2014,1/1/2015,1/1/2015,Adult,52,UK,Results reported in peer-reviewed journal,10/8/2015,26450421,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Tuberculosis,Phase 1,1,Aeras-404 (H4/IC31),Active candidate / in development,Recombinant subunit (non VLP),Protein: specify,"Ag85B, Tb10.4",Novel other: specify,NCT02115815,Completed,Aeras,Product Development Partner,1/12/2008,1/12/2010,1/9/2012,Adult,40,South Africa,Results reported in peer-reviewed journal,6/3/2015,26048780,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Tuberculosis,Phase 3,3,BCG,Registered,"Live, attenuated target organism",Other: specify,BCG,None,NCT02116998,Completed,Radboud University,Academic,1/5/2014,1/9/2014,1/9/2014,Adult,40,Netherlands,Results reported in peer-reviewed journal,6/12/2015,26071565,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Tuberculosis,Phase 2,2,MVA85A,Active candidate / in development,Recombinant viral vector,Protein: specify,Ag85A,None,NCT02201030,Completed,University of Oxford,Academic,1/6/2014,1/1/2015,1/1/2015,Child,90,Uganda,Results reported in peer-reviewed journal,5/4/2017,28472067,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Tuberculosis,Phase 1,1,BCG,Registered,"Live, attenuated target organism",Other: specify,BCG,None,NCT02279589,Completed,Radboud University,Academic,1/11/2013,1/3/2014,1/4/2014,Adult,15,Netherlands,Results reported in registry,,,ClinicalTrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Tuberculosis,Phase 1,1,Ad5-Ag85A,Active candidate / in development,Recombinant viral vector,Protein: specify,Ag85A,None,NCT02366013,"Open, recruiting",McMaster University,Academic,1/4/2017,1/4/2017,1/4/2017,Adult,36,Canada,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Tuberculosis,Phase 1,1,"BCG, Aeras-402 (Ad35 + Ag85A, Ag85B, TB10.4)",Inactive / no longer in development,Recombinant viral vector,Protein: specify,"Ag85A, Ag85B, TB10.4",None,NCT02380508,Completed,Aeras,Product Development Partner,1/10/2009,1/12/2010,1/12/2013,Adult,11,United States of America,Results reported in peer-reviewed journal,11/2/2016,PMC5141283,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Tuberculosis,Phase 1,1,Aeras-456 (H56:IC31),Active candidate / in development,Recombinant subunit (non VLP),Protein: specify,"Ag85B, ESAT-6",Novel other: specify,NCT02388009,Completed,Aeras,Product Development Partner,21/11/2014,24/06/2016,24/10/2016,Adult,22,South Africa,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Tuberculosis,Phase 2,2,H4: IC31,Active candidate / in development,Recombinant subunit (non VLP),Protein: specify,"Ag85B, TB10.4",Novel other: specify,NCT02392325,Completed,Aeras,Product Development Partner,1/5/2015,31/10/2016,9/12/2016,Child,84,South Africa,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Tuberculosis,Phase 4,4,BCG,Registered,"Live, attenuated target organism",Other: specify,BCG,None,NCT02404311,Completed,University of Oxford,Academic,1/2/2015,1/11/2016,1/11/2016,Adult,36,UK,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Tuberculosis,Phase 2,2,BCG & ESAT6-CFP10,Registered,"Live, attenuated target organism",Other: specify,"BCG, ESAT6-CFP10",None,NCT02408913,Completed,AnHui Zhifei Longcom Biologic Pharmacy,Industry,1/4/2015,1/7/2015,1/9/2015,Adult,1044,China,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Tuberculosis,Phase 2,2,VPM 1002 (rBCG),Active candidate / in development,Other: recombinant BCG,Other: specify,whole rBCG,None,NCT02413502,"Open, not recruiting",Vakzine Projekt Management GmbH,Academic,1/6/2015,1/9/2017,1/12/2017,Child,416,South Africa,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Tuberculosis,Phase 1,1,BCG,Registered,"Live, attenuated target organism",Other: specify,BCG,None,NCT02421367,Completed,Aeras,Product Development Partner,1/5/2015,1/9/2015,1/10/2015,Adult,10,United States of America,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Tuberculosis,Phase 2,2,"Aeras-402 (Ad35 + Ag85A, Ag85B, TB10.4)",Inactive / no longer in development,Recombinant viral vector,Protein: specify,"Ag85A, Ag85B, TB10.4",None,NCT02425098,Completed,Aeras,Product Development Partner,1/10/2008,1/7/2010,1/11/2010,Adult,72,South Africa,Results reported in both peer-reviewed journal & registry,1/6/2017,28060545,ClinicalTrials.gov,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Tuberculosis,Phase 1,1,"BCG, Aeras-404 (H4/IC31)",Active candidate / in development,Recombinant subunit (non VLP),Protein: specify,"Ag85B, Tb10.4",Novel other: specify,NCT02440035,Completed,Aeras,Product Development Partner,1/1/2011,1/5/2012,1/11/2013,Adult,70,Switzerland,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Tuberculosis,Phase 1,1,"Aeras-402 (Ad35 + Ag85A, Ag85B, TB10.4)",Inactive / no longer in development,Recombinant viral vector,Protein: specify,"Ag85A, Ag85B, TB10.4",None,NCT02450838,Completed,Aeras,Product Development Partner,1/9/2008,1/6/2009,1/7/2010,Adult,20,Kenya,Results reported in peer-reviewed journal,3/26/2016,27026148,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Tuberculosis,Phase 2,2,ID93+GLA-SE,Active candidate / in development,Recombinant subunit (non VLP),Protein: specify,"Rv3619, Rv1813, Rv3620, & Rv2608",Novel other: specify,NCT02494999,Completed,Infectious Disease Research Institute,Academic,1/6/2015,1/1/2017,1/1/2017,Adult,60,South Africa,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Tuberculosis,Phase 1,1,TB/FLU-04L,Active candidate / in development,Recombinant viral vector,Protein: specify,"ESAT-6, Ag85A",None,NCT02531373,Completed,Research Institute for Biological Safety Problems,Academic,1/10/2013,1/4/2014,1/2/2015,Adult,36,Kazakhstan,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Tuberculosis,Phase 1,1,H56:IC31 with etoricoxib,Active candidate / in development,Recombinant subunit (non VLP),Protein: specify,"Ag85B, ESAT-6",Novel other: specify,NCT02531802,"Open, recruiting",Oslo University Hospital,Academic,1/11/2015,1/4/2018,1/12/2018,Adult,40,Norway,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Tuberculosis,Phase 1,1,D93 + AP10-602 & ID93 + GLA-SE,Active candidate / in development,Recombinant subunit (non VLP),Protein: specify,"Rv3619, Rv1813, Rv3620, & Rv2608",Novel other: specify,NCT02532049,Completed,NIAID,Government,22/10/2015,18/08/2017,25/08/2017,Adult,70,United States of America,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Tuberculosis,Phase 1,1,MVA85A,Active candidate / in development,Other: aerosolized & IM attenuated virus-vectored vaccine,Protein: specify,Ag85A,None,NCT02544698,"Open, recruiting",University of Oxford,Academic,1/9/2015,1/8/2017,1/8/2017,Adult,30,UK,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Tuberculosis,Phase 3,3,BCG,Registered,"Live, attenuated target organism",Other: specify,BCG,None,NCT02628444,"Open, recruiting",Makerere University,Academic,1/7/2016,1/6/2020,1/12/2020,Child,2200,Uganda,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Tuberculosis,Phase 2,2,BCG,Registered,"Live, attenuated target organism",Other: specify,BCG,None,NCT02718469,Completed,Radboud University,Academic,1/4/2016,1/10/2016,1/1/2017,Adult,20,Netherlands,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Tuberculosis,Phase 2,2,RUTI,Active candidate / in development,Inactivated partial (split) target organism,Other: specify,"fragmented, detoxified whole organism in liposomes",None,NCT02728869,Not yet open,University Medical Center Groningen,Academic,1/6/2016,1/12/2017,1/6/2018,Adult,27,Unspecified,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Tuberculosis,Phase 2,2,DAR-901,Active candidate / in development,Other: inactivated non-tuberculosis mycobacterium,Other: specify,whole NTM,None,NCT02729571,"Open, recruiting",Dartmouth Hitchcock Medical center,Academic,1/3/2016,1/6/2018,1/9/2018,Child,650,United Republic of Tanzania,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Tuberculosis,Phase 2,2,MTBVAC,Active candidate / in development,"Live, attenuated target organism",Other: specify,"Whole, attenuated Mtb",None,NCT02771730,"Open, not recruiting","Biofabri, S.L.",Industry,1/9/2015,1/3/2017,1/6/2017,Child | Adult,54,South Africa,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Tuberculosis,Phase 3,3,ESAT6-CFP10,Registered,"Live, attenuated target organism",Other: specify,"BCG, ESAT6-CFP10",None,NCT02830932,Completed,AnHui Zhifei Longcom Biologic Pharmacy,Industry,1/5/2016,1/10/2016,1/10/2016,Adult,1802,China,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Tuberculosis,Phase 2,2,MTBVAC,Active candidate / in development,"Live, attenuated target organism",Other: specify,"Whole, attenuated Mtb",None,NCT02948829,Not yet open,Aeras,Product Development Partner,1/8/2017,1/6/2018,1/9/2018,Adult,120,Unspecified,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Tuberculosis,Phase 1,1,AEC/BCO2,Active candidate / in development,Inactivated whole target organism,Other: specify,"Recombinant, freeze-dried whole Mtb",Novel other: specify,NCT03089879,Not yet open,AnHui Zhifei Longcom Biologic Pharmacy,Industry,15/03/2017,1/10/2017,1/10/2017,Adult,175,China,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Tuberculosis,Phase 3,3,VPM 1002 (rBCG),Active candidate / in development,Other: recombinant BCG,Other: specify,whole rBCG,None,NCT03203421,Not yet open,Serum Institute,Industry,15/07/2017,20/08/2019,20/11/2019,Adult,2000,India,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Tuberculosis,Phase 1,1,GX-70,Inactive / no longer in development,DNA,Protein: specify,"4 MTB antigens, Flt3 ligand",None,NCT03213405,Not yet open,Yonsei University,Academic,1/5/2017,5/3/2018,20/08/2018,Adult,18,South Korea,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Tuberculosis,Phase 1,1,BCG,Registered,"Live, attenuated target organism",Other: specify,BCG,None,NCT03284710,"Open, recruiting",Aeras,Product Development Partner,15/09/2017,1/4/2018,1/6/2018,Adult,15,US,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Tuberculosis,Phase 1,1,GamTBvac,Active candidate / in development,Recombinant subunit (non VLP),Protein: specify,"Ag85A, ESAT6-CFP10",None,NCT03341754,"Open, recruiting",Gamaleya Research Institute of Epidemiology & Microbiology,Government,15/01/2017,15/12/2017,15/02/2018,Adult,60,Russia,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Tuberculosis,Phase 1,1,"""Mycobacterium w"" (Mycobacterium indicus pranii)",Inactive / no longer in development,Other: specify,Other: specify,Heat killed whole M. indicus pranii,None,RPCEC00000173,Completed,University of Cape Town,Academic,1/1/2009,28/02/2014,28/02/2014,Adult,1400,South Africa | India | Mozambique | Nigeria,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Tuberculosis,Phase 2,2,H1: IC31,Inactive / no longer in development,Recombinant subunit (non VLP),Protein: specify,"ESAT-6, Ag85B",Novel other: specify,RPCEC00000243,Completed,Statens Serum Institut,Academic,10/1/2012,10/9/2012,10/9/2012,Adult,48,South Africa,Results reported in peer-reviewed journal,12/9/2014,25490675,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Tuberculosis,Phase 2,2,"Aeras-402 (Ad35 + Ag85A, Ag85B, TB10.4)",Inactive / no longer in development,Recombinant viral vector,Protein: specify,"Ag85A, Ag85B, TB10.4",None,TCTR20170109002,Completed,Aeras,Product Development Partner,7/10/2010,23/01/2014,23/01/2014,Child,481,South Africa,Results reported in peer-reviewed journal,4/28/2015,25936724,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Tuberculosis,Phase 2,2,Ag85B-ESAT-6 (later H1) + IC31,Inactive / no longer in development,Recombinant subunit (non VLP),Protein: specify,"Ag85B, ESAT-6",Novel other: specify,,Completed,Statens Serum Institut,Academic,27/08/2012,19/12/2013,19/12/2013,Child,240,South Africa,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
Tuberculosis,Phase 4,4,BCG,Registered,"Live, attenuated target organism",Other: specify,BCG,None,,Completed,Fundação Oswaldo Cruz,Government,1/1/2010,1/1/2011,1/1/2011,Adult,75,Brazil,Results not yet reported,,,,WHO,http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
